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1. OUTLINE OF THE THESIS 
The sequence-specific transcription factor p53 is considered a master gene of cellular responses 
to homeostasis changes. It is also a prominent tumor suppressor gene with the title of “guardian 
of the genome”. The increasing number of transcriptome analyses in cell lines treated with 
different agents activating p53, continues to add complexity to the vast transcriptional networks 
p53 regulates. To investigate mRNA translational control as an additional dimension of p53-
directed gene expression responses, we performed translatome analyses upon its activation 
either by different agents or cellular contexts. Considered as a proxy for the proteome, the 
translatome allows us to characterize the translational status of each mRNA, independently from 
transcriptional modulations, and to evaluate the implications or correlations of changes in relative 
mRNA translation efficiencies with the phenotypic outcome. 
 
We first performed treatment-specific translatome profiling in MCF7 cells upon Doxorubicin and 
Nutlin-3a treatments. Among translated genes, we detected the presence of translationally 
enhanced mRNAs with a virtually absent transcriptional modulation; those genes were enriched 
for apoptotic functions, suggesting that the apoptotic phenotype might be controlled not only at 
the transcriptional, but also at the translational level. 
Seeking mechanisms underlying the mRNAs translational rate upon p53 activation, we identified 
the modulation of six RNA-binding proteins, where hnRNPD (AUF1) and CPEB4 are direct p53 
targets, whereas SRSF1, DDX17, YBX1 and TARDBP are indirect targets, modulated at the 
translational level in a p53-dependent manner. In detail, we demonstrated the contribution of at 
least two p53-dependent translational mechanisms related to YBX1 translational repression, 
suggesting the presence of a controlled regulon at the crossroad of YBX1 mRNA translation.  
 
Given our finding that apoptotic genes appear to be controlled by p53 also at the translational 
level, we decided to explore whether mRNAs translational control mechanisms are indeed an 
additional checkpoint to the phenotype. To this aim, we performed a cell-type specific 
translatome study upon Nutlin-3a treatment, a drug with evident therapeutic prospective. SJSA1, 
HCT116 and MCF7 cells were chosen as they exhibit different cellular responses to Nutlin-3A (cell 
cycle arrest, apoptosis, or both, respectively). Our preliminary data suggests that translational 
modulation can affect the complex process of cell fate choice upon p53 activation. Indeed, a lack 
of overlap among genes differentially modulated at the translational level was evident. Motif 
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search analysis at the 5’- and 3’-UTR of those genes highlighted the presence of different motifs in 
the three cell lines and the specific correlation of a C-rich motif with the apoptotic phenotype. 
Preliminary data on this motif will be presented and discussed. 
 
Two independent projects will be presented as appendixes, both of them related to the general 
idea that more than one factor may determine the p53 response. Starting from the analysis of 
possible p53 interactions with other transcriptional co-factors, we investigated the cooperative 
interaction between p53 and NFκB. For the second project, combining data previously obtained 
by means of yeast-based p53 transactivation assays, we developed an algorithm, p53retriever, 
to scan DNA sequences and thus identify p53 response elements and classify them based on 
their transactivation potential. 
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2. INTRODUCTION 
2.1. Restoring p53 activity 
After 36 years from its discovery the TP53 gene still captures the scientific scenario because of 
its involvement in an high number of biological processes -metabolism, differentiation, motility, 
cell–cell communication- beyond the indisputable role as tumor suppressor [1]. Indeed, p53 
protects from tumor development by controlling the genome and regulating the cell fate choice 
[2] [3]. Because of its critical functions, p53 is frequently mutated in around 50% of all malignant 
tumors. Nevertheless, the remaining half of cancers expresses wild-type p53, and its activation 
may offer a “smart” therapeutic benefit [4]. The possibility to manipulate p53 activation to 
promote tumor cell death is a very fascinating idea and is also one of the main points of this 
thesis.  
That said, I will start with a brief overview of the main functions of p53 and of the mechanisms 
by which it is regulated. 
a. p53’s modus operandi  
The concept that p53 can kill cancer cells is made even more appealing by the idea that p53 
might selectively induce apoptosis in tumor cells, while causing only a reversible cell-cycle arrest 
phenotype in their normal counterparts; as we will see, however, this is an oversimplification of 
the complex and heterogeneous responses to p53 activation. Numerous studies have sought to 
reveal the molecular mechanisms that underlie the control of the response to p53 activation 
[3]; it is well established that p53 is a sequence-specific transcription factor, modulating the 
expression of an array of different genes in order to mediate its response [5][6].  
Many factors influence the ability of p53 to function as a transcription factor: 
 
- PROTEIN DOMAINS AND DNA BINDING AFFINITY:  
First of all, the p53 binding affinity to target DNA sequences is crucial. Among p53 
domains, the DNA-binding domain (DBD) localized in the core region, allows sequence-
specific DNA binding. Virtually every residue in this ~200 amino acids domain has been 
found to be mutated in human tumors, with frequencies ranging from two fold higher 
for infrequent mutants to more than 1000 times for hot spot mutants, (UMD p53 
database 2007_R1; http://p53.free. fr/) with respect to the ones in the other domains. 
Different p53 mutants in the same region display marked heterogeneity in terms of the 
 C
h
a
p
te
r:
 
IN
T
R
O
D
U
C
T
IO
N
 
 5
 
impact on structure and function; consequently, the transactivation capacity can be 
variably affected as well [7][8], i.e. next to p53 mutants exhibiting a complete loss of 
function, others retain partial function while others can exhibit gain of function.  
At the same time, post-translational modifications may contribute to p53 binding 
affinity. For instance, the C-terminal phosphorylation of different residues are thought 
to enhance the sequence specific DNA binding ability of p53 by inducing a 
conformational change [9]. Similarly, other modifications like ubiquitination, 
acetylation, and sumoylation also affect its proteolytic turnover and sequence-specific 
DNA binding ability [10] [11]. 
 
- COFACTORS AND TRANSCRIPTION FACTORS: 
Concerning the other domains, specific cofactors, some of which have tissue- or stress-
specific expression, can bind to various regions of the p53 protein (mainly at the level of 
the transactivation domains, SH3-like domain and the basic domain at the C-terminus), 
and may thus contribute to p53 transactivation and binding selectivity [12][13]. For 
instance, ASPP1 and ASPP2 (apoptosis-stimulating proteins of p53 1 and 2) bind to p53 
through their C-termini and stimulate the p53 apoptotic but not cell cycle arrest activity. 
Indeed, though the mechanism is still unclear, they can selectively stimulate the binding 
of p53 to the p53REs at the BAX promoter, but not to those in p21 or MDM2, thus 
preferentially promoting apoptosis [14] [15] . On the contrary, the hematopoietic zinc-
finger factor HZF, facilitates p53 binding to the p53 responsive elements in p21 and 14-
3-3σ genes, inhibits p53 binding to those in BAX, while having no effect on p53 binding 
to the MDM2 and HZF promoters [14] [11]. The potential for combined activation of 
transcription factors to generate transcriptional cooperation was recently explored by 
our group for p53 and the Estrogen Receptors [12] and, more recently, for p53 and 
NFκB (see Appendix a). 
 
- DNA TARGET SEQUENCE: 
Features of the p53 binding-site, herein defined as response element (RE), play an 
important role in p53 DNA binding specificity as well as transcriptional specificity. 
Biochemical and functional studies have extensively characterized the p53 RE [16][5]: its 
canonical consensus, found mostly at the promoter of up-regulated p53 target genes, 
consists of two copies of the palindromic half-site RRRCWWGYYY separated by a spacer 
of 0–13nt, in which R = purine, W = adenine or thymine and Y = pyrimidine (Figure 1). 
This rather degenerate consensus sequence reflects the established observation that, 
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virtually in all cases of validated p53 REs, an optimal consensus site is not found. This is 
because of mismatches in some cases resulting in partial binding sites referred to as 
non-canonical REs (see Appendix b).  
This observation has raised the hypothesis of a selection pressure to limit the intrinsic 
potential of p53 proteins to target binding sites, thereby allowing for modulation of 
p53-induced transcriptional changes by signal transduction pathways affecting p53 
protein amount, DNA binding potential, quaternary structures and/or availability of 
multiple trans-factors [17]. For instance, p53 REs with lower DNA binding affinity appear 
to be more frequent in target genes involved in apoptosis. Additionally, cell cycle p53 
REs are reported as more conserved than apoptotic p53 REs, suggesting that the cell 
cycle arrest program may have a more ancient root within the network [18] [14]. 
Genome-wide studies of p53 DNA binding in-vivo using chromatin immunoprecipitation 
(ChIP) in conjunction with hybridization (ChIP-chip) or followed by deep sequencing 
(ChIP-seq) contributed to refine the p53 consensus binding site and to predict a number 
of its target genes [16][6]. More recently, ChIP-exo approaches also allowed binding 
sites identification with a single base-pair resolution [19]. 
 
It must be noted that given the diversity of cell types and treatments being assayed, it is 
nearly impossible to define a common list of targets. For instance, a comparison of 
seven different p53 ChIP-seq experiments retrieved only 81 sites whose p53 occupancy 
is induced by each treatment [20]. 
 
 
 
 
 
 
Figure 1: p53 is a transcription factor that recognize a response element on the promoter of its 
target genes [5]. 
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b. Choosing to activate: main p53-regulators 
As mentioned above, the tumor suppressor p53 is a potent anti-proliferative and pro-apoptotic 
protein that could harm normal cells if not properly regulated: this is why its level is accurately 
controlled in unstressed cells and MDM2 has a major role in this regulation [21][22]. In response 
to various extra- and intra-cellular stresses, including but not limited to oncogene activation, 
DNA damage and hypoxia, different post-translational modifications such as phosphorylation 
and acetylation stabilize and activate p53. Regarding the main MDM2 regulator, p53 and MDM2 
form an auto-regulatory feedback loop by which the two proteins mutually control their cellular 
levels (Figure 2). p53 binds to the promoter and regulates the expression of the MDM2 gene, 
one of its transcriptional targets; as the level of MDM2 rises, it binds and inactivates p53. 
MDM2 binds to the N-terminal transactivation domain of p53 and inhibits its transcription 
factor role. As an E3 ubiquitin ligase, MDM2 mono-ubiquitinates p53, promoting its enhanced 
nuclear export. MDM2 also poly-ubiquitinates p53 thus targeting it for proteasomal 
degradation. As a result, both p53 and MDM2 are kept at very low levels in unstressed cells 
[23]. Recently, three additional proteins, PIRH2, COP1 and ARF-BP1, have been discovered to 
bind p53 and act as p53 ubiquitin ligases. Currently, there is no evidence that any of these p53 
ubiquitin ligases can substitute for MDM2 in the regulation of p53 stability. Furthermore, 
MDMX is a protein with high degree of homology to MDM2, especially in its N-terminal p53 
binding domain; similarly to MDM2, MDMX binds to p53 with high affinity and effectively 
inhibits its transactivation properties. However, although MDMX possesses a RING domain, it is 
unable to ubiquitinate and to degrade p53. In contrast to MDM2, the MDMX (MDM4) gene is 
not transcriptionally regulated by p53, although a p53 bound RE has been mapped [24][25]. 
Overexpression of MDM2 or MDMX, achieved via different mechanisms such as gene 
amplification, increased transcription, enhanced mRNA stability and altered post-translational 
Figure 2: MDM2 is a main regulator 
of the p53 levels in normal 
condition. p53 actively transcribes 
MDM2. As its level rises, MDM2 binds 
and ubiquitinates p53 to inhibit p53 
transcriptional activity and, thus, its 
own expression [23].  
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modifications, leads to the inhibition of p53 in many cancer types, including sarcoma, glioma, 
melanoma and carcinoma [26].  
c. Targeting p53 
All these observations allow envisioning different strategies to restore p53 activity.  
- Un-specific p53 activation 
Various chemotherapeutic drugs, commonly used in therapy, lead to p53 activation. 
Among them, Doxorubicin is a famous example. Through DNA intercalation, this 
drug inhibits topoisomerase II (leading to double strand breaks in the genome [27]) 
and DNA and RNA polymerases (causing replication and transcription arrest [28]). 
Even though it showed potent tumor-growth-inhibiting properties, Doxorubicin 
induces a plethora of cytotoxic effects, also in normal cells.  
- Specific p53 activation 
More recently, new therapeutic approaches have been pursued with the 
development of small molecules able to induce p53 without significant genotoxic 
effects. Re-folding of p53 in tumors carrying point mutations in its gene, appears to 
be an attractive strategy; on the contrary, in tumors expressing wild-type p53, a 
promising approach is to block its major inhibitors, MDM2 and MDMX [29].  
Given the relevance to this project, I will discuss the identification of a number of small 
molecules that relieve the inhibition of p53 caused by MDM2/X. The first discovered molecules 
were Nutlins (cis-imidasoline compounds, developed by Hoffman-Roche), followed by the 
development of spirooxindole compounds (MI series, including MI-63, MI-219), and 
benzodiazepinediones [23][30]. p53 reactivation by Nutlin-3A has been studied by a number of 
labs [6][31]; in different types of cancer cells Nutlin-3A was shown to bind MDM2 with 
nanomolar efficiency, activate p53 and suppress tumor growth, all without inducing the 
cytotoxic side effects associated with traditional chemotherapeutics. These studies provided the 
proof-of-concept of p53 rescue by MDM2 inhibition and a strong evidence for the feasibility of 
this strategy. Several phase I studies of the orally available Nutlin-3A analog, namely RG7112, in 
patients with liposarcoma (prior to de-bulking surgery), solid tumors, hematologic neoplasms 
and soft tissue sarcomas (NCT01143740, NCT01164033, NCT00559533, NCT00623870 and 
NCT01605526 studies) have been completed or are in progress. A second generation MDM2 
inhibitor developed by Hoffman-Roche, RG7388, has even higher potency and selectivity 
[32][33][34]. Nevertheless, a new frontier seems to combine this treatment with other agents 
that would tip the balance toward a rapid response. Moreover, given that MDMX levels may 
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balance out MDM2 levels [35], efforts have been focused on the identification of dual 
MDM2/MDMX antagonists, i.e., ‘two in one’ inhibitors which can offer an effective therapy for a 
broader range of tumors [22].  
In spite of substantial improvements during the last decade, further studies are still needed in 
order to elucidate molecular mechanisms and efficacy of this agent in long term cancer 
treatment. 
 
d. p53: to kill or not to kill? 
It is therefore of utmost importance to understand which p53 function is activated by these 
compounds in various cancers. How does p53 react to genotoxic versus non-genotoxic 
activating agents? Indeed, within its role as TF, the responses p53 can elicit are complex (Figure 
3). For instance, many of our models for p53 function suppose that induction of programmed 
cell death is the key mechanism by which p53 induces the elimination of cancer cells. In other 
words, p53 is a direct trans-activator of many genes acting in the intrinsic and extrinsic branches 
of the apoptotic pathway, including BAX, PUMA and NOXA [36]. Being p53 a cell fate controller, 
the second most obvious tumor suppressor activity it can exert is the inhibition of cell 
proliferation and growth. p53 can effectively block cell cycle progression by activating the 
transcription of the cyclin-dependent kinase inhibitor p21, although several other p53-target 
genes such as 14-3-3 σ (SFN) and miRNA-34a also contribute to this response [3][37]. Moreover, 
each cancer type reacts differently. Of course, cell cycle arrest is deemed the least preferred 
outcomes from a therapeutic perspective, as it is reversible and would lead only to a temporary 
stall in tumor growth for as long as the therapy is administered. This brings us to the interesting 
question of what determines the outcome of p53 activation.  
Figure 3: Dual mechanisms of 
p53 function in tumor 
suppression. P53 can promote 
repair and survival of 
damaged cells or it can 
promote elimination of cells 
[3]. 
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2.2.  Translational control mechanisms 
In the first section, I presented an overview of how complex is the response that p53 can elicit. 
Although an high degree of control takes place at the transcriptional level, the final p53 response 
can be considered as the outcome of a circuit made of collections of factors co-regulating a given 
p53 target gene not only at transcriptional, but also at translational and post-translational level 
[38]. In this thesis, I will analyze the mechanisms implicated in translational control of p53 targets. 
Originally studied in early stages of development in oocytes and embryos [39] [40], translational 
control is now widely accepted as an additional layer of gene expression regulation in somatic 
cells. Compared to transcriptional regulation, it allows rapid changes in protein synthesis rate for 
existing mRNAs [41]. Thus, translational control can be considered a fast and dynamic force 
shaping cell phenotypes. Moreover, these mechanisms can partially explain the lack of correlation 
between mRNAs levels, namely the transcriptome, and protein levels, namely the proteome. 
 
a. The process of translation: an overview. 
Translation proceeds by initiation, elongation, termination, and ribosome recycling, with most of 
the regulatory mechanisms thought to occur during the rate-limiting initiation step [42] [43]. 
In the canonical model, during the first steps of cap-dependent translation initiation, mRNAs are 
associated at their 5’UTR with the eukaryotic initiation factor eIF4F, comprising the cap-binding 
protein eIF4E, the scaffold protein eIF4G, and the 5’UTR unwinding RNA helicase eIF4A that 
operates in conjunction with eIF4B. At the 3’UTR end, associated poly-A binding proteins (PABP) 
bind eIF4G leading to the circularization and activation of mRNAs. The 43S pre-initiation complex 
[composed of the 40S ribosomal subunit, the eIF2 ternary complex (eIF2, GTP, and Met-tRNA), 
eIF3, eIF1, eIF1A, and eIF5] joins the activated RNA structure (via eIF4G and eIF3 interaction) and 
scans 5’UTR until AUG start codon recognition occurs, followed by the hydrolysis of eIF2-bound 
GTP and the release of eIF2-bound GDP, eIF5, eIF3, and eIF1. The subsequent association of the 
60S ribosomal subunit with eIF5B-bound to GTP leads to eIF5B-mediated GTP hydrolysis and the 
release of eIF5B-GDP and eIF1, thus allowing the assembly of the 80S complex, which is then 
ready for translation elongation [43][44].  
mRNAs encoding some stress response proteins must be able to evade this intricate regulatory 
process, especially in conditions of translation inhibition (i.e. hypoxia, nutrient deprivation), and 
several mechanisms have evolved to achieve this. One such mechanism is to bypass cap-
dependent recruitment. An estimated 10% of mRNAs contain internal ribosome entry sites (IRESs) 
in their 5’UTRs and therefore have the potential to be translated by a process which allows 
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recruitment of the translation machinery downstream of the 5’m7G cap at a position within the 
5’UTR. Originally identified in viruses, IRESs are typically structured RNA elements that facilitate 
the binding of the mRNA to 40S subunits, usually involving a subset of cofactors known as ITAFs 
(IRES trans-acting factors). Changes in the abundance or activity of these ITAFs allow precise 
control of IRES-mediated translation, and this mode of initiation is frequently used during stress 
conditions when cap-dependent translation is compromised [45].   
The complex nature of the entire translation process offers a number of regulatory points to finely 
control the translation rate of each mRNA in particular in stress conditions. Most commonly used 
regulatory mechanisms modulate the phosphorylation states of eIFs by stress-related kinases and 
phosphatases (the GCN2, PERK, HRI, and PKR kinases) to control the ternary complex, the 
phosphorylation of the initiation factor eIF2 or of eIF4E-binding protein [45]. Moreover, 
sequences and structural elements, called cis-elements, bound by various kinds of regulators 
(RNA binding proteins or non-coding RNAs) may operate to influence the translation process 
before the ribosome scanning - by the inhibition or, vice versa, the induction of nuclear export 
and of mRNA stability- and during the translation steps influencing capping, alternative splicing, 
polyadenilation and also translation rates (Figure 4).  
b.  cis-elements 
Found mainly in the untranslated regions of the mRNA (5’- or 3’-UTR), a cis-element is a 
recurrent sequence or secondary structure shared by a number of transcripts and defined by a 
specific combination of nucleotides, namely consensus sequence, to which specific trans-factors 
bind to exert their control over the mRNA. TOP-elements (5’ terminal oligopyrimidine tract), 
IRES (internal ribosome entry segments) and G-quadruplexes structures are examples of cis-
elements in the 5’-UTR [46][47]. Regulatory elements bound by RBPs or non-coding RNAs are 
mainly located in the 3’-UTR. Different crosslinking and immunoprecipitation techniques (CLIP, 
PAR-CLIP, iCLIP, CLASH) have allowed the identification of sequence elements, namely motifs, 
bound by specific trans-factors [48]. A well-known example of cis-element is the AAUAAA 
polyadenilation sequence. The CPSF RNA-binding protein binds the sequence and, together with 
the PABPN1 nuclear protein, stimulates the activity of the poly(A) polymerase, which is 
essentially inactive on its own [49]. 
c. RNA-binding proteins 
RBPs often bind to the 5’ UTR of a transcript to modulate translation initiation, and to its 3’ UTR 
to influence its stability or translatability; nevertheless, they have also been well characterized 
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Figure 4: On the right, schematic representation of translation initiation regulation through cis 
elements and trans-acting factors operating in the mRNAs 5’ UTR and 3’ UTR [46]. On the left 
techniques allowing to study translatomes at various observational levels are presented [48]. 
for modulating the initial step of transcripts life; when pre-mRNAs emerge from the 
transcription sites, they are associated with RBPs and RNAs, to form RNA-protein complexes 
also referred to as ribonucleoprotein (RNP) complexes [50]. The RNPs assembled on each mRNA 
by recruiting selected components, which are recombined during the different stages of the 
RNA maturation, from the splicing to the mRNA alternative nuclear polyadenylation, the export 
from the nucleus, the localization in the cytoplasm and cytoplasmic polyadenylation, and the 
final translation potential [51][49][50]. 
A diversity in their composition corresponds to this functional complexity: the human genome 
complement of RBPs is composed at least by 800 genes [52][53] which are characterized by the 
presence of different functional domains, among which the most represented are the zinc-
finger C2H2 domain (787 genes), the RNA-recognition motif (RRM, 233 genes), the sterile alpha 
motif (SAM, 93 genes) and the K-homology domain (KH, 38 genes). Among the least abundant 
domains, we find the Pumilio RNA binding repeat (PUM, 4 genes) and Piwi proteins domain 
(PIWI, 8 genes).  
To obtain a specific cellular outcome, some RBPs may cooperate to modulate a group of 
transcripts, while some may antagonize each other. Various RBPs may share the same binding 
element: the interaction with one RBP may be mutually exclusive, thus, affecting a second 
binding. For instance, ELAVL1 (HuR) and AUF1 (hnRNPD) compete with each other for binding to 
the same AU-rich elements on specific target mRNAs, thus, exerting opposing influences on 
target mRNA stability [54].  
However, in general, the amount of data available on these RBPs, their coordinated modulation 
of groups of mRNAs (RNA regulons) or their combinatorial interactions on individual mRNAs is 
at present rather limited. 
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d. Non-coding RNAs 
Non-coding RNAs have emerged as key post-transcriptional regulators of gene expression, 
involved in diverse physiological and pathological processes. Among them, long non-coding RNA 
(lncRNAs) were recently discovered and their molecular functions are only beginning to be 
revealed [55]. LncRNAs are more than 200 nucleotides in length. They are currently annotated 
as: 1) Intronic lncRNAs that are entirely transcribed from within a single intron of a protein- 
coding gene. (2) Bidirectional lncRNAs which share promoters with protein-coding genes but 
they are transcribed in the opposite direction and therefore have no overlapping sequence. 3) 
Intervening lncRNAs (lincRNAs) transcribed from regions that are at least 5 kb from protein-
coding genes. 4) Antisense lncRNAs (natural antisense transcripts, NATs) which are transcribed 
from the opposite strand of protein-coding genes. It is estimated that 70% of mammalian 
protein-coding genes have an overlapping NAT [56]. The few lncRNAs studied in some depth 
have been characterized as transcriptional modulators or enhancers, while others have been 
associated to nuclear speckles structure [57]. Moreover, new insights suggest their implication 
in post-transcriptional control: they are implicated in the splicing; they may act as molecular 
decoy for microRNAs, or inhibit protein translation. For instance, linc-p21 has been described as 
inhibitor of translation, cooperating with HuR in the regulation of a subset of mRNAs [58]. Their 
implication in translation has been investigated at the level of the ribosomes as well: recent 
studies suggest the ability of lncRNAs to target the ribosome directly. Initially described as 
“contaminants”, these lncRNAs are now studied as an emerging class of non-coding ribo-
regulators of protein biosynthesis [59]. 
Beyond the biological implications, lncRNAs have been considered also as a therapeutic tool to 
specifically boost protein expression in mammalian systems, as suggested by an elegant work 
about an antisense lncRNA transcribed in the opposite strand of the mouse Ubiquitin carboxy-
terminal hydrolase L1 (Uchl1) gene which can specifically induce the translation of Uchl1 under 
certain stress condition [60][61].  
On the other hand, non-coding RNAs of ≈22nt length are defined as microRNAs (miRNAs). A lot 
of work has been already devoted to the characterization of this class of small RNAs; the 
primary transcripts of miRNA genes (pri-miRNAs) are cleaved into hairpin intermediates (pre-
miRNAs) by the nuclear RNase III Drosha and further processed to mature miRNAs by cytosolic 
Dicer, another RNase-III-related enzyme [62]. In their final form, they most often bind to the 
3’UTR of a transcript, inhibiting translation or destabilizing of target messenger RNAs including 
those coding for oncogenes and tumor suppressors. Dis-regulation in miRNAs expression has 
been reported in various cancers and can contribute to tumorigenesis [63]. 
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2.3. Translation control in cancer 
During cancer progression, cells are exposed to different types of stress. Rapid responses based 
on the expression of selected proteins may allow their further growth. Translation regulation is 
a rapid way of tuning gene expression by regulating protein synthesis from existing mRNAs, and 
thus also saves transcription-related energy [43]. Thus, translation regulation may act to the 
advantage of cancer cells. The major signaling pathways that promote carcinogenesis (AKT, RAS, 
MAPK signaling) are involved in this process controlling phosphorylation and regulation of 
translation factors or ribosomal proteins. For instance, AKT signaling inactivates the tuberous 
sclerosis tumor-suppressor TSC1/2 complex, which negatively regulates the mammalian target 
of rapamycin complex 1 (mTORC1), a major regulator of protein synthesis. In its active form, 
mTORC1 phosphorylates 4E-BP, leading to the release and activation of the cap-binding protein 
eIF4E. Inactivation of 4E-BPs by down-regulation or hyper-phosphorylation correlates with 
higher tumor grades and reduced patient survival in prostate and breast cancer, and leads to an 
increase in cap-dependent translation [43]. At the same time, overexpression of eIF4E, a key 
player in cap-dependent translation, leads to oncogenic transformation, and increased eIF4E 
protein levels are found in the majority of human cancers, where its expression correlates with 
a poor prognosis [42][64]. 
Lack of oxygen (hypoxia), starvation, and response to DNA-damage inducing therapy repress 
cap-dependent translation and lead to a reduction in overall protein synthesis, mostly by 
suppression of eIF4F and eIF2 ternary complex assembly by various mechanisms [45]. 
On the other hand, inhibition of protein synthesis allows the enhancement or activation of the 
translation of specific mRNA in a cap-independent manner using IRES. Of importance, these 
structures are present in mRNAs encoding proteins with oncogenic activity that promote the 
development, progression, and survival of cancer cells, such as c-MYC, lymphoid enhancer 
factor (LEF)-1, VEGF, hypoxia-inducible factor (HIF)-1a. In addition, IRES mutations or 
deregulated ITAFs can further increase the translation of oncogenic proteins. In multiple 
myeloma, mutations in c-myc-IRES were shown to enhance its translation initiation, and a more 
recent study in the same cancer type showed an increase in IRES-dependent c-myc translation 
via ITAFs such as Y-box binding protein 1 (YB-1) and polypyrimidine tract-binding protein 1 (PTB-
1) [43]. 
Considering the low number of known mRNAs carrying an IRES in their 5’UTRs and also the 
lower level of knowledge about involved mechanisms, HIF1 and VEGF are the only targets that 
have become attractive in the development of anticancer drugs. Vice versa, the blocking of 
deregulated signaling pathways by kinase inhibitors has shown greater promise for cancer 
treatment. mTORC1 can be inhibited by rapalogs (rapamycin and its derivatives) that bind to 
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FKBP-12 and inhibit mTOR in complex 1. mTORC1/2 inhibitors (e.g., PP242) were more efficient 
in the inhibition of global protein synthesis and in eIF4F complex formation than rapamycin, 
illustrating the more-effective approach of targeting cap-dependent translation in cancer. As an 
alternative to the inhibition of signaling pathways, therapeutic approaches that interfere with 
the deregulated translation typical of some cancers have been studied. Treatment with eIF4E-
specific antisense oligonucleotides reduces eIF4E expression as well as eIF4E-regulated proteins, 
and suppresses tumor growth in nude mice bearing human breast and prostate tumor 
xenografts [43][65]. 
 
 
 
 
 
2.4. p53 in the translation control landscape 
Translational control can be considered as an additional level of control also in shaping p53 
outcomes. Indeed, signaling to mTOR appears to occur also through a p53-dependent pathway 
requiring transcriptional activation of Sestrin1 and Sestrin2, which in turn activate AMP-
responsive protein kinase (AMPK), which then activates the repressor of mTOR TSC2 [43].  
The synthesis of the p53 protein itself has been shown to be modulated by different trans-
factors, miRNAs targeting its mRNA 3’-UTR and by the binding of ribosomal proteins such as 
RPL26 and nucleolin, that showed opposite effect on p53 translation rates [66]. Moreover, p53 
targets can also be regulated at the post-transcriptional level in their protein synthesis rates, 
and the impact of this regulation has been recently reviewed [67]. Indeed, very well-known p53 
targets undergo translational regulation through the action of miRNAs or RBPs that can 
modulate what has to be degraded or stored in the cytoplasm rather than being actively 
translated (Figure 5). For instance, the miR-17-92 cluster binds to the CDKN1A(p21) mRNA 3’-
UTR promoting p21 degradation, although p53 enhances its transcription[68]; on the other 
hand, RBPs such as HuR promote p21 mRNA stability and translation[69]. However, HuR was 
shown to impact also on MDM2 [70], thus outlining a complex regulatory network also at the 
post-transcriptional level.  
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On the contrary, p53 has a direct role on post-transcriptional regulation through 1) the direct 
activation of miRNAs gene expression [71][72][73], 2) the direct interaction with Drosha, 
impacting on the processing of primary miRNAs to precursor miRNAs [74]. By regulating 
miRNAs, the net effect of p53 activation can be modulated in a context-dependent manner by 
negative regulation at the post-transcriptional level, moderating what would otherwise be a 
much greater impact on protein expression of p53 target genes. Therefore, this finely tuned 
regulatory response has a key role in managing the phenotypic outcomes in response to p53 
activation: in particular, miRNA-34a is the most intensely investigated among p53-miRNAs [75]. 
In the same regulatory context, there are isolated evidences that a few RBPs - namely RNPC1, 
Quaking (QKI), PCBP4- are p53 or p53-family targets [76][77][78]. For instance, RNPC1 was 
shown to be a direct transcriptional target gene of both p53 and p63, and to be capable of 
stimulating p21 mRNA translation [79]; instead, PCBP4 resulted as a p53 target that can down-
regulate p21 translation in a p53-independent manner [76]. 
 
 
 
 
 
 
 
 
 
 
 
Figure 5: Post-transcriptional 
regulation of p53 target 
genes. miRNAs and RBPs 
work to enhance or repress 
the expression of p53 target 
protein-coding genes [67]. 
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Figure 6: Schematic representation of our workflow. 
We compared the transcriptome (measure of the total 
mRNAs) with the translatome in order to characterize 
the mRNA fate in the cytoplasm before and after p53 
activation. 
3. Our approach  
The mechanisms defining which cellular response is adopted upon p53 activation remain poorly 
characterized. As mentioned before, lots of efforts have been devoted to clarify the p53-
dependent transcription mechanisms upon p53 induction, under a variety of stress conditions. 
Thus, along with the advance of new technologies, studies on p53-dependent gene expression 
have exponentially increased. New targets are continuously identified, increasing the 
complexity of known p53 cellular responses. However, these analyses are insufficient to explain 
the observed outcome, and more is needed: for instance, translational studies of p53 mRNA 
targets could better reveal why some of these are translated only in specific stress condition, 
thus producing proteins affecting the final phenotype.  
In order to study translational control mechanisms as an additional level in shaping p53-
dependent cellular response, we performed translatome analyses upon its activation (Figure 6). 
In our approach the translatome is analyzed by using the polysomal profiling technique: 
considered as a proxy for the proteome, the polysomal profiling approach allows us to separate 
actively translated mRNAs, bound by polysomes, from not actively translated ones. Thus, guided 
by the comparison between the translatome and the transcriptome, we characterized coupled 
genes -those mRNAs with homo-directional expression changes at both transcriptional and 
translational level upon p53 activation – and uncoupled genes – mRNAs whose transcription did 
not correlate with translation.  
We first performed treatment-
specific translatome profiling in 
MCF7 cells upon Doxorubicin and 
Nutlin-3a treatments. Then, we 
analyzed the cell-type specific 
translatome of SJSA1, HCT116 and 
MCF7 cells, which exhibit different 
cellular responses to the MDM2 
inhibitor Nutlin-3a (cell cycle arrest, 
apoptosis, or both, respectively) to 
study in detail whether different 
groups of uncoupled genes are 
associated with different outcomes. 
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4. RESULTS 
This section will present the results obtained in the two main tasks on which I focused during 
my doctoral period. The first one highlights my specific contributions to the published 
manuscript that is included (Paper 1). The second task is still ongoing and I will present the 
results obtained so far in more details. 
 
4.1. Translatome profiling upon different 
treatments in MCF7 cells 
 
a. Project summary and my contributions 
This study represented the first attempt to provide a global view of the comparison between 
changes at the transcriptional levels and changes in the translation efficiency of mRNAs in 
response to p53-activating stimuli. The well-characterized cell line MCF7, that expresses wild 
type p53, was chosen and the cells were treated with either Doxorubicin or Nutlin-3A, resulting 
in activation of the p53 pathways through different routes, the DNA damage response pathway 
in the first case, and non-genotoxic activation of p53 via inhibition if its interaction with MDM2, 
for the second treatment. Sub-toxic doses of Doxorubicin and Nutlin-3A and a relatively late 
time point (16 hours) were selected, also for the high levels of treatments similarity on cell 
viability levels, status of apoptosis markers and activation of p53 (Figure S1 in the accompanying 
paper 1). Three RNA samples were collected for each treatment: total RNA, cytoplasmic RNA 
not associated with polysomes, cytoplasmic RNA associated with two or more ribosomes -the 
latter two samples collected from sucrose-gradient fractionation-. These RNA samples were 
analyzed using expression microarrays, as described in the accompanying paper. Upon 
identification of differentially expressed genes (DEGs) for each treatment, the correlation 
between treatment-dependent changes at the transcriptional and translational level was first 
analyzed (Figure 1 in the accompanying paper 1).  
We identified a high number of genes exhibiting homo-directional changes both in terms of 
transcriptome and translatome (defined as coupled). The majority of p53 targets, such as 
CDKN1A, MDM2 and BBC3, are included in this category. Even for these well-established p53 
targets, quantitative differences among the transcriptome and polysomal (pol) mRNA levels 
were evident, suggesting a fine-tuning in their expression. Given the significantly higher fold 
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change in the pol fraction than in total RNA, we defined CDKN1A and MDM2 as ‘translational 
thrust’ genes. Vice versa, genes such as BBC3 with an opposite finding were proposed as 
‘translational drag’ genes.  
The focus of the study was then directed towards the differentially expressed genes identified in 
the translatome; analyses on these genes categories led us to identify the contribution of 
translational control mechanisms within p53 responses, considering that p53 does not 
modulate these genes in transcription. Interestingly, when we looked at uncoupled genes 
enhanced in the translatome that did not change in the transcriptome, gene ontology revealed 
enrichment for the term ‘apoptosis’ upon both treatments. Selected genes were validated by 
qPCR; PHPT1 protein increase was also checked by Western Blot analysis (Figure 2 in the 
accompanying paper 1). This suggests that enhanced translation of these uncoupled genes 
might reinforce the apoptotic phenotype, a process that could be important given the generally 
weaker transcriptional control of p53 targets involved in apoptosis.  
Seeking mechanisms controlling the translation of these genes, we identified that a number of 
RBP genes were regulated by either Doxorubicin (67 RBPs) or Nutlin-3a (30 RBPs) or were 
common to both treatments (22 RBPs). Beside the well-known miRNAs role, these 22RBPs can 
be considered primary candidates modulators of the p53-directed translational control. In this 
part of the project, the p53-dependent expression of selected RBPs was validated; we 
confirmed YBX1, SRSF1, DDX17, TARDBP, HNRNPD and CPEB4 as targets (Figure 6 in the 
accompanying paper 1). More specifically, HNRNPD and CPEB4 were proposed as direct p53 
targets, considering their modulation not only at the polysomal levels, but also at transcriptional 
level, as suggested by previously published ChIP-seq data (Figure 5 in the attached paper 1). 
Through their modulation, p53 may impact on its functions, either by acting on the p53 mRNA 
or on the mRNAs of its target genes. In particular, HNRNPD (also known as AUF1) is a member 
of the best characterized family of cis-acting mRNA stability determinants which bind 
adenylate/uridylate-rich elements (AU-rich elements or AREs) frequently contained within the 
3-UTRs of mRNAs encoding cytokines or proto-oncogenes. In general, the presence of an ARE 
accelerates mRNA turnover [80]. Specifically, HNRNPD promotes transcripts decay though the 
downstream recruitment of the mRNA decay machinery [80]. Ample opportunity exists for 
combinatorial as well as competitive relationships among HNRNPD and other ARE-binding 
proteins on specific ARE target sites. For instance, HuR and HNRNPD can compete with each 
other for binding to the same AU-rich elements on specific target mRNAs, with an opposite 
influence [54]. For instance, HuR stabilizes while HNRNPD destabilizes BAX mRNA. In view of 
several reports, we propose that the p53-dependent HNRNPD down-regulation may promote 
 C
h
a
p
te
r:
 
R
E
S
U
L
T
S
 
2
 0
 
the mRNA stability of p53, BAX and other important cancer genes, acting in a reciprocal relation 
with HuR.  
Vice versa, CPEB4 resulted up-regulated. It is one of the four members in the CPEB-family of 
proteins which bind cytoplasmic polyadenilation element (CPE) in the 3’UTR, thus regulating the 
length of the poly(A) tail and therefore the recruitment of 3’ poly(A) tail-binding protein (PABP) 
and the pseudo-circularization of the mRNA [81]. These proteins may mediate both translation 
activation and repression according to selected factors, such as their abundance, the 
arrangement of CPEs sites in the 3’UTR. CPEB1 and CPEB4 have partially redundant functions as 
suggested by previous studies on the poly(A) tail length of mRNAs encoding mitotic factors [82]. 
CPEB1 has been studied more in detail; recent reports suggest that CPEB1 controls the 
polyadenylation-induced translation of p53 mRNA, and thus its mRNA stability [83]. We 
hypothesize that, as its functionally-related CPEB1 family member, the p53-dependent up-
regulation of CPEB4 could influence p53 translation fitness at its own mRNA level.  
 
At the same time, genes involved in mRNA processing and nucleotide binding resulted 
translationally down-regulated at the polysomal and sub-polysomal level. Thus, our analyses 
focused on the validation of RBPs annotated to this ontology category. DDX17, TARDBP, SRSF1 
and YBX1 mRNAs were confirmed as modulated at the translational level by qPCR. Overall, in 
almost all the analyses, protein levels reflect the translatome changes, suggesting that these 
mRNA variations could have a significant impact on the final proteome (Figure 3 and 4 of the 
attached paper 1). Nevertheless, when the same validation experiments were performed at an 
earlier time point (8hours), temporal differences upon Doxorubicin and Nutlin-3a treatments 
were found. Indeed, p53 levels and activity may vary over time after the treatments, thus 
affecting the expression levels of its targets, as previously reported.  
DDX17 (also known as p72) is a putative RNA helicase that by interacting with DDX5 (p68) can 
act as a modulator of p53-dependent transcription [84]. Moreover, p72 is also required for 
recognition of a subset of primary miRNAs in Drosha-mediated processing: p72 knockdown 
abolishes the increase of these selected miRNAs at the precursor and mature levels upon p53 
activation, indicating that p72 is essential for the post-transcriptional up-regulation of several 
p53 targets miRNAs [74]. Thus, p53-dependent modulation of p72 may impact not only on its 
own transcriptional activity, but also on its ability to regulate miRNAs processing.  
SRSF1, also known as alternative splicing factor 1 (ASF1), is the prototypical member of the SR 
protein family, a conserved class of splicing regulators. Besides its central roles in constitutive 
and alternative splicing, SRSF1 regulates other aspects of RNA metabolism, including mRNA 
stability, nuclear export, nonsense-mediated mRNA decay, translation, and miRNA processing. 
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The depletion of the protein triggers genomic instability, cell-cycle arrest, and apoptosis [85]. 
According to recent reports, SRSF1 binds RPL5-MDM2 [86]. Being thus involved in the p53 
stabilization process, its p53-dependent modulation would represent an additional auto-
regulatory mechanism to control p53 levels.  
 
We explored in more detail two mechanisms linking p53 activation with YBX1 mRNA and protein 
down-regulation, namely the inhibition of the mTOR pathway and the up-regulation of miR-34a 
(Figure 4 of the attached paper 1). Being YBX1 a 5’-terminal oligo-pyrimidine tract-like mRNA, 
and thus, modulated by mTOR, we examined that the p53-dependent mTOR inhibition had an 
indirect effect on YBX1 translation. Moreover, on YBX1 3’UTR we found a binding site of one of 
the main and well-known miRNA target of p53, miR-34a; through its binding, miRNA-34a 
contributed to YBX1 mRNA down-regulation. Although we validated two independent 
mechanisms influencing YBX1 translational modulation, we don’t exclude the presence of 
additional ones, participating to the eventual mRNA control.  
YBX1 has been shown to be a multitasking protein with many functions including the regulation 
of both transcription and translation of several genes implicated in cell survival, DNA replication 
and repair, drug resistance and epithelial-mesenchymal transition [87]. Moreover, YBX1 is an 
IRES trans-acting factors implicated in the cap-independent translation initiation mechanism 
[46][65]. Thus, p53-dependent down-regulation of YBX1 may determine a reduction in the cap-
independent translation of specific genes.  
 
Preliminary results to clarify the specific impact of these RBPs on translational regulation after 
p53 activation were also obtained. We chose SRSF1 and YBX1 to explore these potential 
regulatory effects by a siRNA approach, as they both control cell proliferation, cell-cycle 
progression and apoptosis. More specifically, both RBPs have been independently associated to 
c-MYC translation. In our experiments, SRSF1 silencing led to a decrease also in YBX1 protein 
levels, suggesting a cross-talk between the two RBPs via unexplored mechanisms, and this 
resulted in a down-modulation of c-MYC. Hence, we suggested that p53-dependent negative 
regulation of both YBX1 and SRSF1, could lead to an even more robust repression of c-MYC. 
Besides their modulatory effect on c-MYC, both RBPs have been implicated in several aspects of 
cancer progression. In particular, from a clinic prospective, YBX1 has also been associated to 
patient prognosis: its protein levels are elevated in more aggressive tumors and strongly 
associated with poor disease-free survival and distant metastasis-free survival [88].  
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I contributed since the beginning to the project starting from the sample’s collection to the 
microarray hybridization. I realized most of the data analysis process in order to identify each 
DEGs group. After performing pathways and ontologies analyses, I moved on to the validation 
experiments with the aim of investigating p53-dependent RBPs’ modulation more in detail. 
Then, thanks to the AURA2 database and reagents available through an independent project in 
the lab, I focused my analysis on the translation control of YBX1 mRNA. Finally, I co-wrote the 
attached Paper 1. 
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4.2. Cell type-specific translatome profiling upon 
Nutlin-3A treatment 
The previous study constituted the backbone for a larger project that is still ongoing, which I 
developed thanks to a collaboration with the Espinosa lab at UC Boulder, Colorado.  
As mentioned before, p53 activation may offer a “smart” and effective therapeutic strategy. 
However, for clinical utility, the challenge is to be able to direct the outcome of p53-activation 
towards the induction of apoptosis, given that p53-activation can also result in robust cell cycle 
arrest, which in this context is much less desirable as it could provide for tumor resistance. This 
issue is exemplified by the observation that treating a panel of cancer cell lines with Nutlin-3a 
results in variable responses from overt cell cycle arrest, to massive apoptosis, to intermediate 
phenotypes. What is dictating these differences in responses and how will it be possible to shift 
the balance towards the apoptotic phenotype, thus reducing the probability of cell-cycle arrest 
choice [38]? Is the p53-dependent transcriptional network different among cell lines treated 
with Nutlin-3a that undergo cell cycle arrest versus apoptosis, namely are the p53 target genes 
that promote apoptosis less responsive in some cell lines? Is the outcome due to p53-
independent factors, such as the levels or activity of survival proteins? Initial reports suggested 
that Nutlin-3A treatment determines mainly the cell-cycle arrest phenotype, an undesirable 
outcome in cancer therapy, and that MDM2 amplification was the main factor determining cells 
susceptibility to Nutlin-3-induced apoptosis [22]. On the contrary, nude mice bearing xenografts 
established from cells with normal MDM2 levels showed a reduction in the median tumor 
volume as in cells with MDM2 amplification, suggesting that, beyond MDM2, additional factors 
may be involved [4]. 
Given our finding that apoptotic genes appear to be controlled also at the level of translation 
efficiency, we decided to explore whether mRNA translational control mechanisms are indeed 
an additional checkpoint to the phenotype that can be variably active in different cell lines 
contributing to the licensing of the apoptotic response. Hence, we chose three cell lines 
(HCT116, SJSA1 and MCF7), confirmed their specific response to the treatment with Nutlin-3a 
(cell-cycle arrest, apoptosis and an intermediate phenotype between the two, respectively), and 
examined transcriptome as well as translatome changes using RNA-seq. With these datasets we 
were in the position to ask the extent by which the transcriptome of the three cell lines differ, 
to compare the subset of mRNAs that are Nutlin-3a induced or repressed both at transcriptional 
and translational levels, but also potentially identify mRNAs undergoing treatment-induced, 
cell-line selective changes in translation efficiency.  
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Figure 7:  Polysomal profiles upon DMSO or Nutlin-3A treatment in the three cell lines. 
a. Coupled genes are necessary but not sufficient to shape the 
phenotype. 
Because of its promising pre-clinical results [33][22], we selected the MDM2 inhibitor Nutlin-3a 
as p53 stimuli, while HCT116, SJSA1 and MCF7 were chosen as model cell lines. Indeed, these 
exhibit different cellular responses (cell cycle arrest, apoptosis, or both, respectively) to Nutlin-
3A upon 24 and 48 hours treatment [4]. Being an earlier time point a better window to observe 
the mechanisms causing these phenotypes, we performed our analyses upon 12 hours 
treatment, with the goal to capture factors implicated in phenotypic choices implicated in the 
cell cycle choices. Moreover, at this time point, p53 stabilization and activity on its targets was 
previously described in all the three cell lines [89]. A graphical workflow of the experiment is 
presented in Figure 8A. Briefly, we collected total and cytoplasmic RNA, the latter was 
separated on a sucrose gradient and then fractionated in order to recover the fraction of 
mRNAs associated with polysomes (considered as actively translated mRNAs) from those that 
are not (un-translated mRNAs) [90]. Polysomal profiles showed a low variation between control 
and Nutlin-3A samples, indicating small changes in global translational rates (Figure 7). While a 
small increase in the proportion of 80S to polysomes was apparent, the treatment had a similar 
impact at this level of analysis in the three cell lines. The slight reduction in absorbance of the 
polysomal fractions values may be due to a p53-dependent inhibition of the mTOR pathway 
[91].   
Following high-throughput sequencing of poly-A+ selected RNA libraries, we firstly analyzed 
coupled genes. Being transcribed and then translated upon p53 activation, these may embody 
“direct-functional targets” better than genes identified only by a classical transcriptomic 
analysis. Notably, while HCT116 and MCF7 cells displayed a similar number of coupled genes, 
there were fewer in SJSA1 cells: compared to the other two cell lines, a nearly ≈50% reduction 
in the proportion of coupled DEGs was observed (Figure 8B). Thus, more pervasive translational 
control mechanisms could be envisioned in SJSA1 cells that could control the output of “direct-
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functional genes” and the related apoptotic phenotype. Among coupled genes, only 33 up-
regulated and 79 down-regulated genes were in common among the three cell lines (Figure 8C). 
These genes numbers were smaller compared to those revealed by analyses of the 
transcriptomes alone –around 40% of common genes-, suggesting that several targets which are 
commonly modulated at their total mRNA levels are then differently controlled at the 
translational level: the translatome acts as a filter defining which genes, previously selected by 
transcription, need to be translated. Taking into account the translatome status for 
transcriptionally modulated mRNAs, we further analyze common coupled genes. In principle, if 
p53 transcriptional selectivity defines the outcome, well-known p53 targets with regulatory 
functions only in one phenotype should be differentially expressed across the cell lines. For 
instance, in HCT116 cells, cell-cycle arrest inducers such as p21, GADD45 and 14-3-3σ should be 
expressed and induced at higher level than in SJSA1 cells; vice versa, apoptotic triggers such as 
BBC3, BAX and KILLER might be more abundant to start with and should be more differentially 
expressed in SJSA1 than in HCT116 cells. Results are presented in Figure 8D, where both the 
level of treatment-dependent induction and the normalized level of expression in the 
polysomes (RPKM) are reported: all well-known p53 targets listed above were included in the 33 
coupled genes; in other words, these were common across all cell lines independently from the 
Figure 8: Coupled differentially expressed genes. A. Schematic workflow. B. Percentage of coupled 
and uncoupled DEGs in the three cell lines. C. Overlap among coupled DEGs across the three cell 
lines. D. Scatter plots comparing log2FC values of the total and polysomal fractions for coupled 
DEGs. Dots dimension is proportional to RPKM values in the polysomal fraction after Nutlin-3A 
treatment. Red circles = apoptotic genes; Blue circles = arrest genes. 
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Figure 9: Uncoupled polysomal genes upon p53 induction. A. Log2FC distribution of the genes in all 
the three cell lines. * = p-value <0.5;   B. Overlap among uncoupled DEGs with enhanced translation. 
For each category enriched pathways are reported; C. Overlap among uncoupled DEGs with reduced 
translation level and corresponding enriched pathway. 
phenotype they are known to display (Figure 8D). Additionally, even their expression levels in 
the polysomal fraction were comparable, suggesting thus their constitutive induction upon p53 
activation, independently from the cellular outcome. Taken together, these data strongly 
support the hypothesis that coupled genes cannot justify the difference in the observed 
phenotypes by themselves. In other words, transcriptional selectivity by itself, although present, 
does not seem to explain the different cellular responses to Nutlin-3a treatment.  
b. Uncoupled polysomal genes are different across cell lines 
Besides coupled genes, we proceeded to identify uncoupled genes showing a significant 
increase or decrease in their polysomal level, namely genes with enhanced or reduced 
translation, respectively. First of all, we checked whether the treatment affected their fold 
change distribution. Excluding some outliers genes in MCF7 cells, uncoupled polysomal genes 
have comparable up- and down-regulation levels across all the three cell lines (Figure 9A). 
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Despite this similarity, none of the genes enhanced in translation was in common among the 
three cell lines and only two genes were commonly reduced in their translation rates (Figure 9B-
9C). Along with the lack of overlap, the pathway analysis [92] revealed different genetic 
signatures across the cell lines. Notably, in SJSA1 cells uncoupled genes exhibiting enhanced 
translation efficiency were more enriched for the apoptotic signature pathway. Given that, and 
bearing in mind the apoptotic phenotype of these cells, we can suggest that this outcome may 
be regulated also at the translational level. This brought us to the interesting question of what 
determines the translation selectivity of these genes, in spite of the apparent absence of 
transcriptional selectivity.   
 
c.  SJSA1 uncoupled translated mRNAs are enriched for a C-rich 
motif in their 3’UTRs. 
Given the lack of overlap among uncoupled genes enhanced in translation, the three cell lines 
may have different translational tools, namely trans-factors acting on cis-elements, actively 
influencing the translation of different genes. To test this hypothesis, we further investigated 
the existence of enriched sequence motifs in the 5’ and 3’UTRs of all gene categories by means 
of Weeder [93]. Employing the longest 5’ or 3’UTR of each gene, we looked for motifs with a 
length ranging from 6 to 12nt and found in at least 25% of all sequences. When comparing 
results for each category, a motif with a “TGTAC” consensus was found as enriched among 
uncoupled, translated genes in HCT116 cells. Nevertheless, this motif was also present both in 
genes with reduced translation rates of the same cell line and of SJSA1 cells, and, thus, couldn’t 
be considered as a selective feature (Figure 10). On the contrary, a C-rich motif (consensus 
TGGCCCCCATGGCCT) was found as enriched in the 3’UTRs selectively of SJSA1 uncoupled 
translated genes (Figure 10A). Merging all genes list that strongly support the presence of at 
least one C-rich motif in their 3’UTRs (numbered as n°2, n°5, n°8, n°7), we obtained a final list of 
194 out of the 296 translated genes which have at least one instance of this motif in their 
3’UTRs, denoting a widespread distribution. None of the other 5’ or 3’UTRs categories of 
coupled or uncoupled genes carried this motif, not even in the other cell lines; only a minority of 
translated genes in MCF7 cells - 24 out of 218 of which only one, namely FOSL2, is also an 
uncoupled translated gene in SJSA1 cells - carried this motif. Moreover, we found an 
enrichment for the “regulation of apoptosis” gene ontology term (p-value of 4.2E-2) on the 194 
genes carrying the motif that are significantly up-regulated in the translatome only in SJSA1 
cells, suggesting a correlation between these regulated genes and the final phenotype (Table1).  
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Figure 10: Motif discovery analysis suggested by Weeder. A. Alignment of motifs enriched in the 
3’UTRs of uncoupled DEGs enhanced in translation. B. Alignment of motifs enriched in the 3’UTRs of 
uncoupled DEGs with reduced translation. Motifs are numbered in the “motif” column according to 
the order in which they were presented by Weeder. The “genes” column lists the number of genes 
harboring the reported motif at least once. Common nucleotides patterns across the motifs are 
highlighted by different colors.  
Table 1: Gene Ontology 
Analysis. GO terms enriched in 
the 194 genes carrying at least 
one copy of the C-rich motif in 
their 3’UTRs.  
Collectively, we hypothesized a role of this C-rich motif in enhancing the translation of 
uncoupled translated genes only in SJSA1 cells, thus contributing to define the observed 
phenotype.  
Gene Ontology Term Genes p-value 
Nucleotide binding 36 2.7E-2 
Protein transport 15 5.0E-2 
Regulation of apoptosis 15 4.2E-2 
G1/S checkpoint 4 6.5E-3 
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d.  The C-rich motif is functional only in SJSA1 cells treated with 
Nutlin-3A. 
We are currently performing experiments to identify the role of the C-rich motif: preliminary 
data will be presented in this paragraph. 
Firstly, selected translated genes of SJSA1 cells, harboring at least one instance of the C-rich 
motif in their 3’UTR, were validated by qPCR (Figure 11A). Indeed, those genes were up-
regulated only in the polysomal mRNA fraction compared to total mRNA upon Nutlin-3A 
treatment, and in SJSA1 cells only, thus confirming the cell line selective, treatment-dependent 
translational uncoupling. Genes were selected for validation because of their higher level of 
induction in the polysomal mRNA fraction upon Nutlin-3A according to their log2 fold changes 
and corrected p-values level. Considered as a proxy of the proteome [90], mRNAs levels in the 
polysomal fraction may reflect proteins’ expression: thus, EIF5A and BAK1 –two known 
apoptotic targets- up-regulation at the polysomal level was confirmed, by means of Western 
Blot, to be mirrored in protein levels upon Nutlin-3A treatment, once again in SJSA1 cells only 
(Figure 11B).  
 
Figure 11: Validation experiments for selected genes harboring a C-rich motif in their 3-UTRs. A. 
mRNA expression levels in total (tot), sub-polysomal (sub) and polysomal (pol) fractions. qPCR results 
are presented as fold of induction (∆∆Cq) upon 12hours of Nutlin-3A treatments in the three cell lines. 
Log2 Fold Change values (log2FC) obtained by RNAseq in SJSA1 cells are reported.  B. EIF5A and BAK1 
were validated also at protein level by Western Blot analysis. α-actinin was used as reference gene. 
Numbers report the band quantification values after normalization with actinin levels and DMSO level 
in each cell line.     
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Figure 12: C-rich motif in the 3’UTR. A. Relative position of the C-rich motifs along the 3’UTR. Motifs 
numbers resulted from Weeder (see Figure 9). B. Relative luciferase values upon transfection of the β-
actin 3’UTR and Nutlin-3A treatment in its wild-type form (no motif), with the motif in at least one 
position (at the beginning/at the end), with two motifs (2xmotif). Results are presented for the three 
cell lines upon 12h or 24h of Nutlin-3A treatment (Nutlin-3A/DMSO values). ** = p-value< 0.01; * = p-
value<0.05. 
Is the C-rich motif in their 3’UTR responsible for the enhanced mRNA translation efficiency and 
the increase in protein levels? To answer this question, we are currently analyzing whether the 
C-rich motif can ectopically influence mRNA translation and if mutations in the motif sequence 
can inhibit or abolish this enhancement of translation in response to Nutlin-3A treatment. For 
these experiments, we tested the “TGGCCCCCATGGCCT” motif consensus in a luciferase system; 
in details, we cloned the motif in the 3’UTR of the β-actin reference gene lacking any C-rich 
motif. Given the absence of any positional preference for the C-rich motif along the 3’UTRs of 
the SJSA1 uncoupled mRNAs (Figure 12A), the motif was inserted both at the beginning and at 
the end of the β-actin 3’UTR. When these C-rich β-actin 3’UTRs were tested in SJSA1 cells, the 
relative luciferase activity was increased upon Nutlin-3A treatment, compared to the levels 
obtained with the reporter vector containing the wild-type β-actin 3’UTR (Figure 12B). The 
activity was even higher when two motifs, one at the 5’- the other at the 3’ of the UTR, were 
present, especially upon 24 hours of Nutlin-3A treatment. Interestingly, when the same 
experiments were performed in the other two cell lines, we didn’t obtain the same increase. 
This latter finding suggests that the C-rich motif is necessary but not sufficient for the observed 
effects: a trans-factor, such as an RBP, likely differentially expressed in SJSA1 cells with respect 
to the other cell lines, may be needed to mediate its regulatory role. Additional analyses are 
currently ongoing (see Discussion).   
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e. My contributions 
The project started as a collaboration with the Espinosa Lab at the University of Colorado 
Boulder where I spent my period abroad from January 2014 to September 2014. While Matthew 
Galbraith (University of Colorado Boulder) started the analysis of the total RNA-seq data, I 
performed samples collection for the translatome analysis. Then, after completing all libraries 
preparation, I set up the machine to sequence polysomal samples and then I analyzed all the 
results; the motif analysis was performed with the collaboration of Erik Dassi (CIBIO). Since my 
return in the Inga Lab, I’m working on all the validation experiments.  
 
 
f. Materials and methods 
 
Cell lines and culture condition: HCT116 and SJSA1 were maintained in RPMI (Gibco) and MCF7 
in DMEM, both supplemented with 10% FBS, antibiotics (100 units/mL penicillin plus 100 mg/mL 
streptomycin) and 2mM L-glutamine. After seeding in 10cm tissue culture dishes and allowed to 
reach 70-80% of confluence, cells were treated with 10µM Nutlin-3A (Alexis Biochemicals). After 
12 hours, polysomal separation was performed as previously described [94]. Three biological 
samples were analyzed. Concentration, purity and integrity were measured with the Agilent 
2100 Bioanalyzer (Agilent Technologies) discarding RNA preparations with RIN (RNA integrity 
number) value <8. 
Library preparation and data analysis: PolyA+ mRNA isolation was performed using the 
Dynabeads mRNA DIRECT Micro kit (Life Technologies) following the “mRNA isolation from 
purified total RNA” protocol and using 15µg of RNA as input. Then, we proceeded to the library 
preparation according to the Ion Total RNA-Seq Kit instructions. As indicated, we assigned the 
quality and efficiency of each preparation step using the Agilent RNA 6000 Pico kit with Agilent 
2100 Bioanalyzer instrument. After that, each library template was clonally amplified on Ion 
Sphere Particles for sequencing on the Ion Proton System, producing ≈60-80 M raw reads per 
sample. After quality filtering and trimming (minimum read length: 30nt; maximum read length: 
150nt) by FASTX-Toolkit, mapping to the hg19 build of the human genome (February 2009 
GRCh37, NCBI Build 37.1) was performed using GSNAP [95]. Mapping parameters allowed for 
0.03% mismatches. To compute the per-gene reads counts, we used HTSeq [96]. We chose the 
intersection non-empty mode with reads overlapping more than one exonic feature. DESeq R 
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package [97] was used to call Differentially Expressed Genes (DEGs) starting from two replicates 
for each condition. For all analyses on DEGs, two thresholds were set: (1) log2FC >1 and <1 for 
up-regulated and down-regulated genes, respectively; (2) FDR-corrected p-value <0.1. 
Gene ontology and pathway analysis of DEGs: Pathways enrichment analysis for all our 
selected categories of coupled or uncoupled DEGs was performed with ingenuity pathway 
analysis (www.ingenuity.com). Only direct interactions were considered in setting parameters. 
Motif discovery analysis: To search for common sequence motifs in each category of coupled or 
uncoupled DEGs, we used the Weeder tool, setting the following parameters: (1) longest 5’ or 
3’UTR of each gene as input, (2) motifs had to be found in at least 25% of all input sequences, 
(3) the motif could have a length ranging from 6 to 12nt. When the analyses were completed, 
the “adviser” program was started to select the best motifs, especially according to their 
redundancy [93] .  
Cloning strategy and luciferase assay: Full-length β-actin 3’-UTR, β-actin 3’-UTR with the 
addition of a C-rich motif at the 3’UTR beginning or at the 3’UTR end or both, were cloned at the 
luciferase end of a pGL4.13 vector using XbaI as restriction enzyme. Dual-luciferase reporter 
assay was done according to the manufacturer’s instructions (Promega). Briefly, cells were 
plated on a 24-well plate, and then transfected with control pGL4.13 reporter vector or the 
same vector containing the different 3’UTRs, and a Renilla luciferase vector. After 24h, cells 
were treated with DMSO or Nutlin-3A. Luciferase activity was measured on triplicate wells using 
Infinite 200 PRO microplate reader (TECAN) 12 or 24 h post-treatment. 
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5. DISCUSSION 
We described translational control as an additional dimension shaping the p53-directed gene 
response. While lots of efforts have been devoted to study p53-dependent transcriptional 
modulation, we aimed at investigating the less known translational control, using polysomal 
profiling and thus focusing on relative changes in mRNA loading on polysomes as a proxy to 
investigate changes at protein levels, closer to the phenotype. At the same time, we did not aim 
to quantify the proteins amounts upon p53 induction, but rather to determine the translational 
state of p53 target mRNAs and the mechanisms by which those mRNAs are/aren’t driven to 
translation. Indeed, proteomic approaches allow to characterize proteins in a particular context 
although many technological challenges still remain (reproducibility or sensitivity levels, still 
lower than those from a classical transcriptomic analysis), especially if one needs to quantify 
changes across conditions rather than just determine whether a protein is produced or not 
[98][99]. For instance, when iTRAQ analysis was performed to investigate Nutlin-3A changes at 
proteomic levels and at different time points, full coverage of the proteome was not possible, 
and MDM2 binding proteins such as p53 and E2F1 were not quantified [100]. Besides all 
technical issues, relative protein quantification is not instrumental in defining the mechanisms 
behind the choice to translate a particular mRNA. To this purpose, we opted for a polysomal 
profiling approach, a method allowing to characterize the translatome and thus we can 
distinguish actively translated mRNAs from non-actively translated ones [90]; in other words, 
we can determine the mRNAs fate in the cytoplasm to elucidate mechanisms behind the choice 
to translate obtaining an indirect estimate of proteome changes at the same time. Additionally, 
considering the possibility to analyze those mRNAs by means of high-throughput technologies, 
sensitivity and reproducibility levels remain similar to a classic transcriptomic analysis.   
Firstly, a translatome study upon p53 activation by two stimuli, Doxorubicin and Nutlin-3A, was 
performed; we selected drugs and time conditions by which our cell model (MCF7 cells) would 
show a mild phenotype, similar between treatments. Indeed, after 16 hours of sub-toxic doses 
of Nutlin-3A and Doxorubicin, MCF7 cells exhibit a similar viability level associated to low 
apoptotic rates. In summary, by our analysis we demonstrated that translation control 
mechanisms define transcripts’ fate upon p53 induction by both stimuli. Indeed, besides a good 
overall correlation between transcription and translation rate changes, a considerable level of 
uncoupled mRNAs was found. Interestingly, apoptotic genes were enriched among the group of 
uncoupled mRNAs exhibiting enhanced translation in response to the treatments. Given the 
absence of a significant transcriptional modulation, those mRNAs might be considered indirect 
p53 targets, controlled at the translational level in order to synthesize the right amount of pro-
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phenotype proteins. In general, apoptotic genes have been already characterized to be heavily 
regulated, not only by selective p53 cofactors and specific post-translational modifications of its 
protein, but also at their promoter level where a selection pressure exists at the binding site 
level to limit the intrinsic potential of p53 to bind [101]. In this scenario, the translational 
control of apoptotic genes is an additional level to modulate, once again, the irreversible 
decision to the programmed cell-death fate.  
Influenced by temporal differences in p53 stabilization upon treatment, also these mechanisms 
of control showed changes with time, as suggested by our data at an earlier time point (8 
hours): several validated targets were confirmed at both time points, while others were not.  
The even more significant involvement of translated mRNAs in the apoptotic phenotype for cells 
treated with Nutlin-3A led us to the interesting question of what determines their translation 
rates. Indeed, understanding this mechanism may improve our knowledge on how a cell decides 
whether or not to die in response to p53 activation. To further investigate on this aspect, we 
decided to perform a second translatome study, employing a panel of cell lines exhibiting 
different cellular responses to Nutlin-3A [4]. What determines the apoptotic choice instead of 
the cell cycle arrest one upon Nutlin-3A treatment in different cell lines? Are the mechanisms 
controlling mRNAs translation different? A previous study already pointed out the existence of 
several and mostly un-known pro-cell cycle arrest factors, including but not limited to 14-3-3, 
miRNA-34a and p21; in particular, dying cells required a progressive suppression of p21 at 
translational level -p21 gene resulted transcriptionally activated to similar extent in apoptotic or 
not-apoptotic cells [89]-. Since we decided to investigate an early time point, canonical p53 
targets such as p21 didn’t show differences in their transcriptional/translational expression 
rates in cells undergoing apoptosis with respect to HCT116 cells (Nutlin-3A-induced cell-cycle 
arrest phenotype). In other words, this result suggests that canonical and well-known p53 direct 
targets cannot completely explain the difference in the phenotype. Instead, we can determine 
all those additional and still un-known factors involved in defining the phenotype from an 
earlier time of the signal transduction. Indeed, our preliminary results suggest that cells 
undergoing cell death choice have indirect p53 targets involved in the apoptotic pathway, not 
significantly translated in cells exhibiting a cell-cycle arrest phenotype. The enrichment of this 
pathway is even higher than what we found in MCF7 cells, confirmed to have a milder 
phenotype that is a combination between cell-cycle arrest and apoptosis, according to our first 
experimental data. 
A large majority of these indirect p53 targets appear to share a redundant C-rich motif in their 
3’UTR. At this site, the binding of several RBPs may be envisioned, thus contributing to define 
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the translation rates of bound transcripts. Although their translational role is considered even 
more complex and broader than the miRNAs one [49], RBPs involvement in p53 response and 
the identification of the complete mechanisms by which p53 controls their expression remains 
to be investigated. In our study, we confirmed HNRNPD and CPEB4 as targets of a p53-
dependent modulation at the total mRNA. These RBPs can be added to the small list of already 
known RBPs targets of p53 - RNPC1, Quaking (QKI), PCBP4 [67]. Moreover, we validated YBX1, 
SRSF1, DDX17, and TARDBP as indirect p53-targets. For these second RBPs category, their 
translational modulation is not a direct consequence of p53 induction; several upstream factors 
which may or may not be p53 targets cause their changes in translation upon treatment. For 
instance, we investigated more in detail upstream factors involved in YBX1 translational down-
regulation: the inhibition of the mTOR pathway and the up-regulation of miR-34a. These results 
suggest the presence of a p53-dependent regulon made at least by YBX1 mRNA, mTOR factors 
and the miR-34a, contributing to the specific stage of YBX1 mRNA translation. Although we 
validated two independent mechanisms influencing YBX1 translational modulation, we don’t 
exclude the presence of additional ones, participating to the final mRNA control. At the same 
time, we cannot exclude a p53-dependent/independent recombination of all these factors 
during the lifetime of the YBX1 transcript from its transcription to the final translation.   
Mechanisms by which the other identified RBPs are modulated remain to be studied, as well as 
further investigations are needed to clarify their specific impact on the phenotype: which are 
their specific targets? Are those RBPs cooperating with each other in combinatorial fashion to 
determine their and their mutual targets’ translation rates?  
Considering what is already known about the RBPs that we identified as direct/indirect p53 
targets, none of those show binding the C-rich motif that is enriched in mRNAs exhibiting 
enhanced translation in SJSA1 cells undergoing Nutlin-3a dependent apoptosis. Nevertheless, 
PCBP family members (poly-C binding proteins) are our primary candidates: first of all, they are 
known to bind poly-C elements [102]; moreover, in our RNA-seq data, they show different 
expression levels among the analyzed cell lines; hnRNPK, PCBP1, PCBP2, PCBP3 and PCBP4 are 
all members of this family. Besides the shared structure and origins [102], they have been 
studied in different context: hnRNPK mainly as a transcription co-factor [103][104], while 
PCBP1, PCBP2 and PCBP4 also as translational modulators, especially influencing poly(A) 
processing sites [102][105]. In particular, PCBP4 has been reported to regulate p21 in a p53-
independent manner, although transcription from the PCBP4 locus can be induced by DNA 
damage in a p53-dependent manner [76]. Ongoing studies will further elucidate whether these 
factors contribute to the translation of apoptotic genes and which of them is more prominent. 
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In any case, we hypothesize that the direct/indirect modulation of one or more of these RBPs 
upon Nutlin-3A may change the translational fate of more than one target at once, potentially 
more than 140 translated genes in cells undergoing apoptosis containing the C-rich motif. If this 
is true, this small RBPs family may be considered as factors contributing to determine the 
apoptotic response to Nutlin-3A and, at the same time, to avoid the less desired cell-cycle arrest 
phenotype. Thus, their modulation may be envisioned as a new therapeutic approach in 
combination with Nutlin-3A.  
Besides the hypothesized impact on translational control, we cannot exclude the involvement of 
a divergent transcriptional program in defining cell fate choices. Indeed, data obtained by 
analyzing total mRNA differences upon treatment suggests that only 40% of genes are 
commonly differentially induced upon treatment in all cell lines. This dissimilarity may be due to 
the different tissue derivation of our cell lines and to the presence of a different transcriptional 
landscape. In other words, the potential for combined activation of transcription factors, 
generating transcriptional cooperation – e.g. p53 and ER, p53 and NFκB – may lead to different 
starting combinations of expressed genes associated to the final response. In our hypothesis, 
translational control is a filter for transcriptional modulation and a rapid way of tuning gene 
expression through protein synthesis regulation. 
Further aspects may make the scenario even more complicated: studies on the p53 protein gave 
rise to the idea that its isoforms and/or post-translational modifications may influence the 
apoptotic phenotype as well; indeed, according to the “Barcode Hypothesis”, different p53 
protein products arising by alternative promoter usage and alternative splicing may be involved 
considering their divergent transcriptional selectivity [106][37]. Concerning post-translation 
modifications, phosphorylation of Ser6, -15, -20, -37, -46 and -392 are suggested as dispensable 
for p53-dependent apoptosis, comparing cells treated with Nutlin-3A versus other DNA 
damaging agents [30][37]. Implications of these aspects for the apoptotic response are not 
considered by our analyses.  
 
In summary, selectivity at the level of mRNAs translation, in addition to transcriptional 
selectivity, may be considered a critical determinant in shaping the p53-directed apoptotic 
response. In this scenario, RBPs that are direct/indirect p53 targets represent relevant 
contributing factors, strictly implicated in these mRNAs translation.  
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6. APPENDIX a 
During my PhD, I collaborated to a project focused on the cooperative interaction between two 
transcription factors, p53 and NFκB.  
Indeed, cellular responses to changes in the microenvironment require coordinated activation 
of different sequence-specific transcription factors, among which NFκB and p53 have a 
prominent role and often opposing functions. While, the canonical functions of p53 and NFκB 
are consistent with the co-occurrence of p53 inactivation and NFκB hyper-activation that is 
frequent in cancer, recent studies provided examples of positive cooperation between p53 and 
NFκB that would occur in specific cell types, such as antigen presenting cells or macrophages, 
and contribute to physiological responses, such as for example in the process of innate 
immunity and inflammation. Thus, the functional interaction between p53 and NFκB remains an 
open question. To investigate more globally the transcriptional crosstalk between these two 
factors we performed a proof of concept study using breast cancer-derived MCF7 cells treated 
with Doxorubicin, Tumor Necrosis Factor alpha (TNFα) and a combination of the two 
compounds (Doxo+TNFα). Our results demonstrated a synergistic interaction between p53 and 
NFκB transcription factors, which can lead to the reprogramming of cell fate and enhanced 
migratory potential. Seven genes (PLK3, LAMP3, ETV7, UNC5B, NTN1, DUSP5, SNAI1) were 
established as synergistically up-regulated after Doxo+TNFα and dependent both on p53 and 
NFκB. A 29 genes signature of highly synergistic genes up-regulated by Doxo+TNFα appeared to 
have prognostic value in a cohort of luminal breast cancer patients. 
All project results were published (see the attached paper 2 by Bisio et al.). 
I contributed to this work analyzing the microarray data, identifying the list of differentially 
expressed genes (DEGs) after single or combined treatment. For those genes, I performed 
functional analysis by means of DAVID, seeking for most significant gene ontology terms of 
down- or up-regulated DEGs, thus, confirming apoptosis induction as the most significantly 
enriched GO terms among up-regulated DEGs, while TNFα treatment resulted in gene 
annotation terms consistent with NFκB activation. By IPA analysis, I investigated the presence of 
predicted upstream regulators of the DEGs for the indicated treatments (Doxorubicin, TNFα, 
Doxorubicin and TNFα), confirming TP53 as an upstream regulator. Interestingly, this TP53 
enrichment was less significant in the double treatment compared to the Doxorubicin single 
treatment. In a similar manner, I analyzed the DEGs that were synergistically regulated by the 
double treatment. I also contribute to identify the 29 genes signature used to define a 
prognostic signature in breast cancer patients. Moreover, I performed validation experiments 
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for our candidate genes in MCF7 cells by qPCR and Western Blot analyses. For the paper layout, 
I took care of the preparation of Figure 1.  
7. APPENDIX b 
During my PhD, I collaborated to develop of a pattern search algorithm that maps p53 response 
elements and predicts their transactivation potential. 
The canonical p53 response element (RE) found in many identified binding sites of mostly up-
regulated p53 target genes consists of two copies of the palindromic half-site RRRCWWGYYY 
separated by a spacer of 0–13 bp, in which R = purine, W = adenine or thymidine and Y = 
pyrimidine. Because of mismatches, recent reports, including ChIP-seq and ChIP-exo data, 
highlight the extensive presence of non-canonical REs, such as half-sites and 3/4 sites (3Q), 
which have different p53 transactivation potential.  
Functional assays in the yeast S. cerevisiae have been extensively used to characterize the 
transactivation potential of p53 RE and thus to identify functional half-site and 3/4 site (3Q). 
Considering the high correlation reported between results in yeast and transactivation or 
occupancy data in cancer cell lines, we have combined all the data obtained so far with the 
yeast-based p53 transactivation assay and developed an algorithm, p53retriever, to scan human 
DNA sequences, identify p53 REs and classify them based on predicted transactivation potential 
into five broad categories, from 5 (= highly functional REs activity) to 1 (= unlikely functional 
REs). The resulting algorithm has several distinctive features compared to previous tools, 
particularly for scoring interactions among groups of mismatches, non-canonical 3Q sites and 
half sites p53 REs, weighting the impact of consensus mismatches considering their position 
within the full site RE sequence, i.e. giving higher penalty to mismatches in the two internal 
quarter sites, and weighs consensus sequence variations within dinucleotide motifs in the core 
and flanking regions. A prevalence of grade 2 category REs was identified.  
The initial scan of REs in the proximity of all annotated transcriptional start sites of coding 
genes, was then extended at distal enhancers, defined by ENCODE chromatin codes, where the 
frequency of REs of the highly functional group is significantly higher than the frequency found 
in human promoters. To infer the predictive power of the pattern search on p53-dependent 
transcriptional changes, 13 genes were selected and their expression were tested followed by 
qPCR in cell lines differing for p53 status (two derivative MCF7clones, the so called MCF7 vector 
and MCF7shp53, HCT p53+/+ and HCT p53-/-) and at different time points (8, 16, 24 hours) after 
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p53 activation by two different treatments, i.e. Doxorubicin -a genotoxic chemotherapeutic 
drug- and Nutlin-3A. Although the induction was not directly proportional to the REs category 
grade, we confirmed p53-dependent induction by qPCR for all of the 13 chosen gene in 
time/cell line dependent manner and propose DNAJA1, MAP2K3 and potentially YAP1 as new 
direct p53 target genes. 
 
I contributed to define the pattern search rules for p53retriever. When we obtained the 
complete list of REs, I selected 13 genes for qPCR analysis: these experiments had to reflect the 
algorithm output variety, taking into account candidates with/without REs already reported by 
ChIPseq data, as well as the grade attributed to the RE by p53retriever. Moreover, besides their 
p53 binding sites, I selected these candidates because of their reported involvement in cell-cycle 
control and tumor progression (PDE2A, E2F7, GAS6, TRIM32, HRAS, KITLG and TGFA), in 
transcription (KCTD1), and DNA editing (APOBEC3H). Although our algorithm considers the p53 
transactivation potential, it cannot account for the system complexity of transcriptional 
regulation in living cells and the response variability upon each different p53 stimuli. Thus, I 
validated the selected targets in five cell lines systems and using two p53 activators. 
Additionally, I co-wrote Paper 3 with Toma Tebaldi and Alberto Inga. Paper 3 was submitted to 
BMC Genomics; it was recently accepted, and is now in press.  
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p53-directed translational control can shape and
expand the universe of p53 target genes
S Zaccara1, T Tebaldi2, C Pederiva1, Y Ciribilli1, A Bisio1 and A Inga*,1
The increasing number of genome-wide transcriptome analyses focusing on p53-induced cellular responses in many cellular
contexts keeps adding to the already numerous p53-regulated transcriptional networks. To investigate post-transcriptional
controls as an additional dimension of p53-directed gene expression responses, we performed a translatome analysis through
polysomal profiling on MCF7 cells upon 16 hours of doxorubicin or nutlin-3a treatment. The comparison between the
transcriptome and the translatome revealed a considerable level of uncoupling, characterized by genes whose transcription
variations did not correlate with translation variations. Interestingly, uncoupled genes were associated with apoptosis, DNA and
RNA metabolism and cell cycle functions, suggesting that post-transcriptional control can modulate classical p53-regulated
responses. Furthermore, even for well-established p53 targets that were differentially expressed both at the transcriptional and
translational levels, quantitative differences between the transcriptome, subpolysomal and polysomal RNAs were evident. As we
searched mechanisms underlying gene expression uncoupling, we identified the p53-dependent modulation of six RNA-binding
proteins, where hnRNPD (AUF1) and CPEB4 are direct p53 transcriptional targets, whereas SRSF1, DDX17, YBX1 and TARDBP
are indirect targets (genes modulated preferentially in the subpolysomal or polysomal mRNA level) modulated at the translational
level in a p53-dependent manner. In particular, YBX1 translation appeared to be reduced by p53 via two different mechanisms, one
related to mTOR inhibition and the other to miR-34a expression. Overall, we established p53 as a master regulator of translational
control and identified new p53-regulated genes affecting translation that can contribute to p53-dependent cellular responses.
Cell Death and Differentiation (2014) advance online publication, 13 June 2014; doi:10.1038/cdd.2014.79
Discovered nearly 35 years ago, tumor suppressor p53, which
is often described as the ‘guardian of the genome,’ acts
prominently as a transcription factor in many biological
processes including DNA metabolism, apoptosis and cell
cycle regulation.1 Although the role of p53 is generally
considered to be at the level of transactivation via binding to
target sequences, there are several other ways by which it can
determine its cellular responses including, for example,
interaction with other transcription factors.2
Post-transcriptional and translational controls provide fine
tuning of transcriptional outcomes in eukaryotic somatic
cells.3 More than 90% of all coding transcripts appear to be
subject to this regulation, especially at translation initiation,4
considered as the rate-limiting step of the whole process.3,5
By binding mainly to the 50 and 30 untranslated regions
(50UTR; 30UTR) of mRNAs, miRNAs—other non-coding
RNAs and RNA-binding proteins (RBPs)—were shown to
participate in the regulation of translation.6 An unexpected
complexity in the modulation of the fate of mRNAs along with a
widespread alteration of that process in cancer cells was
found in recent studies.7–9 The synthesis of the p53 protein
itself has been shown to be modulated by miR-125b10 or by
RPL26 and nucleolin, that produce opposite effects on the
rate of p53 mRNA translation.11 Moreover, p53 target genes,
including CDKN1A (p21), BBC3 (PUMA) and BAX, can be
regulated post-transcriptionally by miRNAs or RBPs, some of
which can be direct p53 target genes. The impact that this
additional level of regulation can have on the p53 response
networks has been recently reviewed.12–17
All these mechanisms to control the fate of mRNAs may
account for the lack of correlation—referred to as uncoupling—
between relative changes in the total cellular mRNA levels
(corresponding to the transcriptome (transcripts examined from
total RNA extractions)) and protein abundances (the proteome)
after p53 activation.18 To investigate p53-dependent uncoupling
at the genome level, we compared the transcriptome after
doxorubicin (Doxo) or nutlin-3a (Nutlin) treatment with the
translatome (transcript examined from polysomal mRNA extrac-
tions, considered as actively translated), analyzed by polysomal
profiling, a technique that allows quantification of mRNAs
associated with the polysomes as a proxy for the proteome.19
Overall, we identified an evident translation selectivity that
we considered to be an additional dimension by which p53 can
tailor its gene response network.
Results
Coupled differentially expressed genes after doxorubicin
and nutlin-3a treatments are enriched for p53 targets.
To characterize the impact of post-transcriptional
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regulation in shaping the p53-dependent gene response,
we combined polysomal profiling with microarray analysis
on MCF7vector cells20 (containing wild-type p53) upon
doxorubicin (Doxo, 1.5 mM) or nutlin-3a (Nutlin, 10 mM)
treatment for 16 h. Both treatments resulted in high p53
induction and similar low levels of toxicity (Supplementary
Figure S1). Experiments were conducted also on
MCFshp53 cells, which express an shRNA targeting
p53.20 Residual p53 expression was detected in
MCF7shp53 cells, but p21 was not induced by either Doxo
or Nutlin (Supplementary Figure S1C).
No significant effects of the treatments on overall polysomal
distributions were evident (Figure 1a). For the microarray
analysis, we collected subpolysomal (‘sub’) and polysomal
(‘pol’) mRNA fractions so as to analyze mRNAs that are not
actively translated separately from those that are in active
translation.21 Total mRNA (‘tot’) was also collected to quantify
transcriptome changes (see Materials and Methods).
When we measured the global overlap between expression
changes of ‘tot’ (transcriptome) and ‘pol’ (translatome), we
obtained Spearman correlations of 0.65 and 0.67 after Doxo
and Nutlin treatment, respectively (Figure 1b). Hence, many
genes exhibited homodirectional changes both in terms of
transcriptome and translatome (defined as coupled differen-
tially expressed genes (DEGs)). In the three RNA prepara-
tions (tot, pol and sub), we found 239 and 155 commonly
upregulated coupled DEGs (DEGs with homodirectional
expression changes in transcriptome and translatome) after
Doxo and Nutlin treatment and 216 and 301 commonly
repressed coupled DEGs (Figure 1c, green, overlapping
areas). Among them, we counted 107 upregulated coupled
and 118 downregulated-coupled DEGs in both Doxo and
Nutlin treatment. (Supplementary Table S1A). A p53 pathway
signature was revealed by ingenuity pathway analysis for
Doxo and Nutlin upregulated and downregulated coupled
DEGs (Figure 1d). Sixty-four out of 225 genes had expression
changes consistent with p53 activation (P-value: 7.5 39)
(Supplementary Table S2A). Moreover, ingenuity pathway
analysis identified p53 as the main upstream regulator
especially among coupled DEGs (Supplementary Table S3).
Interestingly, gene ontology enrichment did not reveal
differences between Doxo and Nutlin DEGs (Supplementary
Table S2B), consistent with the similarity in cell phenotypes
observed at the doses and time point used (Supplementary
Figure S1).
Three well-established p53 target genes (MDM2, p21 and
PUMA) were validated as coupled DEGs by quantitative PCR
(qPCR), whose sensitivity is higher than the microarray’s
(Figure 1e). Given the significantly higher fold change in
the pol fraction compared with the subpolysomal fraction,
particularly after Nutlin treatment, p21 and MDM2 translation
appeared to be enhanced. We defined this finding a
‘translational thrust’. An 8 h treatment time point was added
for comparison (Figure 1e); (Supplementary Figure S2). At the
earlier time point the induction of the three p53 target genes,
and particularly MDM2, was more robust in response to Nutlin
than to Doxo. The PUMA transcript can also be classified as a
thrust gene after 8 h of Nutlin treatment. However, at the 16 h
time point PUMA-relative expression changes were higher in
total RNA compared with sub and pol, suggesting that, unlike
MDM2 and p21, the PUMA transcript could be subject to an
opposite regulation we define here as ‘translational drag.’ This
latter phenomenon could be dependent on several factors,
including delayed transactivation, slow pre-mRNA matura-
tion, regulation at the nuclear export level or slow assembly of
ribosomes on mRNAs. No evidence of transcriptional or
translational changes was seen in treated MCF7shp53 cells
(Figure 1e).
The majority of direct p53 target genes are coupled.
Nevertheless, we found that expression is uncoupled for
about 70% of DEGs.
The uncoupled, translationally upregulated gene group
is enriched for apoptotic functions. Uncoupled DEGs
are genes with a major change in relative expression levels
compared with mock treatment in only one of the three
mRNA preparations: (a) transcriptome (tot); (b) translatome
(pol); (c) non-translated subpolysomal mRNAs (sub) (red,
blue and yellow circular sectors, respectively, in Figure 1c).
We identified 1432 uncoupled DEGs after Doxo and 987 after
Nutlin treatment.
First, we focused on uncoupled DEGs that were induced in
the translatome but did not change in the transcriptome
(Figure 2a); (Supplementary Table S1B). We found 55
translatome-uncoupled DEGs common to the two treatments
(Figure 2a). Among them, PHPT1 (14-kDa phosphohistidine
Figure 1 Differentially expressed genes in the transcriptome and translatome of doxorubicin- and nutlin-3a-treated MCF7 cells. Overall results and coupled differentially
expressed genes (DEGs). (a) Profiles after sucrose gradient fractionation of cytoplasmic extracts prepared from MCF7vector (upper plot) and MCF7shp53 (lower plot) cell
lines. The conditions tested were mock, doxorubicin (Doxo, 1.5mM) and nutlin-3a (Nutlin, 10mM) after 16 h of treatment. The subpolysomal fractions (sub: free RNA, small-
40S and large-60S and monosomes-80S) and the polysomal fractions (pol) were separated. Sub and pol fractions (see numbers on x-axis) were combined in two separated
tubes for RNA extraction. (b) Scatter-plots representing transcriptional and translational log2 fold changes. Spearman correlation was calculated. DEGs in each category
(transcriptome only, translatome only and homodirectional changes) are classified according to log2 fold change 41 and o 1 for induced and repressed genes,
respectively, and Benjamini–Hochberg corrected P-valueo0.05. Genes without significant changes are shown in gray. (c) Venn diagrams showing the level of coupling/
uncoupling for upregulated (up) and downregulated (down) DEGs after Doxo and Nutlin treatment. The green overlapping areas represent coupled DEGs that are enriched in
all conditions: total RNA (tot), subpolysomal fraction (sub) and polysomal fraction (pol). (d) Coupled DEGs are mainly involved in the p53 pathway. Ingenuity pathways analysis
(IPA) was performed on coupled DEGs after Doxo and Nutlin treatment and each of these genes is considered by IPA according to their log2 fold change and BH corrected
P-value, integrating up- and downregulated DEGs (up and down). Results on the coupled DEGs that are common to both Doxo and Nutlin treatments are also presented
(common coupled DEGs). The y-axis displays the significance of the association between DEGs and the canonical pathways measured by Fisher’s exact test. A P-value cutoff
of 0.05 was used to identify significantly enriched pathways. The plot shows four among the most enriched pathways. (e) Relative expression levels of three established p53
target genes. MCF7vector cells were treated with Doxo and Nutlin for 8 h (upper plots) or 16 h (lower plot). MDM2, p21 and PUMA transcript levels were validated by qPCR in
total RNA (tot), subpolysomal (sub) and polysomal (pol) fractions as positive controls. To establish p53 dependence, all experiments were conducted also in MCF7shp53 cells.
Data are plotted relative to each mock condition and three reference genes. n¼ 3. Means±S.D. are shown. *Po0.05. The basal expression levels in each RNA fraction are
presented in Supplementary Table S7
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phosphatase)22 and TP53RK (p53-related protein kinase)23
were chosen for validation by qPCR owing to their biological
relevance in post-translational control, and because they had
not been previously reported as p53-regulated genes. PHPT1
and TP53RK proved to be translational upregulated genes,
particularly after 16 h of treatment (Figure 2b).
We also compared changes in protein levels by
western blot analysis (Figure 2c). Considered as a
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Figure 2 Uncoupled DEGs upregulated only in translation are enriched in apoptosis function. (a) Top: Venn diagrams from Figure 1b, highlighting the uncoupled
DEGs that are upregulated in translation after doxorubicin and nutlin-3a treatments. Bottom: Venn diagram showing the level of overlap between DEGs with high translation
levels after Doxo and Nutlin treatment. (b) p53 promotes the translation of PHPT1, a modulator of DNA accessibility, and of TP53RK, a putative activator of p53 itself.
MCF7vector and MCF7shp53 cell lines were treated with Doxo and Nutlin for 8 h (upper plots) or 16 h (lower plots). PHPT1 and TP53RKmRNA levels were validated by qPCR
starting from total RNA (tot), subpolysomal (sub) and polysomal (pol) fractions. Data are plotted relative to each mock condition and three reference genes. n¼ 3.
Means±S.D. are shown. *Po0.05. (c) Western Blot analysis of PHPT1 protein level in MCF7vector and MCF7shp53 cells after 8 h (top) and 16 h (bottom) of treatment with
Doxo or Nutlin. Actinin was used as reference protein for loading control. (d) Gene ontology (GO) analysis on upregulated DEGs in the polysomal fraction that did not change in
the total RNA. Plots represent the most enriched GO terms obtained by DAVID analysis. P-values of the enriched categories are reported. The analysis was performed on
upregulated DEGs after both Doxo and Nutlin treatments. (e) p53 promotes the translation of TRIAP1, TRAF4 and GADD45G, three p53 target genes involved in the
apoptotic process. MCF7vector and MCF7shp53 cells were treated with Doxo and Nutlin for 8 h (upper plots) or 16 h (lower plots). mRNA levels were measured by qPCR
starting from total RNA (tot), subpolysomal (sub) and polysomal (pol) fractions. Data are plotted relative to each mock condition and three reference genes. n¼ 3.
Means±S.D. are shown. *Po0.05
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Figure 3 Subpolysomal downregulated DEGs are involved in mitosis and RNA splicing regulation. (a) Top: Venn diagrams from Figure 1b, highlighting the uncoupled
DEGs that were downregulated in the subpolysomal fraction without significant changes at polysomal levels. Bottom: Venn diagram showing the level of overlap
between DEGs downregulated in the subpolysomal fraction after doxorubicin and nutlin-3a treatments. (b) Gene ontology (GO) analysis on DEGs downregulated in the
subpolysomal fraction that did not change in polysomal RNA. Graphs represent the most enriched GO terms obtained by DAVID analysis. P-values of the enriched categories
are indicated. The analysis was performed on downregulated DEGs after both Doxo and Nutlin treatments. (c) DDX17, SRSF1, TARDBP and XRCC2 are indirect p53 targets.
MCF7vector and MCF7shp53 cell lines were treated with Doxo and nutlin-3a for 8 h (upper plots) and 16 h (lower plots). mRNA levels were measured by qPCR in
total RNA (tot), subpolysomal (sub) and polysomal (pol) fraction. Data are plotted relative to each mock condition and three reference genes. n¼ 3. Means±S.D. are shown.
*Po0.05. (d) Western Blot analysis of DDX17 (left side) and SRSF1 (right side) protein levels in MCF7vector and shp53 cells after 8 h (top) and 16 h (bottom) of treatment
with Doxo or Nutlin. GAPDH and actinin were used as reference proteins for loading control. The actinin-loading control for SRSF1 is the same used as the loading control for
PHPT1 in Figure 2c
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proxy of the proteome, the pol level should reflect the
protein level of each transcript. PHPT1 protein levels
were slightly induced by both Doxo and Nutlin in
MCF7vector cells, whereas no changes occurred in
MCF7shp53 (the basal levels were significantly lower)
(Figures 2b and c).
cellular response to stress 7.7E-11
8.1E-9
1.2E-11nucleotide binding
6.1E-4mRNA
processing
a
cellular response to stress 4.4E-6
mitosis 1.5E-5
nucleotide binding
9.2E-3mRNAprocessing
Functional categories 
p-value
p-value
b
11045182
Polysomal Nutlin.down (155)
Translation Doxo.down
Translation Nutlin.down
Polysomal Doxo.down (227)
1.8E-6
cell division
su
b
tot
pol
Nutlin.down
54
101
su
b tot
pol
Doxo.down
157
70
miR
-34a
-psiU
x
miR
636
-psi
Ux
YBX1
GAPDH
em
pty p
siUx
e
GAPDH
p-4EBP1
4EBP1
YBX1
Mock Doxo Nutlin Rapa Torin1 Mock Doxo Nutlin Rapa Torin1
MCF7vector MCF7shp53
1 0.24 0.28 0.39 0.49 1 0.81 0.90 0.60 0.63
g
h
0.69 0.970.71 0.66
YBX1
Actinin
Mock Doxo Nutlin Mock Doxo Nutlin
Control A LNA-antagomiR-34a
1.151
MCF7vectorMCF7shp53
MCF7vector MCF7shp53
NutlinMock Doxo Mock Doxo Nutlin
Mock Doxo Nutlin Mock Doxo Nutlin
c
YBX1
GAPDH
YBX1
GAPDH
8h
16h
d
f
si-Scramble si-YBX1 si-SRSF1
Mock Doxo Nutlin Mock Doxo Nutlin Mock Doxo Nutlin
YBX1
SRSF1
C-MYC
p53
p21
Actinin
p53
Pol
227 155
Functional categories 
Actinin
p53 as a master regulator of translation control
S Zaccara et al
6
Cell Death and Differentiation
Among induced translatome-uncoupled DEGs, gene
ontology analysis revealed enrichment for apoptosis terms
after both Doxo and Nutlin treatments (Figure 2d). This
observation suggests that modulation of translation efficiency
might reinforce the activation of p53-dependent apoptosis, a
process that could be important given the generally weaker
transcriptional control of p53 target genes in the apoptosis
group.24 We validated by qPCR TRIAP1,25 TRAF426 and
GADD45G27 (the full list of genes is presented in
Supplementary Figure S3A). According to ChIP-seq data on
MCF7 cells, these genes are direct p53 targets.28 For all of
them, the increase at the polysomal level, especially after
Nutlin treatment, was confirmed at both time points. For
GADD45G, high level of induction was observed also in the
MCF7shp53 cells (Figure 2e).
Overall, we conclude that even if there was a weak
modulation at the total mRNA level, p53 or p53-inducing
treatments enhanced the translation of these apoptotic genes.
p53 activation reduced the subpolysomal mRNA levels
of DDX17, SRSF1, TARDBP and XRCC2. Relative transla-
tion efficiency can decrease by inhibiting translation without
impacting mRNA stability, or by destabilizing mRNAs. Given
that p53 controls the expression of many miRNAs and
RBPs,12 it could indirectly impact both mechanisms. DEGs
that were selectively downregulated in the sub fraction but
did not change in translation might be considered as
candidate targets for a regulation process that targets more
selectively mRNA molecules not engaged in translation
(Figure 3a). Following Doxo and Nutlin treatments, we
observed, respectively, 305 and 160 subpolysomal down-
regulated DEGs (Supplementary Table S1C) and 81 were
common to the two groups. (Figure 3a). ‘Mitosis’ was the
mostly enriched functional category, among which XRCC229
was also validated by qPCR (Figure 3c). mRNA-processing
categories, such as RNA splicing, were also enriched
(Figure 3b); (Supplementary Figure S3B). As we were
interested in how p53 might modulate post-transcriptional
mechanisms, we also selected three RBPs—SRSF1, DDX17
and TARDBP—for further qPCR validation. DDX17 and
SRSF1 mRNAs were confirmed to be downregulated in sub
but did not change in tot nor pol after Nutlin treatment in
MCF7vector cells. On the contrary, Doxo treatment led
to a less-evident down-modulation in the pol fraction that
generally was p53-independent (downregulation in the
MCF7shp53 cells).
Changes in DDX17 and SRSF1 protein levels were
investigated (Figure 3d). In general, protein levels were more
in agreement with their matched pol changes at the 16 h time
point. Moreover, SRSF1 was consistently upregulated in
MCF7shp53 at 16 h post Nutlin treatment, confirming mRNA
data and literature reports.30
p53 activation leads to translational inhibition of genes
involved in mRNA processing and nucleotide binding,
including YBX1. Although a reduction in subpolysomal
RNA can be interpreted as evidence of reduced mRNA
stability, lower polysomal RNA can be a hallmark for
decreased translation efficiency of specific mRNAs.
Hence, we examined DEGs that were repressed in
polysomal fraction, but did not change in total mRNA
(Figure 4a); (Supplementary Table S1D). Although not as
first enriched term, gene ontology analysis showed an
enrichment for ‘mRNA processing’ after both treatments
(Figure 4b); (Supplementary Figure S3C). DEGs (45) were
common to the two treatments (Figure 4a) including five RBPs
(YBX1, SNRPA, HNRNPA3, KIAA0020 and DGCR8) among
a restricted list (see Materials and Methods).
YBX1 was chosen for validation also because of its reported
interaction with p53.31 Its mRNA was significantly down-
regulated in polysomal RNA, more than in the total RNA,
with a p53-dependent shift from the polysomal to the
subpolysomal fraction (Figure 4c). The same trend was
observed after 8 h, but only in the Doxo treatment. Moreover,
the reduction in pol mRNA corresponds to a reduction in YBX1
protein level (Figure 4d).
The YBX1 transcript was found to have a 50-terminal
oligopyrimidine tract-like mRNA that is suppressed in the
polysomal fraction after mTOR inhibition.32 Furthermore,
p53 can negatively modulate the mTOR pathway via the
Figure 4 DEGs inhibited in translation are involved in mRNA processing and help shaping the p53-dependent response. (a) Top: Venn diagrams from Figure 1b,
highlighting the uncoupled DEGs that were downregulated in the polysomal fraction without significant changes in total mRNA. Bottom: Venn diagram showing the overlap
between DEGs downregulated in the polysomal fraction after Doxo and Nutlin treatments. (b) Gene ontology (GO) analysis on DEGs downregulated in the polysomal fraction
that did not change in total RNA. Graphs represent the most enriched GO terms obtained by DAVID analysis. P-values of the enriched categories are reported. The analysis
was performed on downregulated DEGs after both doxorubicin and nutlin-3a treatments. (c) YBX1 is an indirect p53 target. MCF7vector and MCF7shp53 cell lines were
treated with Doxo and Nutlin for 8 h (upper plot) or 16 h (lower plot). YBX1 levels were measured by qPCR in total RNA (tot), subpolysomal (sub) and polysomal (pol) fractions.
Data are plotted relative to each mock condition and three reference genes. n¼ 3. Means±S.D. are shown. *Po0.05. (d) Western Blot analysis of YBX1 protein level in
MCF7vector and shp53 cells after 8 h (upper panels) and 16 h (lower panels) of treatment with Doxo or Nutlin. GAPDH was used as reference protein for loading control, and is
the same used as loading control for DDX17 in Figure 3d. (e) Western Blot analysis of MCF7vector and MCF7shp53 cell extracts after treatment with Doxo, Nutlin, rapamycin
(Rapa) and Torin1. Protein levels of YBX1, total 4EBP1 and phosho(p-) 4EBP1 were measured as mTOR inhibition would lead to a reduction of 4EBP1 phosphorylation
(p-4EBP1) and the consequent inhibition of cap-dependent translation. As control, p53 protein levels were measured. p53 is stabilized after 16 h of treatment with Doxo and
Nutlin, whereas the treatment with mTOR inhibitors does not have an impact on p53 protein levels. GAPDH was used as a reference protein for loading control. For YBX1,
numbers above the immunoreactive bands represent the relative amount of proteins normalized against both the reference protein and the mock condition (set to 1 separately
for each cell line). (f) Ectopic overexpression of miR-34a in MCF7vector cell line. The empty miR-expression plasmid psiUx condition was used as negative control. miR-636
was overexpressed as an additional control of miR-34a specificity. GAPDH was used as a reference protein for loading control. (g) YBX1 protein levels in MCF7vector cells
transfected with the negative Control A or an LNA-antagomiR-34a and treated after 48 h with Doxo or Nutlin. Actinin was used as a reference protein for loading control.
Numbers above the immunoreactive bands represent the relative amount of proteins normalized using both the reference protein and the mock condition in the control
experiment (set to 1). (h) Western Blot analysis on MCF7vector cell extracts after silencing YBX1, SRSF1 or scramble control, either in the mock condition or after Doxo or
Nutlin treatment. Protein levels of YBX1 and SRSF1 confirm the silencing. c-MYC protein levels were measured because it is a recognized downstream target of both YBX1
and SRSF1. As additional controls, p53 as well as p21 levels were measured. Actinin was used as a reference protein for loading control
p53 as a master regulator of translation control
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Figure 5 Enrichment of sequence features or of regulatory elements in the UTRs or coding sequence of uncoupled DEGs. (a) The upper plots show the length distribution for
the 50-untranslated region (UTR), coding region (CDS) and 30-UTR of the indicated list of our DEGs. Common refers to the overlap between Doxo and Nutlin DEGs. The lower plots
present the GC content for each of these categories. All distributions are compared with the background distribution of the whole set of human genes (all). The significant shifts in
distribution are shown in dark gray (Mann–Whitney test, P-valueo0.01). (b) Heatmap based on the enrichment P-values adjusted for multiple testing with the Benjamini–Hochberg
method. DEGs upregulated in the subpolysomal fraction, upregulated in the polysomal fraction or downregulated in the polysomal fraction are presented for each treatment (Doxo
and Nutlin). The enrichment of regulatory elements for DEGs common to both treatments are also presented, referred to as ‘common’. (c) hnRNPD and CPEB4 are direct p53
targets. MCF7vector and MCF7shp53 cell lines were treated with Doxo and Nutlin for 8 or 16 h. hnRNPD and CPEB4 levels were measured by qPCR in total RNA (tot),
subpolysomal (sub) and polysomal (pol) fractions. Data are plotted relative to each mock condition and three reference genes. n¼ 3. Means±S.D. are shown
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upregulation of Sestrins (SESN1–2).33 SESN1 was among
the coupled upregulated DEGs that we identified
(Supplementary Table S1A). As apparently p53 could impact
on YBX1 mRNA through the mTOR pathway, we examined
the impact of Doxo and Nutlin treatments on mTOR activity in
comparison with two mechanistically different mTOR inhibi-
tors rapamycin (an allosteric mTORC1 inhibitor) and Torin1
(a selective ATP-competitive mTOR inhibitor) as controls. The
amount of p-4EBP1 was reduced by Torin1 and, to a limited
extent, by rapamycin, but also by Doxo or Nutlin treatment in
MCF7vector cells (Figure 4e). Although YBX1 protein levels
were markedly lower after Torin1 and rapamycin treatment
independently from p53 status, the reduction was even more
evident after both Doxo and Nutlin treatment in MCF7vector
cells. This was despite the apparent lower inhibition of mTOR
in MCF7shp53 cells, based on p-4EBP1 levels. Collectively,
these results suggest an additional mTOR pathway-
independent, p53-dependent mechanism of YBX1 transla-
tional regulation.
We searched for published evidence of RBPs or miRNAs
that could modulate YBX1 mRNA translation/stability. YBX1
was reported as a target of miR-137 in multidrug-resistant
MCF7/ADAM cells,34 but we were unable to detect miR-137 in
our cell lines, both in treated and untreated conditions. On the
basis on a recent CLASH analysis,35 miR-34a, a p53-target
miRNA,12 was found to bind YBX1 30UTR. We confirmed that
Doxo and Nutlin increased miR-34a expression only in
MCF7vector cells (Supplementary Figure S4A). Moreover,
miR-34a ectopic overexpression led to a reduction in YBX1
protein (Figure 4f; Supplementary Figure S4B). Vice versa,
upon inhibition of miR-34a, YBX1 levels were slightly
increased in the mock condition and were reduced less by
Doxo, but not by Nutlin, treatment (Figure 4g; Supplementary
Figure S4C). Therefore, an additional effect between
p53-dependent miR-34a overexpression and p53-related
reduction in the mTOR activity on YBX1 can be hypothesized.
Transcriptional and translational cross-talk between
p53, YBX1, SRSF1 and c-MYC. We established that p53
indirectly modulates the expression of at least four RBPs
(DDX17, SRSF1, TARDBP and YBX1). By binding to their
target mRNAs, RBPs could in turn contribute to the tuning of
the p53-induced responses both at the transcriptional and
translational levels. We chose SRSF1 and YBX1 to explore
these potential regulatory modules by an siRNA approach,
as they both control cell proliferation, cell-cycle progression
and apoptosis36,37 (Figure 4h). We confirmed data indicating
that SRSF1 reduction leads to a lower stabilization of p53
protein and to lower induction of p21.30,38 We then examined
c-MYC protein levels, given that c-MYC translation is
reported to be upregulated by YBX1,39 and SFSRF1
depletion was associated with reduced c-MYC oncogeni-
city.36 Interestingly, silencing SRSF1 led to a concomitant
decrease in YBX1 protein and even more so in the c-MYC
protein. On the contrary, YBX1 silencing did not impact on
SRSF1 or c-MYC protein levels in the mock condition.
CPEB4 and hnRNPD, mediators of translational control,
are new p53 transcriptional targets. General RNA
sequence features of the 50 and 30UTR as well as coding
sequence (CDS) influence post-transcriptional regulation
of each mRNA.40,41 In order to identify potential post-
transcriptional regulatory sequences embedded in the
transcripts of our DEGs, we performed a distribution analysis
of the length and the GC content of their 50UTR, CDS and
30UTR regions (Figure 5a). When compared with the
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Figure 6 Five RBPs are regulated by p53 and can contribute to post-transcriptional control of p53 responses. Cartoon highlighting functional links between wild-type p53
and six RBPs that are established or confirmed in our work. Solid red lines and arrows represent functional interactions discovered or experimentally validated in this work.
Black lines represent functional interactions reported in the literature (citation numbers are near those arrows). Blue lines are used when the mediators of the functional
interactions are unknown. The impact of CPEB4 on p53 is hypothetical, based on results with the related CPEB1 protein
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background distribution of the whole set of human genes,
translatome upregulated DEGs showed significantly shorter
CDS regions and higher GC content, both in the CDS and the
UTRs. On the contrary, coupled downregulated genes
showed a decreased GC content, more significantly in the
30UTR region. UTR sequences of our DEGs were analyzed
for the enrichment of specific regulatory elements using
experimental annotation contained in the Atlas of regulatory
UTR activity 2 (AURA 2)42 (Figure 5b); (Supplementary
Figure S5). Target mRNAs of hnRNP-A1, -C and -F were
enriched among downregulated DEGs. Conversely, hnRNPD
(AUF1)-binding sites were enriched among upregulated
uncoupled DEGs for both Doxo and Nutlin treatments (BH
P-value: 0.00027). Furthermore, our array data identified
hnRNPD to be a downregulated coupled DEG upon Doxo
treatment, a result confirmed by qPCR (Figure 5c). Hence,
hnRNPD should be included in the growing list of p53 target
genes coding for RBPs, also considering ChIP-seq data.43
ZNF469, ZNF488 and CPEB4 were instead upregulated-
coupled RBP DEGs common to both treatments and CPEB4
was validated by qPCR. As already reported by ChIP-seq
data,28,43 we confirm that CEBP4 is a direct p53 target gene.
Other groups of transcriptionally/translationally uncoupled
genes are described in Supplementary Figure S6.
Discussion
Genome-scale transcriptome analyses have been instrumen-
tal in describing the p53 gene response networks under a
variety of stress responses.28 Nevertheless, the mechanism
defining which cellular response is adopted remains poorly
characterized.25
Here, we describe post-transcriptional gene expression
control as an additional dimension to potentially shape the
p53-directed gene response. Moreover, the global implica-
tions of several RBPs on that mechanism are also taken into
account, given their involvement in mRNA translation.
Quantitative proteomics would theoretically be an ideal tool
to assess the p53-dependent translational output. Never-
theless, the coverage of proteomic studies is still a limiting
factor.44 In our approach the translatome can be considered
as a proxy for the proteome, although the experimental
methods maintain the sensitivity typical of RNA expression
studies.
To shape the downstream response networks p53
modulates RBPs that act as molecular sieves. Guided
by the comparison of transcriptome and translatome data,
but also considering DEGs within the free cytoplasmic pool
(sub), we identified a number of RBPs that could be
regulated by either Doxo (67 RBPs) or nutlin-3a (30 RBPs)
or would be common to both treatments (22) (Supplementary
Table S4). These 22RBPs are primary candidates for
p53-directed control. Indeed, in the validation experiments
we confirmed YBX1, SRSF1, DDX17, TARDBP, HNRNPD
and CEBP4 as targets of p53-dependent modulation at the
total mRNA or polysomal mRNA levels or both (Figure 6).
In particular, we focused on targets that could directly or
indirectly modulate p53 functions, either by acting on the p53
mRNA or on the mRNAs of p53 target genes.
Interestingly, hnRNPD had already been reported to target
and destabilize the mRNAs of p53,45 BAX and other important
cancer genes, often in a reciprocal, alternating association
with HuR, an mRNA-stabilizing factor.45 We propose that
through the transcriptional downregulation of hnRNPD,
p53 can engage a positive feedback and potentially also
a feed-forward regulatory loop. Consistently, we found
enrichment for hnRNPD target mRNAs among the group of
translationally upregulated DEGs (Figure 5a).
CPEB4 was an upregulated-coupled DEG whose
enhanced expression was abated by p53 silencing. Notably,
CPEB4 is a member of the CPEB family, and CPEB1,
functionally related with CPEB4, was shown to sustain p53
translation, thereby participating in the activation of the
senescence response.46,47 We suggest that p53 could impact
its own translation fitness and functions via its direct target
gene CPEB4.
DDX17, TARDBP, SRSF1 and YBX1 are confirmed as
modulated at the post-transcriptional level. Overall, in almost
all the analyses, protein levels reflect the subpolysomal or
polysomal mRNA changes, suggesting that these mRNA
variations could have a significant impact on the final
proteome. Although TARDBP functions are still under
investigation, DDX17/p72 is a putative RNA helicase48 that
by interacting with DDX5 (p68) can act as a modulator of
p53-dependent transcription and DNA damage response.
SRSF1 was repressed by both doxorubicin and nutlin-3a
treatments particularly in the subpolysomal RNA fraction,
and the p53-dependent negative modulation was apparent
comparing MCF7vector with MCF7shp53 cells. As it was
recently reported that SRSF1 overexpression provides
resistance to oncogenic transformation via stabilization of
p53,30,49 we propose that we have uncovered a negative
feedback loop by which p53 inhibits a positive regulator.
We explored in more detail two mechanisms linking p53
activation with YBX1 mRNA and protein downregulation,
namely the inhibition of the mTOR pathway32 and the
upregulation of miR-34a.12 Although p53 can negatively
impact on mTOR, via the transcriptional activation of SESN1
and SESN2,33 the high dependency of mTOR function on the
cell metabolic state can also influence our results. The
dynamics by which p53 modulates all these RBPs is an
additional, critical point. Here, we measured the expression of
these genes also after 8 h of treatments to begin exploring
this issue. Temporal differences in p53 stabilization upon
doxorubicin and nutlin-3a treatments have been already
reported50 and are confirmed by our analysis. Overall, the
qPCR results revealed correlations (e.g., p21, PUMA,
TRIAP1, TRAF4, XRCC2, hnRNPD and CPEBP4) as well
as differences (MDM2, PHPT1, TP53RK, GADD45G, DDX17,
SRSF1, TARDBP and YBX1), between the two time points
and also between mRNA and protein levels.
Further investigations are needed to clarify the specific
impact of RBPs on post-transcriptional regulation after p53
activation. In our experiments SRSF1 silencing led to a
decrease also in YBX1 protein levels, suggesting a cross-talk
between the two RBPs via unexplored mechanisms, and this
resulted in down-modulation of c-MYC. Hence, p53-
dependent negative regulation of both YBX1 and SRSF1,
could lead to repression of c-MYC, and contribute to cell cycle
p53 as a master regulator of translation control
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arrest. Importantly, for c-MYC and potentially many
other targets, p53 could also impact indirectly on mRNA
translation efficiency via transcriptional inhibition of the
Fibrillarin gene.51
Apoptosis can be regulated also at the level of transla-
tion efficiency of p53 target genes. Gene ontology of
DEGs that were uncoupled and upregulated only in the
polysomal fraction revealed an enrichment for the term
‘apoptosis’, which was even more significant in cells treated
with nutlin-3a. This finding uncovers a new layer of complex-
ity in the modulation of the classical p53-dependent
apoptosis (Supplementary Figure S7). Several studies have
shown that transcriptional activation of apoptosis gene
targets can be influenced by selective cofactors or specific
post-translational modifications of the p53 protein.24 We
suggest that translational controls may promote the synth-
esis of those pro-apoptotic proteins contributing to the actual
induction of programmed cell death. Recently, Ribo-seq was
used to profile MCF7 cells treated with nutlin-3a.52 Ribo-seq
maps ribosome-protected fragments, but, unlike polysomal
profiling, it does not separate actively translating polysomes
from monosomes (80S), nor does it address subpolysomal
RNA. Consistently with our results, downregulation of
cell-cycle genes was observed but the modulation of
apoptosis or mRNA-processing pathways was not apparent
in Ribo-seq data.
In summary, our analysis of uncoupled mRNAs, namely
mRNAs undergoing translational control, reveals a large
number of new indirect p53-regulated targets that would not
have been identified through a traditional transcriptome study.
On the basis of the functions of these genes, it becomes
apparent that selectivity at the level of mRNA translation, in
addition to transcriptional selectivity, is a critical contributing
factor in the shaping of p53-directed responses and at least
six RBPs directly or indirectly modulated by p53 may be
implicated. Our study opens up a scenario where further
investigations will clarify the impact of p53-dependent
post-transcriptional regulation as well as the involvement of
RBPs on cellular outcomes.
Materials and Methods
Cell lines and culture conditions. MCF7 cells stably expressing an
shRNA targeting p53 (MCF7shp53) or control cells (MCF7vector) were kindly
provided by Dr Agami.20 Cells were normally maintained in RPMI (Gibco, Life
Technologies, Milan, Italy) supplemented with 10% FBS, antibiotics (100 units/ml
penicillin plus 100mg/ml streptomycin) and 2mM L-glutamine. Puromycin (Sigma-
Aldrich, Milan, Italy) was used to maintain the selection, at 0.5mg/ml as final
concentration.
Polysomal RNA fractionation and extraction. MCF7vector cells
(3.5 106) were seeded into 10 cm tissue culture dishes and allowed to reach
70–80% confluence before treatment with 1.5mM doxorubicin (Doxo) or 10mM
nutlin-3a (Nutlin). Doxo was purchased from Sigma-Aldrich, whereas nutlin-3a was
obtained from Alexis Biochemicals (Enzo Life Science, Exeter, UK). After 8 or
16 h, polysomal separation was performed as previously described.53 Briefly,
samples were loaded in 15–50% linear sucrose gradients, ultra-centrifuged and
fractionated with an automated fraction collector. All the fractions containing
subpolysomal or polysomal RNA were identified and pooled in two separate tubes.
RNA was purified by extraction with 1 volume of phenol–chloroform and adding a
washing step in 70% v/v ethanol in order to remove phenol contaminations.
DNAse treatment (RNase-Free DNase Set, Qiagen, Hilden, Germany) was
performed to remove DNA contamination after the RNA extraction. Three
biological replicates were performed. For validation studies, all these steps were
repeated also for the MCF7shp53 cell line, seeding 2 106 cells/dish.
Total RNA extraction. MCF7vector and MCF7shp53 cell lines were seeded
into six-well plates and allowed to reach 70–80% of confluency before treating with
1.5mM Doxo or 10mM Nutlin. After 8 or 16 h of treatment, cells were harvested
and total RNA was extracted using the Agilent Total RNA Isolation Mini Kit (Agilent
Technologies, Milan, Italy) according to the manufacturer’s instructions. In-column
DNAse treatment (RNase-Free DNase Set, Qiagen) was performed to remove
DNA contamination during the extraction. Three biological samples were analyzed.
Microarray hybridization and data analysis. Purity of all extracted
RNAs (A260/A280 value of 1.8–2.1) and concentrations were measured using the
Nanodrop spectrophotometer. An additional quality control was performed with the
Agilent 2100 Bioanalyzer (Agilent Technologies) discarding RNA preparations with
RIN (RNA integrity number) value o8. mRNAs extracted after 16 h of treatment
with Doxo or Nutlin were hybridized to an Agilent-014850 Whole Human Genome
Microarray 4x44K G4112F-Probe following the manufacturer’s protocol. Raw data
and procedures were deposited in Gene Expression Omnibus (GSE50650). That
output was analyzed with the tRanslatome package54 using the Limma method
(http://www.bepress.com/sagmb/vol3/iss1/art3) comparing each treatment of every
tested RNAs with the mock condition. Moreover, Supplementary Table S5 shows
the detailed list of all our DEGs. For all further analysis on DEGs, two thresholds
were set for each comparison: (1) log2 (fold change) 41 and o 1 for
upregulated and downregulated genes, respectively; (2) Benjamini–Hochberg (BH)
corrected P-value o0.05.
Gene ontology and pathway analysis of DEGs. Gene-annotation
enrichment analysis for all our selected categories of coupled or uncoupled DEGs
was performed with the DAVID resource.55 The significance of overrepresentation
was determined at a false discovery rate of 5% with BH multiple testing correction
and an enrichment score 41.5. All pathways analyses were performed using
ingenuity pathway analysis (www.ingenuity.com). Only direct interactions were
considered in setting parameters.
Analysis of UTR sequence features. UTR and CDS sequences were
downloaded from the UCSC Genome Browser (http://genome.ucsc.edu/),
assembly GRC37/hg19. For each HGNC gene the longest transcript variant
was selected as representative of the gene. Distribution analysis was performed
on the length and GC content of 50UTR, CDS and 30UTR regions of the lists of
DEGs. All the distributions were compared with the background distribution
corresponding to the whole set of human genes, and significant shifts were
identified with the Mann–Whitney test, selecting a 0.01 significance threshold on
the resulting P-value.
Analysis of 50-30UTRs and of RBP genes. The AURA 2 database
(http://aura.science.unitn.it/) was used to perform the analysis of the enrichment of
regulatory elements at the 50–30UTR of coupled or uncoupled DEGs. Given that
AURA 2 is a database containing only experimentally validated post-transcriptional
interactions at the UTR level, we used AURA to select enriched RBPs for further
validations. The presented enrichment P-values were adjusted for multiple testing
with the BH-method. We matched our DEG classes with a restricted RBPs’ list to
obtain the number of RBP genes that were modulated after Doxo and nutlin-3a
treatments. The restricted list was compiled including all canonical RBPs (i.e.,
proteins containing at least one recognized RBP motif), translation factors and
non-canonical RBPs reported in previous studies.56,57
RT-qPCR reaction. cDNA was generated from 1 mg of RNA using the
RevertAid First Strand cDNA Synthesis Kit (Fermentas, Milan, Italy) in 20 ml final
volume following manufacturer’s instructions. All qPCR assays were performed on
a CFX Touch Real-Time PCR Detection System (Bio-Rad, Milan, Italy) in a
384-well plate format. Assays contained 2X KAPA Probe FAST qPCR Master Mix
(Kapa Biosystems, Resnova, Rome, Italy), 20 PrimeTime ZEN Double-
Quenched Probes Assay (IDT, Tema Ricerca, Bologna, Italy) and 25 ng of cDNA.
Primers are all commercially available according to their catalog number. In
addition, we validated some targets using the 2 KAPA SYBR FAST qPCR Kit
(Kapa Biosystems, Resnova) and specific primers purchased from Eurofins
(MWG, Operon, Ebersberg, Germany). The list of primers is presented in
Supplementary Table S6. All these primers were validated according to the MIQE
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guidelines.58 We present the mRNA quantification relative to the mock condition
for each fraction (tot, sub and pol) in order to highlight changes upon treatment. To
clarify variation in the mock variation, the DCq data of the mock condition are
reported in Supplementary Table S7. The relative quantification was obtained
using the comparative Cq method (DDCq), where glyceraldehyde 3-phosphate
dehydrogenase (GAPDH), b-2microglobulin and tyrosine 3-Monooxygenase/
TRYPTOPHAN 5-Monooxygenase Activation Protein, Zeta Polypeptide (YWHAZ)
served as reference genes. The relative folds of change were analyzed using a
t-test approach considering three biological replicates (Po0.05).
Antibodies and western blot analysis. Antibodies used for western blot
analysis were p53 (DO-1), p21(C-19), YBX1(59-Q), 4EBP1(R-113), GAPDH(6C5),
alpha-Actinin (B-19), SRSF1 (3G268), MYC (9E10) and PHPT1 (N-23) from
Santa Cruz Biotechnology (Heidelberg, Germany), p-4EBP1(Thr37/46) from Cell
Signaling Technology (Milan, Italy) and DDX17 (ab70184) from Abcam
(Cambridge, UK). MCF7vector and MCF7shp53 cells were seeded into six-well
plates and allowed to reach 70–80% of confluency before treating with Doxo
(1.5mM), Nutlin (10mM) for 16 or 8 h and rapamycin (250 nM) and Torin1 (250 nM)
for 2 h. The concentration and time point used for rapamycin and Torin1 are based
on a previous paper.59 Rapamycin (Sigma-Aldrich)–Torin1 (Tocris Bioscience,
Bristol, UK). Proteins were extracted using RIPA buffer as previously described,2
supplemented with protease inhibitors and phosphatase inhibitor cocktail2
(Sigma-Aldrich) and quantified using the BCA assay (Thermo Scientific, Pierce,
Milan, Italy). The relative molecular mass of the immunoreactive bands was
determined using PageRuler Plus Prestained Protein Ladder (Fermentas). The
semi-quantitative analysis was performed using GAPDH or Actinin as reference
proteins for loading control.
Silencing of YBX1 and SRSF1 proteins. To perform YBX1 or SRSF1
silencing, we used DsiRNA Duplex purchased from IDT (si-YBX1:
HSC.RNAI.N004559.12.3, si-SRSF1: HSC.RNAI.N006924.12.1). MCF7vector
cells were seeded into six-well plates and allowed to reach 30–40% of
confluence. After 24 h, 25 nM of the different DsiRNAs were transfected using
INTERFERin (Polyplus, Euroclone, Milan, Italy). As a negative control, we
transfected cells with the si-scramble si.NC1 at the same final concentration.
Fifty-six hours after the transfection, cells were treated with doxorubicin and nutlin.
Antisense effects were assessed 16 h after the treatments, thats is, 72 h after
transfection.
Apoptosis assays. MCF7vector cells were seeded in 96-well plates
(Corning, Lowell, MA, USA) at the density of 15 000 cells/well. After 24 h, cells
were treated with 0.75, 1.5 and 3 mM of Doxo and 5mM, 10mM and 15mM of
Nutlin. After 16 h, cells were exposed to 10 ml/well of Cell Proliferation Reagent
WST-1 (Roche, Milan, Italy) for 30min before measuring the absorbance at 460
and 600 nm using an Infinite 200 PRO microplate reader (TECAN, Milan, Italy).
A reduction in the absorbance signal is proportional to a reduction in the activity of
mitochondrial dehydrogenases that is considered as a marker of cell viabilty. Doxo
(1.5mM) and 10mM Nutlin were chosen for all subsequent experiments. We chose
a 16 h time point after doxorubicin and nutlin treatment of MCF7 cells at relatively
low doses because we were interested in identifying p53-directed or stress-
response-directed mechanisms of post-transcriptional control. For Fluorescence-
activated cell sorting analysis, MCF7vector cells were seeded into 10-cm dishes
and treated the following day. In order to have more information about cells
viability, we recovered and analyzed also cells that were in suspension after the
treatments. The FITC AnnexinV Apoptosis Detection kit I (BD Pharmingen, Milan,
Italy) was used for the staining following the manufacturer’s protocol. TO-PRO-3
Iodide (1 mM) (642/661) was used as a nucleic acid dye (Life Technologies).
miRNA extraction and quantification. MCF7vector and MCF7shp53
cells were seeded into six-well plates and allowed to reach 70–80% confluence
before treating with Doxo or Nutlin. After 16 h, cells were harvested and total RNA
was extracted using 300ml of TRIZOL reagent (Invitrogen, Life Technologies).
After 5 min of incubation at room temperature, 60 ml of chloroform were added,
followed by another incubation step of 3 min at room temperature. Three different
phases were obtained following centrifugation at 4 1C for 15min at 12 000 g.
We recovered only the aqueous phase containing the RNA to continue with
isopropanol precipitation and subsequent ethanol 75% wash. mRNA quality was
controlled as described above. Mature miR expression levels were quantified
using pre-made Exiqon assays, using the small nuclear snRNA U6 as reference
and following the manufacturer’s instructions for cDNA reaction (Universal cDNA
Synthesis kit, Exiqon, Woburn, MA, USA) and qPCR with the ExiLENT
SYBRGreen Master Mix (Exiqon).
miRNA overexpression. To overexpress pre-miR-34a, we used an
siRNA-expressing vector (psiUx) based on the strong and ubiquitous RNA PolII-
dependent promoter of the human U1 small nuclear RNA (snRNA) gene.60
Transfection of the empty psiUx was used as a control.61 miR-636 was
overexpressed as an additional control to confirm a specific effect of miR-34a.
MCF7vector cells were seeded into six-well plates. After 24 h, cells were
transfected with the different plasmids using FuGENE HD Transfection Reagent
(Promega, Milan, Italy). Forty-eight hours after the transfection, cells were
harvested and miRNAs or proteins were extracted for quantification assays, as
described in the previous sections.
miRNA inhibition. To inhibit miR-34a, MCF7vector cell lines were seeded
into six-well plates. When cells reached 30–40% of confluence, miRCURY LNA
miR-34a Inhibitor (Exiqon) was transfected using INTERFERin transfection
reagent (Polyplus). After optimization experiments, we used 50 nM of miR-34a
inhibitor final concentration for the transfection. As a negative control, we
transfected cells with miRCURY LNA microRNA Inhibitor Negative Control A at the
same final concentration. Thirty-two hours after the transfection, cells were treated
with Doxo and Nutlin. Effects were assessed 16 h after the treatments, that is, 48 h
after transfection.
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ABSTRACT
The p53 and NFκB sequence-specific transcription factors play crucial roles 
in cell proliferation and survival with critical, even if typically opposite, effects 
on cancer progression. To investigate a possible crosstalk between p53 and NFκB 
driven by chemotherapy-induced responses in the context of an inflammatory 
microenvironment, we performed a proof of concept study using MCF7 cells. 
Transcriptome analyses upon single or combined treatments with doxorubicin 
(Doxo, 1.5μM) and the NFκB inducer TNF-alpha (TNFα, 5ng/ml) revealed 432 up-
regulated (log2 FC> 2), and 390 repressed genes (log2 FC< -2) for the Doxo+TNFα 
treatment. 239 up-regulated and 161 repressed genes were synergistically regulated 
by the double treatment. Annotation and pathway analyses of Doxo+TNFα selectively  
up-regulated genes indicated strong enrichment for cell migration terms. A panel 
of genes was examined by qPCR coupled to p53 activation by Doxo, 5-Fluoruracil 
and Nutlin-3a, or to p53 or NFκB inhibition. Transcriptome data were confirmed for 
12 of 15 selected genes and seven (PLK3, LAMP3, ETV7, UNC5B, NTN1, DUSP5, SNAI1) 
were synergistically up-regulated after Doxo+TNFα and dependent both on p53 and 
NFκB. Migration assays consistently showed an increase in motility for MCF7 cells 
upon Doxo+TNFα. A signature of 29 Doxo+TNFα highly synergistic genes exhibited 
prognostic value for luminal breast cancer patients, with adverse outcome correlating 
with higher relative expression. We propose that the crosstalk between p53 and NFκB 
can lead to the activation of specific gene expression programs that may impact on 
cancer phenotypes and potentially modify the efficacy of cancer therapy.
INTRODUCTION
Cancer cells are continuously exposed to a number 
of signaling cues that reflect the distinct nature of the 
microenvironment at primary tumor site, metastastic 
lesions and potentially also during circulation in the blood 
stream [1–4]. Therapeutic intervention strategies can 
result in acute changes in microenvironment signaling, 
acting also through non-transformed cellular components 
resident at the primary tumor site [3, 5]. Cellular responses 
to changes in the microenvironment requires coordinated 
activation of sequence-specific transcription factors [6], 
among which NFκB and p53 have a prominent role and 
often opposing functions [7].
The p53 tumor suppressor gene is activated in 
response to a large number of cellular stress signals, 
including genotoxic stress, carbon and oxygen 
deficiencies, excessive proliferation signals [8, 9]. 
There are >150 established p53 target genes that link 
p53 to many different biological outcomes [10–14]. 
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The NFκB family of sequence-specific transcription factors 
consists of essential regulators of immune, inflammatory, 
proliferative and apoptotic responses [15], and their 
activation generally results in the onset of pro-survival 
signals [16]. The most common form of the NFκB complexes 
is the p50/RELA (p65) heterodimer. p53 and NFκB 
activation occurs simultaneously in response to diverse 
stress conditions, including genotoxic stress and NFκB 
proteins are frequently de-regulated in cancer, resulting in 
constitutive activation [17]. Competition between p53 and 
NFκB for a common limiting cofactor such as p300 can 
result in mutual inhibition [17, 18]. However, examples of 
positive interactions have also been reported. For example, 
it was shown that p65 can induce the p53 target gene p21 by 
direct binding to its promoter [19] and participates in p53-
dependent apoptosis [20]. Several human Toll-like receptors 
(TLRs), whose signaling leads to NFκB activation [21], 
were identified as direct p53 target genes both in cancer cells 
and primary cells [22] and it was demonstrated that p53 and 
NFκB can cooperate in the activation of pro-inflammatory 
genes in primary human monocytes and macrophages [23].
To investigate more globally the transcriptional 
crosstalk between p53 and NFκB we performed a proof 
of concept study using breast cancer-derived MCF7 
cells treated with Doxorubicin, Tumor Necrosis Factor 
alpha (TNFα) and a combination of the two compounds 
(Doxo+TNFα). Our results demonstrated a synergistic 
interaction between p53 and NFκB transcription factors, 
which can lead to the reprogramming of cell fate and 
enhanced migratory potential. Seven genes (PLK3, 
LAMP3, ETV7, UNC5B, NTN1, DUSP5, SNAI1) 
were established as synergistically up-regulated after 
Doxo+TNFα and dependent both on p53 and NFκB. A 29-
gene signature of highly synergistic genes up-regulated 
by Doxo+TNFα appeared to have prognostic value in a 
cohort of luminal breast cancer patients [24].
RESULTS
Striking transcriptome changes upon the 
combination of Doxorubicin and TNFα treatment 
of MCF7 cells
We first investigated the potential crosstalk between 
Doxorubicin (Doxo) and TNFα treatment using gene 
reporter assays in the human breast adenocarcinoma-
derived MCF7 cells (Figure S1A). p53-dependent 
responsiveness of the P21 and MDM2 promoter plasmid 
constructs was observed following Doxo treatment and 
confirmed by p53 silencing. The transactivation of the 
P21 and MDM2 constructs was reduced upon addition 
of TNFα to Doxo, suggesting possible inhibition of p53 
activity by NFκB. Mutual inhibition of the p53 and p65/
RELA proteins has been previously shown on p21 [17], 
while both inhibition and cooperation were reported at the 
BAX gene [18, 20]. However, this effect was not observed 
at the level of the endogenous P21 and MDM2 genes 
(Figure S1B), which showed similar level of activation 
in response to either Doxo alone or Doxo+TNFα. An 
NFκB reporter construct was responsive to both Doxo and 
TNFα as single treatments and showed a strong increase 
following the double treatment that was unaffected by 
p53 silencing. On the contrary, the endogenous TNFα 
and MCP1 NFκB target genes were weakly responsive 
to Doxo alone, highly induced by TNFα treatment, 
and showed intermediate induction levels upon double 
treatment. Hence, canonical p53 or NFκB target genes 
did not exhibit synergistic transcriptional responses to the 
combined treatment with doxorubicin and TNFα.
Next we performed a genome-wide transcriptome 
analysis after Doxo, TNFα, or the combination of the 
two compounds using the Agilent 4 × 44k array and 
single color labeling. Differentially expressed genes 
(DEGs) were selected based on rank product test, 
setting a threshold of 0.05 on the percentage of false 
positives (pfp) and a threshold of 2 on the absolute log2 
fold changes. The double treatment more than doubled 
the number of DEGs (Figure 1). The vast majority 
of DEGs resulting from the single treatments were 
also differentially expressed in the double treatment. 
Gene Ontology (GO) as well as pathway and upstream 
regulators analyses (DAVID, http://david.abcc.ncifcrf.
gov/; IPA, http://www.ingenuity.com/) confirmed 
activation of p53 signaling upon Doxo treatment as 
most significant pathway, and apoptosis induction 
as the most significantly enriched GO terms among 
up-regulated DEGs (Figure 1A-C). TNFα treatment 
also resulted in gene annotation terms consistent with 
NFκB activation, such as regulation of T cell activation. 
The gene annotation of DEGs resulting from the double 
treatment was enriched for terms typical of the two 
single treatments (e.g. T cell activation and apoptosis 
regulation among the up-regulated DEGs). TP53 as an 
upstream regulator was less significant in the double 
treatment compared to the Doxo single treatment, while 
p65/RELA, NFKBIA, IRF7 and STAT1 appeared to 
be even more enriched in the double treatment compared 
to TNFα single treatment (Figure 1B). The double 
treatment not only led to a higher number of DEGs, but 
resulted in quantitative differences in gene expression 
levels compared to the single treatments. We applied a 
rigorous filter and identified 212 repressed, 361 induced 
DEGs that were synergistically regulated by the double 
treatment Doxo+TNFα (see Methods) (Figure 1D). 
Notably, this subgroup of up-regulated DEGs was 
enriched for cell migration GO biological process 
along with the expected canonical terms for p53 and 
NFκB. Collectively, our systematic analysis indicates 
a vast network of genes that can be mutually affected 
by combined activation of p53- and NFκB-dependent 
responses.
Oncotarget12113www.impactjournals.com/oncotarget
Doxorubicin + TNFα transcriptional synergy 
identifies new direct p53 and NFκB target genes
We selected fifteen genes for validation experiments 
based on (a) statistical analysis of synergistic up-regulated 
DEGs, (b) prior knowledge on direct regulation by either 
p53 or NFκB, (c) availability of ChIP-seq data for both 
transcription factors, and (d) gene functions in relation to 
cancer biology. The selected list contains genes encoding 
players of the control of various cellular processes, 
e.g. cell proliferation (PLK3, DUSP5, PLAU, GBX2, 
ETV7, EDN2), apoptosis (TNFRSF10B, UNC5B), 
inflammation (LAMP3, EGR2), development (GBX2, 
SOX9, NPPC, FOXC1) and cell migration (SNAI1, 
PLAU, UNC5B, NTN1, EDN2).
For twelve of the 15 genes we confirmed a 
synergistic response to the Doxo+TNFα treatment by 
qPCR (Figure 2A). Most of them were independently 
reported as putative targets of either p53, p65 or both 
according to published ChIP-seq data (for p65, http://
genome.ucsc.edu/ENCODE) [14, 25]. A potential direct 
contribution of NFκB on the observed gene expression 
Figure 1: A vast array of genes responds selectively to Doxorubicin and TNFα in MCF7 cells. (A) Number of DEGs 
identified after single or combined treatment (see Methods for statistical filters). Most significant gene ontology terms of down- or 
up-regulated DEGs, according to DAVID (http://david.abcc.ncifcrf.gov). (B) Predicted upstream regulators of the DEGs for the indicated 
treatments, according to IPA (IPA, http://www.ingenuity.com). The color code reflects the enrichment or depletion of the listed transcription 
factors targeting the DEGs from the array analysis. (C) Statistically relevant pathways predicted to be modulated in response to the 
indicated treatments according to IPA. (D) Number of DEGs that are synergistically regulated by the double treatment according to two 
different statistical filters (see Materials and Methods). The most significant gene ontology terms are also indicated.
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changes was evaluates using the small molecule 
inhibitor BAY 11–7082 (BAY) used as single agent or in 
combination with Doxo or/and TNFα (Figure 2B). Eight 
of the twelve validated synergistic DEGs were tested 
and for five of them BAY markedly inhibited the effect 
of Doxo+TNFα, or of TNFα alone. TNFα treatment led 
to higher levels of nuclear p65, while Doxo alone or in 
the combined treatment did not significantly impact p65 
nuclear protein levels. BAY treatment led to a slight 
reduction of p65 nuclear levels, which was paralleled 
by an increase in the cytoplasm (Figure 2C). p53 protein 
levels were induced to similar levels by the different 
treatment combinations (Figure S2).
The five genes that showed more convincing 
p65 dependence on the synergistic response to 
Doxo+TNFα (PLK3, NTN1, UNC5B, ETV7, LAMP3) 
were investigated more deeply to establish a direct role 
of wild type p53 in their transcription. MCF7 cells were 
treated with the chemotherapeutic agent 5-Fluorouracil 
(5FU) or with the MDM2 inhibitor Nutlin-3a, alone or in 
combination with TNFα. Both p53-inducing molecules 
were at least additive with TNFα in the responsiveness 
of the five genes (Figure 2D). Although the magnitude 
of the synergistic response was higher with Doxo, the 
fact that three different p53-activating treatments led 
to up-regulation of these five genes strongly suggested 
a direct role of p53. We next employed an MCF7 clone 
with stable knock-down of p53 and the HCT116 p53-/- 
cell line, to further establish p53-dependence of the five 
genes expression upon Doxo treatment. Matched MCF7 
vector and HCT116 p53+/+ were used as a comparison 
(Figure 2E, F). Invariably, Doxo responsiveness was 
strongly reduced in the p53-defective cells. Previous 
reports in the literature demonstrated or suggested p53-
dependent regulation of PLK3, NTN1 and UNC5B. Our 
results confirm those findings and establish, for the first 
time, the possibility of synergistic regulation by NFκB. 
PLK3, a polo-like kinase, is an important regulator of 
the cell cycle and it is involved in the control of hypoxia 
signaling pathway [26]. NTN1 is ligand for both DCC1 
and UNC5B receptors whose signaling can potentially 
modulate p53 activity, impacting on the decision between 
cell survival and cell death [27]. LAMP3 is a lysosomal 
membrane associated protein important in dendritic 
cells and potentially involved in tumor invasion [28], 
while ETV7 is a transcription factor associated to cell 
proliferation and tumorigenesis [29].
Given the lack of definitive evidence for LAMP3 
and ETV7 being direct p53 targets and since our finding 
of synergistic responsiveness, we examined p53 and 
(Continued )
Figure 2: p53- and p65-dependent up-regulation of selected synergistic DEGs. (A) Twelve out of fifteen selected synergistic 
DEGs were validated by qPCR. Plotted are the average fold change relative to the mock condition and three reference genes (GAPDH, 
B2M, ACTB) and the standard deviations of three biological replicates. “^” marks genes responding in synergistic manner to the double 
treatment. p53 and p65 occupancy data from available ChIP-seq datasets are summarized below each gene name. (B) Impact of the NFκB 
inhibitor BAY 11-7082 on the synergistic gene expression response plotted as in panel A. “*” Significant inhibition of by BAY when 
combined to Doxo + TNFα (t-test, p<0.01). NPPC and SNAI1 were also tested but their expression levels were not affected by BAY 
treatment. 
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p65 occupancy in MCF7 cells treated with Doxo or TNFα 
(Figure 3). p53 occupancy was detected both for ETV7 
and LAMP3 as well as for the positive control P21, in 
Doxo treated cells. For ETV7 p53 occupancy appeared 
to increase also after TNFα treatment. P21 was the only 
target for which p53 appeared to be bound also in the 
mock condition, a result consistent with previous data 
[30]. p53 occupancy levels were not distinguishable 
between Doxo and Doxo+TNFα treatment.
Both LAMP3 and ETV7 exhibited p65 occupancy in 
TNFα treated cells, although to a lower extent compared 
to the positive control MCP1. For the three promoter 
regions, occupancy was increased also by Doxo treatment 
alone, but no additive effect of the double treatment was 
apparent, except for a trend with LAMP3. On the contrary 
lower occupancy at MCP1 was detected in double treated 
cells. This latter result is consistent with the MCP1 mRNA 
expression changes (Figure S1B).
Hence, we identified genes whose expression is 
co-regulated by Doxo and TNFα. The gene expression 
studies conducted with different p53-activating molecules, 
the use of cells lines with different p53 status, and the 
chromatin immune-precipitation studies collectively 
established a direct role for p53 and p65 on the 
transcriptional regulation of PLK3, NTN1, ETV7, UNC5B 
and LAMP3. However, we did not find a direct correlation 
between occupancy levels at predicted promoter binding 
sites and gene expression changes.
Figure 2: (C) p65 nuclear (NE) and cytoplasmic (CE) relative protein levels under the different treatments used in panel B. M = mock; 
D = Doxo; T = TNFα; B = BAY. Proteins were fractionated as described in Materials and Methods. GAPDH and histone 3 (H3) served 
as controls for cytoplasmic and nuclear fraction respectively. As controls, a cytoplasmic mock fraction sample (CE) is loaded together 
with the nuclear proteins and vice versa a nuclear mock sample (NE) in included in the cytoplasmic blot. (D) 5-fluorouracil and Nutlin-3a 
induced expression of 5 selected DEGs alone or in combination with TNFα. Results were obtained and are plotted as in A. (E), (F) The 
relative expression of the 5 selected genes shown in panel C was tested in doxorubicin treated matched cell lines differing for p53 status 
(MCF7 vector and shp53, D; HCT116 p53+/+ and p53-/-, E).
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Doxorubicin + TNFα treatment enhances the 
migration potential of MCF7 cells
Both the gene ontology enrichments of synergistic 
DEGs and the known function of the fifteen genes chosen 
for validation suggested the possible activation of gene 
expression programs influencing cell motility, epithelial 
mesenchymal transition (EMT) or even stem-like 
phenotypes. Projected to an in vivo context, the crosstalk 
of signals present in an inflammatory microenvironment 
could have a negative impact on the efficacy of 
chemotherapy, possibly by enhancing tumor cell plasticity. 
To begin exploring this hypothesis, we investigated 
migration and invasion potential of MCF7 cells treated 
with Doxo, TNFα or both. Three different experimental 
approaches consisting in real-time cell migration analysis 
(Figure 4A), transwell migration test (Figure 4B) and 
wound healing assay (Figure 4D) consistently showed 
higher migration potential of double-treated MCF7 cells, 
while the invasion phenotype was unaffected by all three 
types of treatment (Figure 4C).
Several studies suggest that EMT not only enhances 
the motility and invasiveness of cancer cells, but also 
provides additional aggressive features such as stemness 
and therapeutic resistance [31]. Indeed, several of the 15 
synergistic DEGs we validated are directly or indirectly 
associated with acquisition of stem-like phenotypes in 
normal or cancer cells, particularly SNAI1 [32, 33], 
SOX9 [34] and GBX2 [35]. Different lines of evidence 
indicate that breast cancer stem cells (BCSCs) display 
increased cell motility, invasion, and overexpress genes 
that promote metastasis [36] and can be traced by CD44+/
CD24-/low surface marker expression [37]. We asked if 
the Doxo+TNFα treatment could enhance the stem-like 
subpopulation of the MCF7 cell line (Figure 4E). FACS 
analysis showed that the CD44+/CD24- subpopulation 
virtually disappeared after all treatments. Therefore, the 
higher motility observed upon double treatment cannot be 
directly related to the expression of these surface markers, 
hence to putative stem-like features.
Prognostic value of Doxorubicin + TNFα 
synergistic DEGs
Since luminal type breast cancer, of which MCF7 
is considered as a model, frequently retains wild type 
p53 and NFκB responsiveness, we asked if Doxo+TNFα 
synergistic DEGs could be endowed with prognostic 
significance. Up-regulated DEGs were further filtered 
by selecting genes that were strongly responsive to the 
double treatment but minimally responsive to the single 
ones (see Materials and Methods). A signature list of 
Figure 3: Occupancy analysis establishes ETV7 and LAMP3 as direct p65 and/or p53 target genes. (A) Relative 
quantification of immune-precipitated gene fractions by qPCR from MCF7 cells subjected to Doxo or TNFα single treatments and to the 
double treatment. The antibodies used for the immune-precipitations are listed. P21 was used as positive control, while ACTB was used 
as a negative control. Plotted are the average percentages relative to input signals. Error bars represent the standard errors of at least three 
biological replicates. (B) as in A, but probing p65 occupancy. MCP1 was used as positive control. The IgG antibody controls were anti-
mouse (A) or anti-rabbit (B) to match the specific primary antibodies. (C) The position of the primers used for the qPCR and the location 
of predicted p53 and p65 binding sites in the ETV7 and LAMP3 genes are depicted.
Oncotarget12117www.impactjournals.com/oncotarget
????? ??? ????? ? ?? ?? ?? ??????????????
??? ???????????????????????????????????????????????????
?? ???????????????????
?????
???? ???? ???? ????????????????????
??????????????? ??????????????????? ???????????????????????????????
???? ???? ???? ??????????????
???????????????
??????????????
?????????????????
?
?
?
?
?
????? ??? ????
????? ??? ?????????????? ??? ????
Figure 4: Doxo+TNFα leads to enhanced MCF7 motility but ablates the stem-like side population. (A) Real-time migration 
assays examined by xCELLigence. Plotted are the average results of four biological repeats. Cell Index is proportional to the number of cells 
migrating through a hole in the culture plate. The treatments relative to the different curves are indicated. (B) Relative transwell migration 
values quantified by a fluorescence readout (see Materials and Methods). Average and standard deviation of triplicate biological replicates are 
presented. The applied treatments are listed on the x-axis. (C) As for B, but measuring the invasion potential of MCF7. (D) Images of a wound 
healing assay obtained at T0 or T24. Composite (3×3) images were acquired using an automated Zeiss microscope and the AxioVision3.1 
software. (E) Cell sorting results based on intensity of CD44 and CD24 surface markers on 30000 cells. Q1 individuates the CD44+/CD24-(low) 
cells, considered as stem-like. The percentages in the four quadrants after the various treatments are presented in the table.
Oncotarget12118www.impactjournals.com/oncotarget
29 genes (DT29) was generated (Figure 5A) and used to 
interrogate clinical data using the KM plotter tool [38]. 
Interestingly, breast cancer patients with luminal type A 
diagnosis who underwent chemotherapy and exhibited 
higher relative expression of DT29 genes showed poorer 
prognosis (Figure 5B). The same was true for luminal A 
patients with lymph node infiltration or luminal A grade 2 
(Figure 5C, D).
Analysis of Doxorubicin and TNFα crosstalk in 
lung cancer-derived and HUVEC cells
We extended our analysis to another pair of cancer 
cell lines that differ for p53 status. A549 (p53 wild type) 
and H1299 (p53 null) lung cancer derived cells were 
treated with Doxo or/and TNFα or/and BAY. Expression 
of PLK3, NTN1, ETV7, UNC5B and LAMP3 was 
measured by qPCR (Figure 6A-E). The impact of the 
various treatments on p65 nuclear and cytoplasmic, p53 
and p21 protein levels was also evaluated (Figure 6F, 6G). 
In the p53 null H1299 cells the relative expression changes 
of all the genes was invariably much lower compared to 
A549 cells. However, NTN1 was weakly TNFα inducible 
and ETV7 was weakly Doxo+TNFα responsive. Instead in 
A459 cells NTN1, ETV7 and LAMP3 were synergistically 
up-regulated by Doxo+TNFα, while PLK3 and UNC5B 
were additive. The magnitude of induction upon Doxo 
was often one order of magnitude higher compared 
to TNFα alone. Transient transfection assays with the 
κB luciferase reporter construct were performed using 
different concentrations of TNFα or BAY (Figure S3). 
Based on the results, 10ng/ml TNFα and/or 20μM BAY 
were chosen for the qPCR experiments, although the 
reduction of TNFα-induced reporter activity was modest, 
albeit significant. At the endogenous gene level in A549 
cells we did not observe the inhibitory effect of BAY on 
either TNFα-induced changes or Doxo+TNFα, with the 
possible exception of UNC5B (Figure 6A-E). However, 
BAY treatment reduced the Doxo responsiveness of these 
genes, which might be dependent on its effect on the 
activation of NFκB by endogenous production of TNFα. 
In the p53 wild type A549 cells, p53 and p21 protein 
levels were induced by Doxo and not affected by the 
treatment with TNFα. Total p65 levels were unaffected 
by all treatments in both cell lines (Figure 6F). Nuclear 
p65 protein levels were increased in response to TNFα or 
Figure 5: Prognostic significance of a 29-gene list of synergistic Doxo+TNFα DEGs. (A) Top list of 29 genes (DT-29) 
exhibiting minimal responsiveness to Doxo or TNFα as single agents, but strong synergy upon combined treatment. A heat map view of 
the gene expression results is presented (see Materials Methods for statistical filters). Occupancy of both for p65 and p53 in the vicinity 
of the transcription start sites of these genes has been summarized from ChIP-seq data available in the literature. (B-E) Kaplan-Meier 
plots stratifying a breast cancer patient cohort based on the relative expression of the DT-29 gene list and relapse free survival. Graphs 
were generated with the KM-plotter tool (ref). Patients’ numbers are listed below the graph. Hazardous Ratio and the statistical analysis is 
reported for selected patients subgroups: (B) luminal A patients who underwent chemotherapy treatment (n = 111); (C) luminal A patients 
with a Grade 2 cancer at diagnosis (n = 385); (D) luminal A patients with lymph node infiltration at diagnosis (n = 447) and (E) the entire 
cohort of luminal A patients (n = 1509). Patients with a diagnosis of Luminal A breast cancer subtype were selected as the p53 status is not 
available in KM plotter, but this subgroup of breast cancer is expected to be strongly enriched for cases retaining wild type p53 protein.
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Figure 6: PLK3, NTN1, ETV7, UNC5B and LAMP3 responsiveness in lung cancer cell lines. (A-E) Relative fold change 
expression of the indicated genes and after the listed treatments in A549 (p53 wild type) and H1299 (p53 null) cells, measured by qPCR. 
Average and standard deviations of three biological replicates are presented. (F) Western blot of total p65, p53 and the p53 target p21. 
GAPDH was used as loading control. (G) Western blot of nuclear and cytoplasmic protein fractions were performed as for Figure 2C.
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Doxo+TNFα in both A549 and H1299 cells (Figure 6G). 
Interestingly, BAY treatment alone or in combination led 
to a reduction in p65 nuclear accumulation (Figure 6G).
HUVEC primary cells were also subjected to Doxo 
and TNFα single or double treatment and the expression 
of the same panel of five genes was tested by qPCR 
(Figure S4). Results among biological repeats varied, but 
in the majority of tests, all genes with the exception of 
LAMP3 were Doxo responsive; NTN1 and ETV7 were 
also TNFα responsive. No synergistic up-regulation by the 
double treatment could be consistently established. p53 
and p65 protein levels confirmed i) the activation of p53, 
with a similar level of p53 protein in the double treatment, 
and ii) the p65 proficiency of this cell line.
DISCUSSION
Wild type p53 functions are intricately related to 
multiple tumor suppressor pathways, primarily acting 
in cell autonomous manner to restrain cell proliferation 
and including cell death and senescence in response 
to genotoxic and many other types of cellular stresses 
[8, 9]. Furthermore, p53 also contributes to modulate 
the microenvironment in a non-cell autonomous 
manner [39]. p53 has also been linked to inhibition of 
EMT, for example through an indirect stimulation of 
E-cadherin expression [40]. At the same time, paracrine 
signaling in mice triggered by Doxorubicin were found 
to stimulate EMT and metastatic potential of cancer 
cells, in part through NFκB activation [3]. Many studies 
have highlighted the potential contribution of NFκB-
induced signaling in the acquisition of cancer cell traits 
conducive to chemoresistance and higher metastasis 
risk [2] [41]. While, the canonical functions of p53 and 
NFκB are consistent with the co-occurrence of p53 
inactivation and NFκB hyper-activation that is frequent in 
cancer [7], recent studies provided examples of positive 
cooperation between p53 and NFκB that would occur 
in specific cell types, such as antigen presenting cells or 
macrophages, and contribute to physiological responses, 
such as for example in the process of innate immunity and 
inflammation [12, 22, 23, 42].
Here we modeled the impact of a first line 
chemotherapeutic drug leading to genotoxic stress and 
p53 activation, using exposure to the immune cytokine and 
NFκB activator molecule TNFα as a variable, mimicking 
the effect of an inflammatory microenvironment. We 
used transcriptome analysis as primary endpoint and 
uncovered a vast network of differentially expressed 
genes that selectively responds to combined treatment 
with Doxorubicin and TNFα. Furthermore, genes that 
were synergistically up-regulated by both treatments 
appeared to endow cells with higher motility potential 
in vitro. Analyses of the annotated gene functions related 
to the aforementioned genes also revealed the possibility 
of an induced epithelial mesenchymal transition upon 
combination of the treatments. For example, SNAI1 
appeared to be regulated in more than additive manner 
by the double treatment, as well as LAMP3, a lysosomal 
protein previously associated with metastasis risk [28, 
43]. Multiple cytokines and secreted factors, including 
IL6, IL17, IL15 and its receptor, S100A8 and S100A9, 
CXCL12 and several Serpins were also identified as 
synergistic DEGs (Table S1). The presence of S100A8, 
S100A9 and CXCL12 among synergistic DEGs raises 
the possibility that, unlike the case of the triple negative 
cell line MDA-MB-231 for which S100A8-mediated 
signaling appeared to require heterotypic cell interactions 
[3] contributing to metastasis potential, in MCF7 cells 
this signaling could become homotypic or even autocrine. 
A marked difference in secreted factors and associated 
signaling among MDA and MCF7 cells was elegantly 
shown in recent studies [4].
A direct contribution of p65/RELA and p53 
in the observed gene expression changes elicited by 
Doxorubicin and TNFα was inferred for some of the 
synergistic DEGs by modulating pharmacologically or 
genetically p65 or p53 activities. However, we cannot 
exclude at this stage a (Doxo+TNFα)-dependent, but 
p53- or NFκB- independent gene expression changes. 
For example, NFkB can functionally interact with 
AP-1 [44–46] or ER [47], which in turn can modulate 
p53-dependent responses [48] [49] [50].
Among the most synergistic genes, 29 appear to 
be prognostic in luminal A breast cancer patients who 
underwent chemotherapy, where their higher expression 
correlated with adverse outcome. The majority of luminal 
A breast cancers are wild type for p53 [51], although data 
is not available to stratify patients for p53 status in the 
KM plotter tool [24]. Based on available ChIP-seq data 
[14, 25, 52, 53], 20 of these 29 genes are putative targets 
of either p53 or p65 and 10 of them are putative targets of 
both factors (Figure 5). This result raises the possibility 
of an unexpected negative outcome of chemotherapy in 
the context of an inflammatory microenvironment. The 
prognostic significance of this gene signature needs 
in-depth evaluation in independent patients cohorts. If 
confirmed, the results would further support the value 
of combining treatments activating p53 and repressing 
NFκB [7].
Given that the crosstalk between Doxorubicin 
and TNFα and the interplay between p53 and NFκB 
would occur in cells residing or infiltrating the tumor 
microenvironment, the ultimate in vivo outcome of these 
functional interactions may vary and cannot be directly 
predicted from our study using a pure culture of MCF7 
cells in vitro. Here we have explored Doxo+TNFα 
impact on HUVEC cells and also on a p53 wild type lung 
adenocarcinoma-derived cancer cell line. Although limited 
by the number of genes tested, the results suggest that a 
positive crosstalk between Doxorubicin and TNFα can 
be a general characteristic of different cell types and is 
Oncotarget12121www.impactjournals.com/oncotarget
at least in part p53-dependent, based on the results with a 
p53 null lung cancer cell line. Furthermore, while we have 
addressed here the functional interactions between two 
small molecules, cells are constantly exposed to a complex 
milieu of signaling factors. However, both p53 and NFκB 
are master regulators, often contributing a dominant trait 
in gene expression changes to their target genes. Nuclear 
receptors, including Estrogen Receptors (ERs) can also 
modulate NFκB as well as p53 functions [54–56] and 
have critical roles in breast cancer etiology. We also 
explored the impact of ER function in the transcriptional 
programs responding to Doxorubicin and TNFα exposure, 
using estrogen-depleted culture conditions and adding 
17β-estradiol (10-9M, E2) as variable (Table S2 and GSE 
24065). However, the combination of E2 to Doxo and 
TNFα resulted only in 15 and 11 selective up- and down-
regulated DEGs, respectively (Table S3). A hierarchical 
cluster analysis of all the treatments confirmed graphically 
the large difference between TNFα- and Doxo-induced 
transcriptomes and also the significant impact of TNFα 
when combined to Doxo, while E2 had a minor effect both 
in the combination with Doxo and with Doxo + TNFα 
(Figure S5).
With this study we established an example of 
positive cooperation between p53 and NFκB, in the 
context of the responses of an epithelial cancer cell to 
standard chemotherapy but in the presence of active 
signaling by a pleiotropic inflammatory cytokine, such as 
TNFα. A signature gene of the consequent transcriptional 
reprogramming appears to be prognostic in breast cancer 
patients. Associated gene functions indicate the potential 
acquisition of enhanced cell plasticity and motility and 
provide a rationale to investigating mechanisms resulting 
in acquired chemoresistance, particularly for luminal A 
breast cancer, but potentially with general implication 
for p53 wild type tumors of different tissue types, and 
for overcoming such resistance by targeting NFκB. The 
unexpected positive crosstalk between p53 and NFκB 
emerging from our and other very recent studies [23] 
may represent an evolutionary consequence of anti-
viral and infection responses towards which NFκB is 
an established master regulator [57], but the p53 and 
p73 family member are emerging as important/critical 
contributors [42, 58, 59].
MATERIALS AND METHODS
Cell lines and culture conditions
MCF7 (p53 wild type, expressing p65 and positive 
for ERs) and HUVEC (Human Umbilical Vein Endothelial 
Cells) cells were obtained from ICLC (Genoa, Italy), while 
A549 from ATCC (Manassas, VA, USA). H1299 cells were 
a gift of Dr. Resnick’s laboratory (NIEHS, NIH, RTP, NC, 
USA); HCT116 p53+/+ and p53-/- of Dr. Vogelstein’s (John 
Hopkins Kimmel Cancer Center, Baltimore, MD, USA). 
MCF7-shp53 or control MCF7-vector cells were provided 
by Dr. Agami (Netherlands Cancer Institute, Amsterdam, 
The Netherlands). Cells were cultured in DMEM or 
RPMI media supplemented with 10% FBS, or Medium 
199 (Lonza Milan, Italy) supplemented with 50 units/
ml Low Serum Growth Supplements (Life Technologies, 
Milan, Italy) in the case of HUVEC cells that were also 
cultured on 0.1% gelatin pre-coated plastics. Media were 
supplemented by 2mM L-Glutamine and 1XPenicillin/
Streptomycin mixture (Pen/Strep), and Puromycin (0.5 μg/
mL) in the case of MCF7-shp53 and –vector cells. When 
appropriate, cells were maintained in DMEM without 
Phenol Red (Lonza) supplemented with Charcoal/Dextran 
treated FBS (Hyclone, GE Healthcare, South Logan, 
UT, USA).
Drug treatments
Doxorubicin (Doxo, 1.5 μM), 5-Fluorouracil (5FU, 
375 μM), Nutlin-3a (10 μM) were used to stabilize p53 
protein. When needed TNFα (5ng/ml in MCF7 and 10ng/
ml in H1299, A549 and HUVEC cells –based on dose-
response tests with gene reporter assays) or BAY11-7082 
(10μM or 20μM in H1299 and A549) were added to the 
culture medium. All compounds were from Sigma-Aldrich 
(Milan, Italy).
Microarray experiment and data analysis
Total RNA was extracted from 4 biological 
replicates using the Agilent Total RNA Isolation Mini Kit 
(Agilent Technologies, Santa Clara, CA, USA). Samples 
with RNA Integrity Number (RIN) above 9 (Agilent 2100 
BioAnalyzer) were processed. Details are provided with 
the Gene Expression Omnibus (GEO) (www.ncbi.nlm.
nih.gov/geo) submission (GSE24065) and in [56]. The 
output of Feature Extraction (Agilent standard protocol 
GE1_107_Sep09) was analyzed with the R software for 
statistical computing and the Bioconductor library of 
biostatistical packages. Probes with low signals were 
removed in order to filter out the unexpressed genes 
and keep only probes with acceptable signals in most 
of the replicates. Signal intensities across arrays were 
normalized by quantile normalization. Signal intensities 
from probes associated with the same gene were averaged. 
This procedure resulted in quantitative signals for 14095 
HGNC genes. To identify potential target genes of 
Doxorubicin and TNFα, we compared the signals after 
the double treatment (Doxo+TNFα) and the two single 
treatments relative to the untreated control (mock). 
DEGs were selected applying a statistical test based on 
rank products implemented in RankProd Bioconductor 
package, setting a threshold of 0.05 on the percentage of 
false positives (pfp) and a threshold of 2 on the absolute 
log2 fold changes [60]. Every treatment was compared to 
the mock condition (Table S1, S2 and Figure S5).
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To select genes with synergistic effect, i.e. genes 
whose expression variations were more than additive in 
the double treatment with respect to single treatments, a 
further comparison between the double treatment samples 
and all the remaining samples (single treatments and 
control samples) was performed (double treatment vs all). 
Synergistic DEGs were selected applying an additional 
pfp filter (pfp<0.005) derived from this comparison, to 
the list of DEGs resulting from the “double treatment 
vs mock” comparison. A more stringent criterion was 
obtained by calculating the synergistic effect (SE) of 
the double treatment as the observed difference between 
the fold change of the double treatment and the sum of the 
fold changes of the single treatments (SE=log2 FC double 
treatment – (log2 FC Doxorubicin + log2 FC TNFα). 
We filtered genes with SE>0 for up-regulated DEGs, 
SE<0 for down-regulated genes (Figure 1). To select 
genes where the up-regulation contribution of each single 
treatment was low respect to the up-regulation of the 
double treatment, the ratio of the single/double treatments 
was calculated, applying a 0.25 filter on them (FC 
Doxorubicin/FC double treatment <0.25 and FC TNFα/
FC double treatment <0.25) (see Table S1, S2).
RNA isolation and quantitative qPCR
Total RNA was extracted using Qiagen RNeasy Kit 
(Qiagen). cDNA was converted from 1 µg of RNA using 
M-MuLV reverse transcritptase and RevertAid cDNA 
Synthesis kit (ThermoFisher, Milan, Italy). qPCR was 
performed on a Bio-Rad CFX384 (Bio-Rad, Milan, Italy). 
TaqMan gene expression assays (Applied Biosystems, Life 
Technologies) and Probe MasterMix (Kapa Biosystems, 
Resnova, Rome, Italy) were used starting with 25ng of 
cDNA as previously described [56, 61]. GAPDH, B2M or 
ACTB served as reference genes.
Western blot
Protein extraction and immunodetections were 
performed as previously described [62], using ECL Select 
detection reagent (GE Healthcare) and anti-p53 (DO-1) 
anti-RelA/p65 (C-20) anti- p21 (C19), anti-GAPDH (6C5) 
(Santa Cruz Biotechnology, Heidelberg, Germany). When 
appropriate, nuclear and cytoplasmic fractionation was 
performed. MCF7, A549 and H1299 cell lines were seeded 
on 100mm Petri dishes and treated at 80% confluence 
with Doxo, TNFα, BAY or the combination of the drugs 
for 16 hours. Cells were harvested and cytoplasmic and 
nuclear proteins were extracted using NE-PER Nuclear 
and Cytoplasmic Extraction Kit (Pierce, ThermoFisher 
Scientific), following the instructions provided by the 
manufacturer. 20 μg of nuclear and cytoplasmic extracts 
were loaded on a 12% poly-acrylamide gel and transferred 
to nitrocellulose membranes. Antibodies used for detection 
were: anti-Histone H3 (clone #: ab1791, AbCam, Milan, 
Italy) and anti-Lamin A/C (clone #: 2032, Cell Signaling, 
Milan, Italy) used as nuclear loading control, and anti-
GAPDH used as cytoplasmic loading control.
Chromatin immunoprecipitation assay
We used previously described protocols [63, 64]. 
The following antibodies were used: anti-p53 (DO-1), 
anti-p65 (C-20) and IgG (sc-2025 or sc-2027) (Santa Cruz 
Biotechnology). ChIP-qPCR experiments were performed 
using Sybr MasterMix (Kapa Biosystems) and 2 μl of 
enriched DNA. Results were analyzed by the comparative 
Ct method (ΔCt) and normalized as % of input. Regions 
in the promoter of GAPDH or ACTB and p21 or 
MCP1 genes served as negative and positive controls, 
respectively. Primers were selected using Primer 3 
(http://primer3.ut.ee/).
Migration and wound healing assays
The migration potential of MCF7 cells was 
monitored by a real-time technique using the 
xCELLigence Instrument (Acea Biosciences, Euroclone) 
and CIM-16 plates, following manufacturer’s instructions. 
Prior to the analysis, cells were grown in estrogen-free 
medium for two days and left untreated (mock) or treated 
with Doxo, TNFα or the combination. 16 hours after 
the treatments, cells were detached and added to the top 
chamber in serum-free medium. Migration was detected 
every 10 minutes for 24 hours. We used 0.5% and 5% 
FBS as chemo-attractant. Migration and Invasion were 
also measured by QCMTM Fluor 24-Well Cell Migration 
and Cell Invasion kits (Merck-Millipore, Milan, Italy), 
according to manufacturer’s instructions. For wound 
healing, cells were seeded in 12-well plates and treated 
with Doxo, TNFα or the combination. After 16 hours a 
scratch was introduced using a 10 μl pipette tip. Images of 
the same field were acquired immediately (T0) and after 
24 hours (T24) using an automated Zeiss microscope and 
the AxioVision3.1 software in multidimensional mode 
with mosaic (3x3) acquisition.
Flow cytometry
MCF7 cells, seeded and treated as described 
above, were washed with PBS and harvested by 0.05% 
trypsin/0.025% EDTA. The cells were washed again 
with PBS containing 2% FBS before being subjected 
to antibody binding, a combination of fluorochrome-
conjugated monoclonal antibodies against human CD44 
(APC) and CD24 (FITC) or their respective isotype 
controls (BD Biosciences, Milan, Italy) and incubated on 
ice in the dark for 30 minutes. Cells were then washed 
twice with PBS/2% FBS and resuspended in PBS. Flow 
cytometry analysis was conducted using a FACSCanto II 
instrument (BD Biosciences).
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6 Abstract
7 Background: Many recent studies using ChIP-seq approaches cross-referenced to trascriptome data and also to
8 potentially unbiased in vitro DNA binding selection experiments are detailing with increasing precision the p53-directed
9 gene regulatory network that, nevertheless, is still expanding. However, most experiments have been conducted
10 in established cell lines subjected to specific p53-inducing stimuli, both factors potentially biasing the results.
11 Results: We developed p53retriever, a pattern search algorithm that maps p53 response elements (REs) and ranks
12 them according to predicted transactivation potentials in five classes. Besides canonical, full site REs, we developed
13 specific pattern searches for non-canonical half sites and 3/4 sites and show that they can mediate p53-dependent
14 responsiveness of associated coding sequences. Using ENCODE data, we also mapped p53 REs in about 44,000 distant
15 enhancers and identified a 16-fold enrichment for high activity REs within those sites in the comparison with genomic
16 regions near transcriptional start sites (TSS). Predictions from our pattern search were cross-referenced to ChIP-seq,
17 ChIP-exo, expression, and various literature data sources. Based on the mapping of predicted functional REs near TSS,
18 we examined expression changes of thirteen genes as a function of different p53-inducing conditions, providing
19 further evidence for PDE2A, GAS6, E2F7, APOBEC3H, KCTD1, TRIM32DICER, HRAS, KITLG and TGFA p53-dependent
20 regulation, while MAP2K3, DNAJA1 and potentially YAP1 were identified as new direct p53 target genes.
21 Conclusions: We provide a comprehensive annotation of canonical and non-canonical p53 REs in the human genome,
22 ranked on predicted transactivation potential. We also establish or corroborate direct p53 transcriptional control
23 of thirteen genes. The entire list of identified and functionally classified p53 REs near all UCSC-annotated genes
24 and within ENCODE mapped enhancer elements is provided. Our approach is distinct from, and complementary
25 to, existing methods designed to identify p53 responsive elements. p53retriever is available as an R package at:
26 http://tomateba.github.io/p53retrieverQ6 .
27
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28 Background
29 The p53 tumor suppressor is certainly one of the most
30 studied sequence-specific transcription factor to date.
31 Yet, much has still to be learned to fully describe its
32 transcriptional regulatory network, both in terms of the
33 crosstalk with other transcription factors and in terms of
34 the entire spectrum of regulated transcriptional target genes,
35 that can be both up-regulated or down-regulated [1–6].
36 Recently, several genome-scale techniques such as
37 ChIP-on-chip, ChIP-seq, and, more recently, ChIP-exo,
38 have provided us with different and largely non-
39overlapping maps of p53 bound sites in the human gen-
40ome in response to specific stimuli [7–17]. Correlation
41between occupancy data and modulation of transcrip-
42tion levels of nearby genes helped identifying additional
43direct p53 target genes, of which >200 have been estab-
44lished [2, 15]. Furthermore, new methodologies are re-
45fining the potential to map the p53 network taking also
46into account the kinetics of transcriptional initiation
47[18, 19]. It is worth noting that, to date, most experi-
48ments have been developed in cancer-derived cell lines
49that may represent an adapted environment potentially
50biasing a comprehensive annotation of physiological
51p53 target sites [7, 20]. To this respect, the impact of
52specific p53-inducing stimuli and the differentiation/
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53 tissue context of the cell have not been systematically
54 investigated [4, 7, 8, 21, 22].
55 Considerable attention has been given to the sequence
56 and structural features of p53 binding sites that provide
57 for p53 recruitment to target sites [2, 5, 6]. It is now
58 more clear that the loose definition of p53 response
59 element (RE) [23] that has been used for many years
60 comprises a wide range of DNA binding affinity, occu-
61 pancy rates and transactivation potentials measured by
62 various types of assays, and that specific differences in
63 the definition of p53 REs are evident between purely
64 in vitro biochemical assays and in vivo occupancy mea-
65 surements [24–28] .
66 The canonical p53 consensus found in many identified
67 binding sites of mostly up-regulated p53 target genes
68 consists of two copies of the palindromic half-site
69 RRRCWWGYYY separated by a spacer of 0–13 bp, in
70 which R = purine, W =A or T and Y = pyrimidine. The-
71 oretically, each p53 monomer binds five nucleotides –
72 i.e., one monomer binds the I° quarter site R1R2R3C1
73 W1 and the second monomer the II° quarter site
74 W2G1Y1Y2Y3-. As reviewed previously, the rather degen-
75 erate p53 consensus sequence, reflects the established
76 observation that in virtually all cases of validated p53
77 REs, an optimal consensus site is not found, because of
78 mismatches, in some cases resulting in partial binding
79 sites, referred to as non-canonical REs [5, 24, 29]. This
80 has raised the hypothesis of a selection pressure to limit
81 the intrinsic potential of p53 proteins to target binding
82 sites, thereby allowing for modulation of p53-induced
83 transcriptional changes by signal transduction pathways
84 affecting p53 protein amount, DNA binding potential,
85 quaternary structures and/or availability of multiple
86 trans-factors [30–36]. For example, p53 REs with lower
87 DNA binding affinity appear to be more frequent in tar-
88 get genes involved in apoptosis [28]. Consistent with this
89 hypothesis, optimized p53 REs have been recently stud-
90 ied in experimental models and in vitro for their kinetic
91 and thermodynamic interactions with p53 as well as
92 transactivation potential and shown to provide for high
93 level of p53-mediated transactivation even at low p53
94 protein levels [25].
95 Functional assays in a defined experimental setting
96 provided by the yeast S. cerevisiae has been extensively
97 used to characterize the transactivation potential of p53
98 RE in isogenic conditions and exploit variable expression
99 of p53 under an inducible promoter to yield a matrix of
100 transactivation results, to some extent comparable in
101 precision to that of a biochemical assay in a test tube [5,
102 24, 26, 28, 37–41]. Further, high correlation was re-
103 ported between results in yeast and transactivation or
104 occupancy data in cancer cell lines [24, 27]. For example,
105 experiments in this model system led to identify functionally
106 active half-site and 3/4 site (3Q) p53 REs, a group of REs
107collectively considered as non-canonical that were then
108mapped and validated also in human cells [7].
109Here we have combined all the data obtained so far
110with the yeast-based p53 transactivation assay and devel-
111oped an algorithm, p53retriever, to scan DNA sequences,
112identify p53 REs and classify them based on predicted
113transactivation potential into five broad categories. As
114unique features, this algorithm takes into account co-
115operative interactions between groups of mismatches in
116two p53 dimers and scores also non-canonical REs.
117Specifically we used this approach to map functional
118p53 REs in the proximity of all annotated coding genes,
119searched for high affinity p53 REs in the entire genome,
120and mapped functional p53 REs within ENCODE-
121defined distant enhancer regions. The predictive power
122of mapping p53 REs with high functional score near
123transcription start sites (TSS) was validated for a panel
124of 13 genes, using cell lines differing for p53 status, two
125p53-inducing stimuli and measuring relative expression
126by qPCR at three time points. APOBEC3H, E2F7, GAS6,
127TRIM32, PDE2A, KCTD1, DICER, MAP2K3, DNAJA1,
128HRAS, KITLG, TGFA and potentially YAP1 were con-
129firmed or identified as p53 target genes.
130Results and discussion
131Development and implementation of p53retriever, a
132pattern search code that identifies canonical and
133non-canonical p53 REs based on predictions from
134transactivation assays
135In general, the degree of p53 binding depends on various
136factors including the state of the p53 protein, its cofac-
137tors, and the sequence composition of the p53-RE [5,
13832]. Because easier to predict than the p53 state, compu-
139tational algorithms were developed to explore p53 bind-
140ing through sequence motif analysis. The majority of
141these algorithms, such as p53MH [42], do not directly
142consider the response element (RE) potential to drive
143p53-dependent transactivation. On the contrary, p53re-
144triever is based on a set of manually curated rules, de-
145rived from a compendium of p53 transactivation data
146obtained using a yeast-based assay [24, 26, 37, 43, 44].
147REs are scored from five (= highly functional REs ac-
148tivity) to one (= unlikely functional REs) (Fig. F11a). The
149grade represents the inferred transactivation potential
150rather than being an indication of the percent similarity
151to the canonical p53 consensus sequence. For full site
152p53 REs the grade considers a severe negative impact of
153a spacer between the two half sites larger than two nu-
154cleotides (Fig. 1c). Variable p53-RE spacer lengths are
155known to affect transactivation capacity. Only two previ-
156ous studies tried to incorporate the spacer length as one
157of the relevant features [11, 45], calculating a penalty
158score directly proportional to spacer length. Also in our
159algorithm, based on previous results, we attribute high
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160 negative impact to spacers longer than two nucleotides
161 (Fig. 1c). Indeed, REs with a long spacer length are also
162 confirmed to be rarely bound by p53 in vivo [7, 14, 46,
163 47]. Many of the computational approaches for identify-
164 ing putative p53-REs define how similar that putative
165 binding site is to the consensus, but do not consider the
166 local context of single mismatches within the RE. In our
167 approach mismatches from consensus are also weighted
168 depending on their position within the RE 20-mer se-
169 quence, given the finding that mismatches in the quarter
170 sites at the interface between the two half sites have a
171 more severe impact likely due to cooperative interac-
172 tions among two p53 dimers [28] (Fig. 1b). In addition,
173 interaction effects between groups of mismatches are also
174 considered. In general, any combination of mismatches is
175 penalized in a different way according to their location,
176 considering that p53 is functionally active as a tetramer,
177 that each p53 monomer interacts with a 5 nt motif (quarter
178 site) and that the p53 tetramer is thought to be assembled
179 as a dimer of dimers [48]. If groups of mismatches are lo-
180 calized in the same “quarter” of the RE, the score is less pe-
181 nalized than if the same mismatches were scattered in
182different quarters (Fig. 1b). Importantly, non-canonical REs
183consisting of 3Q sites and ½ sites [5, 7] are considered
184functional p53 REs with specific pattern searches. A
185graphical view of these features presented as “penalty
186matrix” summarizes the main features of our pattern
187search (Fig. 1c). The complete list of the rules used to
188attribute the functional score is presented (Additional
189file 1). The p53retriever pattern search algorithm, together
190with functions to better visualize search results, has been
191implemented as an R package and is available for
192download at: Q7http://tomateba.github.io/p53retriever.
193Distribution of identified p53 response elements around
194human promoters
195We applied p53 retriever to the set of sequences in the
196human genome placed around annotated transcriptional
197start sites (TSS), selecting a window from -10 kb to
19810 kb. The entire list of identified REs, chromosomal co-
199ordinates, official gene name, distance from TSS and RE
200sequence features resulting in the given grade, is avail-
201able in Additional file 2.
Fig. 1 Summary of RE sequence features and associated grades in p53retriever. a Grade: classification of REs reflecting associated functional
scores. The color code matching the 5 different grades will be maintained in all figures. b Mismatch label: classification of mismatches in different
positions. High penalties are given to mismatches located in the core consensus sequence (label A and B), lower penalties are given when
mismatches are gradually distant from the core (label C and D). Label O is given to a site without mismatches. Mismatches group penalties:
different penalties are attributed to groups of mismatches according to how they are scattered or grouped along the site. c Schematic
representation of the main rules on which p53retriever search algorithm is based. The full list of rules is listed in Additional file 1. The p53
consensus sequence is presented, grouping dinucleotide motifs that were revealed to provide a specific impact on transactivation potentials,
based on our previous studies (see text for details) [28]. Penalties are indicated by an increment in the number of the “-” symbol and a color
code broadly matching the grade scale. Single mismatches are more penalized when affecting a base in the internal portion of the RE, as
indicated. On the contrary, the AT motif at the center of the CWWG core is a positive feature, particularly in the case of non-canonical REs
(3Q = 3Q sites and half sites)
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202 The distribution of identified p53 REs grouped based
203 on the functional score, shows a very large preponder-
204 ance of “grade 1” REs, that are considered as unlikely
205 functional (Fig.F2 2a). Also, the distribution of RE scores is
206 highly skewed, with only 0.05 % of REs obtaining the
207 highest grade, supporting the hypothesis of a selecting
208 pressure to reduce p53 binding affinity and provide plasti-
209 city in the modulation of p53-mediated stress responses
210 in vivo [4, 28]. Very recent analyses confirmed that p53
211 REs that are more highly conserved in evolution are rela-
212 tively weak p53 RE sites displaying lower levels of occu-
213 pancy compared to higher affinity REs that exhibit low
214 evolutionary conservation [47]. Grade five sequences ei-
215 ther lack entirely mismatches, or contain two or fewer
216 mismatches in the external positions (R1,Y6/R4,Y3, see
217 Fig. 1c), and contain the positive AT motif in the CWWG
218 core. The vast majority of REs that can be considered
219 functional are in the grade two category. Predicted to be
220 poorly responsive on their own, these REs could partici-
221 pate in the regulation of gene expression conditional to
222 other features, such as the local sequence context of pro-
223 moter architecture. Included in the grade two category are
224~30 % of all half sites mapped (Fig. 2a). A unique feature
225of our search tool is the specific pattern search for non-
226canonical 3Q sites. Interestingly, even though mismatches
227in the two internal quarter sites have an higher impact on
228p53 transactivation for 3Q sites compared to full sites, and
229thus result in a final lower grade, many 3Q sites obtained
230a grade higher than 2. Hence, a great number (13,744)
231of p53 REs are predicted to be functional even though
232the entire motif is not present. This observation
233strongly supports recent reports suggesting that p53
234REs match the consensus in one half site, with the two
235central quarter sites being somehow less variable [14].
236It is also consistent with the recent report of the
237frequent identification of p53 half-sites among p53
238ChIP-seq peaks lacking full sites [47].
239We compared the results obtained searching within
240human promoters with what we would expect by
241chance, by applying p53retriever to sets of scrambled se-
242quences obtained by local permutations of real promoter
243sequences (see Methods and Supplementary Additional
244file 3: Table S1). Local permutations allowed us to pre-
245serve the local GC content of promoter regions, showing
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Fig. 2 analysis of p53 REs found in human promoters. a Pie chart displaying the distribution of grades associated to REs found in all human
promoters. b Comparison between the frequencies of REs found in human promoters, and the frequencies of REs found in scrambled promoter
sequences after applying local permutations (to preserve the local GC content). The comparison is shown for each grade. The ratio is 1 if the
frequency is the same, > 1 if the frequency is higher in real promoters, <1 if the frequency is higher in scrambled promoters. All enrichments are
significant, the binomial test p-value is 4.84E-04 for grade 5 (**), <1E-15 for all the other grades (***). c p53 occupancy metaprofile, based on the
position of REs in all human promoters, centered on the TSS position. The grey histogram displays the probability distribution of all REs independently
from the grade. Colored lines represent the density distribution of REs with higher grades (the grade threshold corresponding to each color is
displayed in the legend). The specific positions of grade 5 REs are dotted in yellow under the histogram. d p53 occupancy metaprofile, based
on the position of REs in the human promoters of 228 p53 target genes, published in [15]. The color scheme is the same as in panel C. The
specific positions of grade 4 and 5 REs are dotted under the histogram (in yellow for grade 5, red for grade 4)
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246 in fact an increase in GC content around the TSS (see
247 Additional file 3: Figure S1). From this analysis we could
248 determine that the frequency of REs in the global set of
249 human promoters is slightly but significantly higher than
250 the frequency of REs in scrambled sequences (Fig. 2b).
251 This soft enrichment is plausible, given that we are con-
252 sidering all known human TSS and not specific popula-
253 tions of genes. Grade five and three are the most
254 enriched class of REs when comparing the frequency of
255 each grade (Fig. 2b).
256 Mapping all the REs considering their position with re-
257 spect to the TSS, we obtained an occupancy metaprofile
258 of p53 REs, displayed in Fig. 2c. This occupancy profile re-
259 veals a general decrease of REs in the region proximal to
260 TSS (from -2 kb to +2 kb). This decrease affects all REs,
261 independently from the grade, and appears to be a conse-
262 quence of the local increase in GC content, since we ob-
263 served the same effect in scrambled sequences when
264 applying local permutations (Additional file 3: Figure S2).
265 Overall the REs reduction (approximately of ¼.) could be
266 interpreted as a selection against a high density of active
267 p53 REs from promoter regions of non-target genes that
268 is limited to about 2 kbs from TSS. This reduction is
269 driven by the general increase in GC content around the
270 TSS, which more globally is instrumental in the interplay
271 between chromatin conformation and transcription pro-
272 cesses. On the other hand, when restricting our analysis to
273 the promoter region of known p53 targets, we found an
274 entirely different landscape. Fig. 2d displays the promoter
275 occupancy metaprofile of REs identified by p53retriever in
276 a group of 189 HGNC genes listed as targets of p53 in lit-
277 erature and collected in [15, 45]. Interestingly, this profile
278 shows the highest probability density in the region closer
279 to the TSS, especially for functional REs with grade four
280 and five (red line in Fig. 2d). Indeed, recent data reported
281 a prevalence of p53 REs nearby the TSS of known target
282 genes [16, 47].
283 Comparison with other p53 binding site datasets and
284 search tools
285 >To further verify if p53retriever recognized already
286 established p53 binding sites, we compared our ap-
287 proach with lists of p53 target genes and REs previously
288 reported. The detailed results of all comparisons are
289 contained in Additional file 4.
290 First, we used our method to score 81 REs sequences
291 that are consistently bound by p53 according to seven
292 different ChIP-seq datasets, reported in [15]. All these
293 sequences were picked by p53retriever as potentially
294 functional. Interestingly, excluding one sequence, all
295 p53 REs from this list obtained a grade greater than
296 one with the majority being of grade 5, confirming that
297 our tool can discriminate functional and well-known
298 REs (Fig.F3 3a).
299Next, we applied p53retriever on p53 REs obtained by
300Chip-exo analysis [14], providing near-nucleotide reso-
301lution of p53 bound sites in response to a variety of geno-
302toxic stresses. (Fig. 3b). While 28 % of sites were not
303classified, the majority of bound sequences from ChIP-exo
304obtained a grade greater than 1, with a predominance of
305grade four and five, (Fig. 3b, left panel). Interestingly, we
306saw a clear correlation between higher relative occupancy
307and higher RE grade (Fig. 3b, right panel). Looking in
308more detail to the “no grade” group, we noticed that all
309non-scored sequences differed from the canonical RE site
310for features which are highly penalized by our algorithm,
311like a number of mismatches higher than three scattered
312on three different quarter sites. Nevertheless, we could
313show that these not-scored sequences are mostly charac-
314terized by low occupancy values (white boxplot in Fig. 3b
315right panel, Wilcoxon rank sum test p-value=1.29E-09).
316Consistently, when considering the subset of regions in-
317creasingly bound by p53 after all the stimuli used in [14],
318the percentage of “no grade” drops to 17.6 % (Additional
319file 3: Figure S3).
320We also extended the comparison to a Chip-seq data-
321set, reported in [17] (Fig. 3c) and obtained an overall
322similar distribution of RE grades. The percentage of re-
323gions with “no grade” is 22.8 %.
324Next, we extended the comparisons to other lists of
325REs, starting from two small collections of reported p53
326REs, based on heterogeneous experimental approaches
327[2, 15, 45]. Only a minority of those REs obtained the
328highest grade, and the proportion of sequences not
329scored as potentially functional was approximately 40 %
330(Additional file 3: Figure S4). It has to be said that the
331REs reported in those lists are not guaranteed to be the
332ones actually or solely responsible for the responsiveness
333of the associated genes to p53.
334Even though total mRNA levels are an indirect meas-
335urement of p53 transcriptional activity, they reflect the
336transcriptome status upon p53 activation. Thus, we did
337an additional comparison using microarray data ob-
338tained after p53 activation upon Doxorubicin treatment
339of MCF7 cells [49]. The majority of differentially
340expressed, up-regulated genes turned out to have a p53
341binding sites with grade three (Fig. 3d), and exhibited a
342specific enrichment of REs with grade >3 near the TSS
343(Additional file 3: Figure S5). Similar comparisons were
344done with lists of p53 target genes in curated databases
345such as TRANSFAC and IPA. Again, the majority of
346these genes have a RE of grade three predicted by p53re-
347triever in their promoter region (Fig. 3d). Using Ingenu-
348ity Pathway analysis (IPA), grade five and grade four
349human promoters revealed a strong p53 pathway signa-
350ture (Additional file 5).
351Finally, we compared p53retriever results with the
352standard PWM approach, using two PWMs provided by
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353 the JASPAR database (see Methods). All REs identified
354 by p53retriever in the set of human promoters were
355 scored in parallel with both JASPAR PWMs: the com-
356 parison with the JASPAR PWM derived from ChIPseq
357 data is shown in Fig. 3e. Although there is a high agree-
358 ment on REs with the maximum grade, very close to the
359 optimal p53 consensus, the comparison shows diver-
360 gences between the two methods for the lower grades.
361 For example, a considerable population of REs assigned
362 to grade four by p53retriever receives very low scores
363 from JASPAR. This is likely due to the presence of ¾
364 sites that are over-penalized by the PWM approach. On
365 the other hand, many REs with low grades are highly
366 scored by JASPAR, that doesn’t penalize groups of scat-
367 tered mismatches. Apart from grade 1, we can observe a
368 linear trend between the two scoring systems if we look
369 at the median values of the boxplots displayed in Fig. 3e,
370 so we can conclude that the two approaches are distinct
371 and complementary. On the other hand, the second
372 JASPAR matrix, based on SELEX data, gives misleading
373 results, since even optimal REs (grade 5) receive low
374 scores (Additional file 3: Figure S6).
375High grade p53 REs are enriched in distant enhancers
376Recent functional genomics approaches, particularly
377resulting from the ENCODE initiative, have revealed
378that transcription is rather pervasive, that enhancer se-
379quence can be very distant, at least in terms of primary
380sequence, from genes, and that active enhancers can be
381mapped based on specific histone code marks [50, 51].
382Hence, we exploited this rich body of available informa-
383tion to map p53 REs in distal enhancer sites, using
384DNAse hypersensitive sites tracks. We filtered out sites
385overlapping with promoter regions defined in the previ-
386ous sections, and considered a population of 43,787 dis-
387tal regions, whose length distribution is displayed in
388Fig. F44a. p53retriever was run on this set of regions, and
389the complete results are provided in Additional file 6.
390The grade distribution of REs found in distal DNAse re-
391gions is displayed in Fig. 4b. The frequency of REs in
392these regions is significantly higher than the frequency
393found in human promoters and also in random se-
394quences (Fig. 4c and Additional file 3: Figure S7). The
395overall fold enrichment is 3.54, but this trend grows pro-
396portionally to the grade of the REs, reaching a peak with
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Fig. 3 comparison of p53retriever with other p53 binding site datasets and tools. a Pie chart displaying p53retriever classification on a list of 81
regions commonly identified by 7 different ChIP-seq experiments [15]. b Left panel: pie chart displaying p53retriever classification on a list of
2250 regions identified by ChIP-exo [14]. Right panel: boxplot displaying for each grade assigned by p53retriever to ChIP-exo sequences, the
distribution of the corresponding ChIP-exo occupancies, measured in [14]. n.g. = no grade given by p53retriever. c Pie chart displaying p53retriever
classification on a list of 4416 regions identified by ChIP-seq in [17]. d p53 target gene lists from curated databases (Biobase and IPA) or from
expression datasets (Doxo up: genes up-regulated upon doxorubicin treatment) were compared to the list of p53 promoter REs obtained with
p53retriever. Presented in the bar graph are the predicted p53 REs grouped by the maximum functional grade identified by p53retriever in
their promoter. e Comparison between p53 REs identified in human promoters by p53retriever, and the corresponding score given by Jaspar
p53 PWM (MA0106.2), based on ChIPseq data. REs are divided in 5 groups along the horizontal axis, corresponding to the grade assigned by
p53retriever. For each group, the distribution of the scores given by Jaspar PWM is represented as a violin plot, i.e., a box plot with a rotated
kernel density plot on each side. Jaspar scores range from 0 (the RE is not identified) to 1 (the RE is optimal)
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397 grade 5. In fact, 144 high grade REs are found within
398 DNAse hypersensitive sites (Fig. 4b), more than in the
399 entire human promoter dataset. The fold enrichment of
400 grade five REs is 16.3 (Fig. 4c). Presently, it is undeter-
401 mined if this enrichment for high quality binding sites
402 reflects a common trend for sequence-specific transcrip-
403 tion factors or a distinct feature of p53 family proteins.
404 Consistent with our results, higher levels of p53 occu-
405 pancy in distal enhancers compared to promoters was
406 very recently reported based on ChIP-seq analysis of
407 lymphoblastoid cell lines treated with doxorubicin [47].
408 Additionally, Chip-seq analysis reported in [17] allowed
409 us to expand the study of p53 REs in enhancers regions.
410In fact that paper provided p53 bound regions classified
411as enhancers based on ENCODE annotation or as proto-
412enhancers, where p53 could act as pioneer transcription
413factor. Interestingly, this latter group showed an enrich-
414ment for high scoring (grade four and grade five) p53 REs
415according to p53retriever and a lower proportion of se-
416quences with no grade (Fig. 4d, top panel).
417New direct p53 target genes identified based on the p53
418RE functional search tool
419High-activity, or non-canonical p53 REs predicted to be
420moderately active were mapped by our tools near the
421TSS of genes that are not completely established or
422novel putative direct p53 target genes. To infer the pre-
423dictive power of the pattern search on p53-dependent
424transcriptional changes, 13 genes were selected and their
425expression were tested followed by qPCR in cell lines
426differing for p53 status (MCF7, two derivative clone so
427called MCF7 vector and MCF7shp53, HCT p53+/+ and
428HCT p53−/−) and at different time points (8, 16, 24 h)
429after p53 activation by two different treatments, i.e.,
430Doxorubicin -a genotoxic chemotherapeutic drug- and
431Nutlin-3A -an MDM2 inhibitor- (Fig. F55a) (Additional file
4327). Results support p53-dependent up-regulation for
433most genes. The p53-dependency is confirmed by the
434absence of induction in HCT p53−/− and MCF7shp53
435cell lines, despite the different p53 status between the
436two cells lines (a p53-null and a partial knockdown cell
437line, respectively). In some cases, the increase in gene
438expression compared to the mock condition was time-
439dependent. Differences in these kinetic features were
440apparent between the two treatments applied. E2F7 was
441inducible by doxorubicin at different time points, while
442after Nutlin-3A treatment an early up-regulation was
443followed by repression, which appeared to be p53-
444dependent. GAS6 and KCTD1 had a similar trend espe-
445cially in MCF7 cells. Differences were noted between
446MCF7 and the MCF7-vector derivative clone in the
447magnitude or the kinetics of relative expression changes
448(e.g., PDE2A, APOBEC3H, KCTD1, DNAJA1, DICER).
449Nine of the thirteen candidates (PDE2A, GAS6, E2F7,
450APOBEC3H, KCTD1, TRIM32, TGFA, KITLG, HRAS)
451were selected among the list of genes having both a
452predicted binding sites in our algorithm output with a
453grade higher or equal to 2, and a reported p53 binding
454sites on ChIPseq datasets [7, 8]. For all of them except
455TRIM32, total mRNA levels are also reported as upregu-
456lated after Doxorubicin treatment by microarray data [49].
457Although the induction is not directly proportional to the
458grade, we confirmed p53 dependent induction by qPCR
459for all of them in time/cell line dependent manner. Even
460though TRIM32 is not upregulated after Doxorubicin
461treatment in all the tested cell lines, it is upregulated upon
462Nutlin-3A treatment, confirming ChIP-seq data. Besides
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463 their p53 binding sites, these candidates were selected
464 because of their reported involvement in cell-cycle control
465 e tumor progression (PDE2A, E2F7, GAS6, TRIM32,
466 HRAS, KITLG and TGFA), in transcription (KCTD1), and
467 DNA editing (APOBEC3H) (see Supplementary Text in
468 Additional file 3).
469 For the remaining four genes, whose REs are displayed
470 in Fig. 5b, we performed a chromatin-immunoprecipitation
471 experiment in MCF7 cells treated with Doxorubicin for
472 16 h. Weak p53 occupancy was observed by qPCR at
473 DNAJA1 and MAP2K3 loci after doxorubicin treatment,
474 while a region containing a predicted grade 3 category p53
475 RE in the YAP1 gene showed evidence for p53 occupancy
476 in the mock condition. Our results did not support direct
477p53 binding to the DICER promoter, consistent with a pre-
478vious study [52] (Fig. 5c).
479Overall, we propose DNAJA1, MAP2K3 and poten-
480tially YAP1 as new direct p53 target genes, although the
481level of transactivation was relatively low.
482DNAJA1 can act as a co-chaperone of Hsc70 that was
483previously associated to radioresistance phenotype in
484wild type p53 glioblastoma cells treated with farnesyl-
485transferase inhibitors [53]. Recently, overexpression of
486DNAJA1 was associated with a reduction of pancreatic
487cancer cell survival and with c-Jun repression [54].
488MAP2K3 participates in the MAP kinase cascade and
489can phosphorylate p38. This protein was identified as a
490senescence-promoting factor in human breast epithelial
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Fig 5 p53-responsiveness of target genes associated with predicted functional REs. a qPCR results of 13 selected genes. Fold of changes values
(ΔΔCq) upon each treatment are presented as a heatmap Upper part shows mRNAs level after Nutlin-3A treatment while the lower shows the
same after Doxo treatment. Expression levels were tested in different cell lines (MCF7, HCT +/+, HCT −/−, MCF7 vector and MCF7 shp53) and at
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491 cells [55]. However, it has also been associated to tumor
492 invasion potential and to be regulated at transcriptional
493 level by NFY, NFkB and gain-of-function mutant p53 [56].
494 The Yes-associated protein 1 (YAP1) is a transcrip-
495 tional regulator involved in the Hippo signaling pathway.
496 Evidences support both an oncogenic and a tumor sup-
497 pressor role for YAP1, linked to ABL1-induced apoptosis
498 [57]. YAP1 protein was found capable to bind the p53
499 promoter and a positive feedback loop was proposed
500 based on the finding that p53 can bind the YAP pro-
501 moter [58]. In part consistent with this view we found
502 p53-dependent YAP1 gene up-regulation both after
503 doxorubicin and Nutlin-3A treatment.
504 Conclusions
505 Several previous tools were developed to identify bona
506 fide p53 response elements, starting with pioneering
507 in vitro selection experiments that led to the initial and
508 still accepted definition of the consensus p53 RE [11, 42,
509 45, 59, 60]. The majority of these tools were based on
510 position weight matrices derived from results of in vitro
511 approaches, namely competitive gel shift assays and
512 SELEX, more recently integrated with results obtained
513 from Chromatin immunoprecipitation experiments. A
514 systematic effort to quantify changes in DNA binding
515 affinity (dissociation constants) using fluorescence anisot-
516 ropy titration led to the development of a p53 binding site
517 predictor algorithm [60]. This tool was also used to search
518 genome wide for high affinity p53 REs and to map natur-
519 ally occurring single nucleotide polymorphisms (SNPs)
520 that can impact on the DNA binding affinity of p53. The
521 functional relevance of SNPs within p53 REs has been
522 established in several reports [15, 24, 27, 44, 61].
523 All position weight matrix approaches assume additive
524 contributions of the individual positions within the RE
525 sequence, and except for [45] and [11], all tools do not
526 specifically weigh the impact of spacers between half site
527 decameric RE motifs in the 0-13 nt range. This spacer
528 length was in fact considered neutral in the initial
529 in vitro experiments [23]. However, DNA binding as-
530 says where RE sequence are embedded in longer DNA
531 molecules, competitive binding experiments in micro-
532 fluidics, Chromatin Immunoprecipitation assays, yeast-
533 and mammalian-cell based transactivation assays all
534 indicate that even a single nucleotide spacer between
535 p53 RE half sites can reduce transactivation potential
536 [5, 24, 27, 44]. In fact, when the spacer is longer than
537 2–3 nt the two decameric half sites no longer show co-
538 operative interactions [24, 28, 62], although when the
539 distance in primary sequence approach one helical pass,
540 transactivation potential appears to increase beyond ad-
541 ditivity [24], yet remaining much lower compared to
542 the absence of a spacer. The negative impact of spacer
543 is even more dramatic for TAp73 [62] and TAp63
544proteins, but not for ΔNp63 [63], suggesting that the
545structure as well as the sequence of DNA binding sites
546can lead to conformational changes in the quaternary
547tetrameric structure of p53 family proteins, and that in-
548trinsic differences exist in the oligomerization state of
549these proteins [64].
550We have coded in p53retriever sequence and struc-
551tural features of p53 REs impacting on transactivation
552potential that were revealed in the past several years
553using our yeast-based transactivation assay [5, 26, 28, 63,
55465, 66]. The resulting algorithm has several distinctive
555features compared to previous tools, particularly for
556scoring interactions among groups of mismatches, non-
557canonical 3Q sites and half sites p53 REs, weighting the
558impact of consensus mismatches considering their pos-
559ition within the full site RE sequence, i.e., giving higher
560penalty to mismatches in the two internal quarter sites,
561and weighs consensus sequence variations within di-
562nucleotide motifs in the core and flanking regions [28]
563(Fig. 1, Additional file 1). Possible interactions between
564nearby half site p53 REs or clusters of full site and 3Q
565sites are currently not considered by our algorithm.
566We mapped and ranked functional REs near TSS for
567all annotated transcripts in UCSC (Additional file 2).
568Further, we exploited ENCODE data and provide a car-
569tography of ranked p53 REs within distant DNAse
570hypersensitive sites, considered as distant enhancers
571(Additional file 6). In these regions we found a signifi-
572cant 16-fold enrichment of high grade REs with respect
573to the basal frequency expected by chance or observed
574in promoter regions. An enrichment for high grade REs
575was also found among proto-enhancer sequences bound
576by p53 identified by ChIP-seq [17]. It is worth noting that
577our results represent a projection from all DNAse hyper-
578sensitive sites, irrespective of the specific tissues in which
579they are active. Tissue variability may influence which REs
580are selectively bound. An additional layer of complexity is
581represented by the known interplay between different
582transcription factors. This important aspect is not in-
583cluded in our analysis that is focused on p53 alone.
584Although the data on which the algorithm is construed
585are the outcome of transactivation assays measured from
586chromatinized promoter-reporter construct, the isogenic
587nature of the yeast-based functional assays, minimizes
588most variables potentially impacting on transactivation
589by p53; at the same time distinct chromatin features of
590the natural context of the REs’ location in vivo may cer-
591tainly influence the associated gene transcriptional re-
592sponsiveness to p53. Hence the yeast-based results might
593be more similar to ChIP-seq and ChIP-exo results, albeit
594with a more quantitative power.
595Undoubtedly different ChIP-seq experiments do not
596agree with each other and there is limited overlap
597among the results obtained with different cell lines or
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598 using different treatments to activate p53. While global
599 differences in occupancy could be related to differences
600 in accessibility between different tissue-derived cells or
601 to distinct p53 post-translational modifications or cofac-
602 tors activated by different treatments, it was interesting
603 to find that the list of p53 bound sites that are common
604 to multiple ChIP-experiments were highly enriched for
605 high scoring (grade four and grade five) REs and none of
606 them failed to be classified by our tool (Fig. 3a). Instead,
607 when examining individual ChIP-seq or even, although
608 to a lower extent, ChIP-exo data, 20 % to 30 % of p53
609 bound fragments did not contain a motif scored by
610 p53retriever. While those sites may represent examples
611 of p53 proteins tethered to DNA by protein interactions,
612 the manual inspection of “no grade” sites from the
613 ChIP-exo datasets showed that the majority of these
614 sites resemble p53 response elements but contain several
615 (three or more) “core” mismatches scattered on three
616 different quarter sites. These multiple mismatched REs
617 are not presently scored by p53retriever, but would
618 probably result in weak responsiveness. Consistently, the
619 majority of no grade ChIP-exo REs showed lower occu-
620 pancies (Fig. 3b right panel).
621 Finally, we decided to validate a few of the predictions
622 from the pattern search, particularly for non-canonical
623 3Q sites using cell lines as a model.13 genes with
624 mapped functional REs were chosen. Overall, despite
625 our algorithm doesn’t consider the system complexity of
626 transcriptional regulation in living cells and the response
627 variability upon each different p53 stimulus, results sup-
628 port p53-dependent transactivation for the majority of
629 them. Based on the combined qPCR and ChIP results
630 we conclude that DNAJA1, MAP2K3, and potentially
631 YAP1 can be considered new direct p53 target sites,
632 linking p53 to yet additional potential biological out-
633 comes. Furthermore, our data further establish the very
634 recent findings of PDE2A, GAS6, E2F7, APOBEC3H,
635 KCTD1, TRIM32, HRAS, KITLG and TGFA as p53 tar-
636 get genes.
637 Methods
638 Implementation of pattern search rules in p53retriever
639 We implemented the set of manually curated rules
640 (Additional file 1) in an R package called p53retriever.
641 p53retriever source and binary files are available
642 on Github, at (Q8 http://tomateba.github.io/p53retriever/).
643 p53retriever contains a main function that identifies
644 potential REs. This function needs as input an arbi-
645 trary DNA sequence, and returns a table containing
646 information about the identified REs, such as position,
647 sequence, spacer length, mismatch label and grade.
648 The format of the output is similar to Additional file
649 6. Many functions are also provided in order to graph-
650 ically display the results. The package is documented
651with usage examples, and fully integrated with other
652CRAN and Bioconductor packages. In particular,
653p53retriever depends only on the previous installation
654of the Bioconductor Biostrings package.
655Human promoters dataset
656Human promoter sequences were extracted from the
657UCSC database ( Q9http://genome.ucsc.edu/) considering,
658for each transcript with a distinct TSS, the 20 kB region
659surrounding the transcription binding site (genome build
660GRCh37/hg19). The final dataset consists of 23,541 pro-
661moter sequences, associated to distinct UCSC identifiers
662and corresponding to 18,355 HGNC genes.
663Human distal DNase regions dataset
664Encode DNase-seq regulatory regions (genome build
665GRCh37/hg19) were obtained from the following cell
666lines: Gm12878, H1hesc, Helas3, Hepg2, Hmec, Hsmm,
667Hsmmt, Huvec, K562, Monocd14, Nha, Nhdfad, Nhek,
668Nhlf, Osteobl, Hsmmfshd, Lncap, Nb4, Nt2d1,Panc1.
669The consensus was defined as the merge of all the regions
670that were present in at least two cell lines. Only distal
671regions, with more than 10 kb from the nearest annotated
672TSS, were kept in the dataset, in order to avoid overlap
673with promoter regions. The final dataset consists of
67443,787 regions, with a mean length of 673.3 bases.
675Simulations with random sequences
676Sets of scrambled promoter sequences were generated
677by local permutations (bin size = 500 nt) of human pro-
678moter sequences (−10 kb, +10 kb from TSS). This
679allowed to preserve the local GC content in the random
680model; p53 REs were then identified and classified with
681p53retriever. The random simulation was run ten times,
682and the results were compared to REs identified in real
683human promoters.
684Set of random sequences were generated, with the
685same number and the same GC content (44 %) of hu-
686man DNA sequences; p53 REs were then identified and
687classified with p53retriever. The random simulation was
688run ten times, and the results were compared to REs
689identified in human distal DNase regions promoters.
690Pathway analysis of DEGs
691All pathways analyses were performed using IPA
692( Q10www.ingenuity.com). Only direct interactions were
693considered in the setting parameters.
694Comparison with other datasets
695Several lists of p53 targets, identified by their HGNC
696symbol, were extracted from online databases such as
697Biobase TRANSFAC ( Q11http://www.biobase-international.-
698com/product/transcription-factor-binding-sites) and IPA,
699or from previous publications, referenced in the main text.
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700 These lists were used to select populations of genes
701 among our dataset of human promoters, and analyze
702 the grade of the REs identified by p53retriever (as
703 shown in Fig. 2d).
704 Several sets of p53 RE sequences or p53 bound regions
705 were taken from previous publications, referenced in the
706 main text. p53retriever was run directly on these se-
707 quences (as shown in Fig. 3a, b, c).
708 Comparison with JASPAR PWMs
709 Two PWMs for p53 were downloaded from the JASPAR
710 database (Q12 http://jaspar.genereg.net/). One PWM, MA0106.1,
711 is built on SELEX data, while the second, MA0106.2, is built
712 on ChIPseq data. The original values of the dowloaded
713 PWMs were based on nucleotide frequencies and therefore
714 more similar to Positional Frequency Matrices. These
715 frequency values were transformed in log2 probability
716 ratio values with the PWM function implemented in
717 the Bioconductor Biostring package, using a multi-
718 nomial model with a Dirichlet conjugate prior to calcu-
719 late the estimated probability of base b at position i.
720 The final score of a match ranges from 0 to 1. All REs
721 identified by p53retriever in the set of human pro-
722 moters were scored with JASPAR PWMs: the compari-
723 son with MA0106.2 is shown in Fig. 3d, while the
724 comparison with MA0106.1 is shown in Additional file
725 3: Figure S2.
726 Cell lines and culture conditions
727 The human breast adenocarcinoma-derived MCF7 cell
728 line (p53 wild type) was obtained from the InterLab Cell
729 Line Collection bank, ICLC (Genoa, Italy) while the
730 colon adenocarcinoma HCT116 (p53+/+) cell line and its
731 p53−/− derivative were a gift from B. Vogelstein (The Johns
732 Hopkins Kimmel Cancer Center, Baltimore, Maryland,USA).
733 MCF7 cells stably expressing an shRNA targeting p53
734 (MCF7shp53) or control cells (MCF7vector) were kindly
735 provided by Dr. Agami (ref.). Cells were normally main-
736 tained in DMEM or RPMI (BioWhittaker, Lonza, Milan,
737 Italy) supplemented with 10 % FCS, antibiotics (100 units/
738 ml penicillin plus 100 mg/ml streptomycin) and 2 mM
739 glutamine. Puromycin (Sigma-Aldrich, Milan, Italy) was
740 used to maintain the selection, at 0.5 μg/mL as final
741 concentration.
742 RNA extraction
743 Cells were seeded into 6-well plates and allowed to reach
744 70-80 % of confluence before treating with 1.5 μM
745 Doxorubicin or 10 Μm Nutlin-3A. Doxorubicin was
746 purchased from Sigma-Aldrich (Milan, Italy) while
747 Nutlin-3A was obtained from Alexis Biochemicals (Enzo
748 Life Science, Exeter, UK). After 8 h, 16 h or 24 h of
749 treatment cells were harvested and total RNA was ex-
750 tracted using RNeasy Mini Kit (Qiagen, Milan, Italy)
751according to the manufacturer’s instructions. In-column
752DNAse treatment (RNase-Free DNase Set, Qiagen,
753Hilden, Germany) was performed to remove DNA con-
754tamination during the extraction. Purity of RNAs
755(A260/A280 value of 1.8–2.1) and concentration were
756measured using the Nanodrop spectrophotometer.
757qPCR
758cDNA was generated starting from 1 μg of RNA by
759using the RevertAidTM First Strand cDNA Synthesis Kit
760(Fermentas, Milan, Italy) in 20 μL as final volume fol-
761lowing manufacturer’s instructions. Primers were de-
762signed by Primer-BLAST performing in silico analysis as
763well as standard curves to define assay specificity and
764efficiency (Additional file 7). All qPCR assays were per-
765formed on CFX Touch Real-Time PCR Detection Sys-
766tem (Bio-rad, Milan, Italy) in a 384-well plate format.
767Optimal primer concentrations (200nM-400nM) were
768determined by identifying conditions resulting in the
769lowest Cq combined with absence of primer dimer for-
770mation. Reaction volumes were set at 10 μl. SYBR Green
771assays contained 5X KAPA SYBR FAST qPCR Master-
772mix (Kapa Biosystems, Resnova, Rome, Italy), 400 nM
773each primer (MWG, Operon, Ebersberg, Germany) and
77425 ng of cDNA. Initial thermal cycling conditions were
7751 cycle of 95 °C for 3 mins, followed by 40 cycles of 95 °
776C for 30 s, 60 °C for 20 s, 72 °C for 60 s. At the end a
777melt curve analysis was performed. Post-run relative
778mRNA quantification was obtained using the comparative
779Cq method (ΔΔCq), where glyceraldehyde 3-phosphate
780dehydrogenase (GAPDH) and β-2microglobulin (B2M)
781served as reference genes.
782ChIP assays
783MCF7 cells were cultured in complete medium in a 150-
784mm Petri dishs and when reaching 70/80 % confluence
785were treated for 16 h with Doxo. The procedure for
786crosslinking, sonication, IP and analysis followed a previ-
787ously described protocol ( Q2Lion, 2012). Antibodies used
788for ChIP assays were: p53 (DO-1) and IgG (sc-2025 or
789sc-2027) (Santa Cruz Biotechnology®) (Millipore). ChIP
790analysis was performed with the comparative Cq method
791(ΔΔCq) and normalized as % of input, using β-actin
792gene as negative control and p21 as positive control for
793p53 enrichment.
794Availability of supporting data
795The data sets supporting the results of this article are
796included within the article and its additional files. p53re-
797triever source and binary files are available on Github, at
798( Q13http://tomateba.github.io/p53retriever/).
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799 Additional files
800
802 Additional file 1: Complete list of the rules used to attribute the
803 functional score in the pattern search algorithm.
804 Additional file 2: Complete list of identified REs within human
805 propoter regions (−10 kb, 10 kb from TSS). The list contains
806 chromosomal coordinates, official gene name, distance from TSS and RE
807 sequence features resulting in the given functional grade.
808 Additional file 3: Figures S1–S7, Table S1 and Supplementary
Information.
809 Additional file 4: Comparison between p53retriever classification
810 and lists of published p53 bound regions.
811 Additional file 5: Gene lists from data curated Ingenuity Pathway
812 (TP53 Canonical Pathway) were compared to prediction and
813 functional ranking of p53 REs. The RE grade is stated in the name of
814 the various worksheets. A) Grade four and grade five. B) All grade 3, 4,
815 and 5.
816 Additional file 6: Complete list of identified REs within ENCODE
817 distal DNAse regions. The list contains chromosomal coordinates and
818 RE sequence features resulting in the assigned functional grade.
819 Additional file 7: qPCR data summarized in Figure 5. For each gene,
820 time point and treatment time, the average fold change of three
821 biological repeats is presented along with the Standard Deviation. The
822 results obtained with different cell lines are presented in different
worksheets
823 Abbreviations
824 RE: Response element; TSS: Transcription start site; 3Q: 3/4 binding site.
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